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Résumé 
La scoliose est la déformation de la colonne vertébrale la plus répendue. Elle atteint 
3 à 4% de la population pédiatrique et dans 85% des cas, aucune cause n’a été identifiée. 
Ces cas sont appelés idiopathiques et les symptômes apparaissent durant la puberté; d’où le 
terme de ‘scoliose idiopathique de l’adolescent (SIA). Cette pathologie atteint le plus 
souvent les jeunes filles, en nombre et en sévérité. Ces dernières années, plusieurs 
hypothèses ont été proposées afin d’élucider l’étiologie de cette pathologie. Celles-ci ont 
mis de l’avant différents facteurs génétiques, biochimiques, méchaniques, neurologiques, 
musculaires ou hormonaux. Plusieurs études ont rapporté des formes familiales de scoliose, 
soutenant la thèse d’une prédisposition génétique. Nous avons démontré que les patients 
souffrant de SIA présentent un défaut de signalisation cellulaire médiée par les protéines Gi 
et un taux élevé d’ostéopontine (OPN) circulante. En utilisant une approche de type ‘gène 
candidat’, nous avons montré que la protéine tyrosine phosphatase µ (PTPµ) régule 
l’activité du complexe d’intégrines α5/β1 (récepteur de l’OPN) via la protéine kinase 
PIPKIγ. Dans ce but, nous avons utilisé des cultures primaires d’ostéoblastes issues de 
biopsies de patients et de cas traumatiques comme sujets contrôles. Les biopsies ossscuses 
de patients ont été obtenues lors de l’intervention chirurgicale à partir des vertébres T3 à 
L4, selon les différentes procédures. Les biopsies issues de cas traumatiques proviennent 
d’autres types d’os (tibia, crête iliaque, fémur). Les profils d’expression du gène PTPRM 
(codant pour la protéine PTPµ) ont été étudiés par PCR quantitative (qPCR). Les taux de 
protéines PTPµ ont été analysés par immunoprécipitation suivi d’un western blot. Pour 
évaluer le rôle de cette protéine, nous avons bénéficié d’un modèle murin. Machida et al. 
ont démontré qu’il existe un taux plus élevé de scoliose parmi les souris C57Bl/6 bipèdes 
obtenues suite à l’amputation des membres supérieurs, sous anesthésie, cinq semaines après 
la naissance. Nous avons utilisé des cultures primaires d’ostéoblastes issues de la colonne 
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vertébrale de souris C57Bl/6 bipèdes, délétées du gène PTPRM (souris dites ‘KO’), afin 
d’évaluer le niveau de signalisation cellulaire spécifique des protéines Gi par un test 
fonctionnel: la technique de spectroscopie cellulaire di-électrique (SCD). Selon nos 
données, 85% des souris bipédales ‘KO’ pour le géne PTPRM développent une scoliose 
(modérée à sévère) contre 55% des souris contrôles C57Bl6 bipèdes. De plus, les niveaux 
de PTPµ exprimée par les ostéoblastes de 34 patients SIA se trouvent diminués par 
comparaison à 17 sujets contrôles.  Nos études de souris bipèdes ont montré que 
l’inactivation du gène PTPRM augmente l’incidence et la sévérité de la scoliose, sans pour 
autant affecter les taux circulant d’OPN ou l’expression de ses récepteurs. Par ailleur, dans 
ce même contexte, nous avons remarqué une augmentation de l’intéraction entre l’OPN et 
l’intégrine β1 en l’abscence du gène PTPRM. Les cellules issues de ces souris bipèdes KO 
montrent une réduction dans leurs niveaux de signalisation cellulaire médiée par les 
protéines Gi après stimulation par l’OPN. Cette diminution est en grande partie récupérée 
après traitement des cellules par un siRNA spécifique de la protéine PIPK1γ, substrat de 
PTPµ qui favorise la fixation de ligands aux intégrines. Ces études apportent les premières 
indications que la perte d’expression de PTPµ est impliquée dans le développement de la 
SIA, en amplifiant probablement l’effet inhibiteur de l’OPN sur la signalisation cellulaire 
médiée par les protéines Gi. 
Ces études permettent une meilleure compréhension de l’étiologie de la SIA. Elles 
pourraient avoir une contribution importante dans le développement futur de méthodes 
diagnostique et thérapeuthique dans le but d'arrete l’apparition et l’évolution de la maladie 
chez les enfants atteints. 
Mots-clés : Scoliose idiopathique adolescente (SIA), protéines G, signalisation, 
osteopontin, protéine tyrosine phosphatase µ (PTP µ) 
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Abstract 
          Adolescent idiopathic scoliosis (AIS) is the most common form of scoliosis that 
affects 3-4% of the global pediatric population. In more than 85% of  cases, no specific 
cause can be identified. Such cases are called idiopathic and occur mostly during 
adolescence. AIS affects mainly females in number and severity. Over the past years, many 
hypotheses were proposed to explain the etiology of AIS, including genetic, biochemical, 
mechanics, neurological, muscular and hormonal factors. Several studies have reported a 
high incidence of scoliosis in some families, which argues for a genetic cause of this 
disease. We demonstrated that AIS patients have a Gi protein signaling defect and exhibit 
high levels of circulating Osteopontin (OPN). The goal of this thesis is to identify the 
mechanisms regulating OPN signaling activity in AIS patients. We have used a candidate 
gene driven approach and discovered that protein tyrosine phosphatase µ (PTP µ) regulates  
α5β1 integrin (a known OPN receptor) through phosphate kinase type 1 gamma (PIPK1γ). 
To achieve our goal, we have used primary osteoblast cell cultures derived from AIS 
patients and biopsies from control subjects. Bone specimens were obtained intraoperatively 
from vertebras (varying from T3 to L4 according to the surgical procedure performed) 
while with trauma cases used as non-scoliotic controls, bone specimens were obtained from 
other anatomical sites (tibia, femur or iliac crest). Expression profiles of the RPTPM gene 
(encoding for PTPµ) were studied by qPCR. On the other hand, PTPµ protein levels were 
determined by immunoprecipitation followed by western blot. To evaluate the role of this 
protein in AIS etiopathogenesis, we took advantage of an animal model exhibiting a higher 
scoliosis incidence when maintained in a bipedal state. [1], [2] Bipedal surgeries were 
performed on C57Bl/6 mice after weaning (5-weeks after birth) by amputation of the 
forelimbs and tail under anesthesia as reported by Oyama et al. (2006). [1] We used the 
same approach with PTPµ knockout mice and primary osteoblast culture were derived from 
  
 
iv
the spine of these mice to assess Gi protein signaling through a functional assay termed 
Cellular Dielectric Spectroscopy (CDS).  
Bipedal PTPµ knockout mice develop scoliosis more often (85%) in number and 
severity, than control C57Bl/6 bipedal mice (55%). Interestingly, functional analysis of 
osteoblasts derived from PTPµ KO mice by CDS method showed a flaw in the transmission 
of Gi protein coupled receptor signaling similar to a specific AIS patient subgroup. 
Furthermore, the clinical relevance of PTPµ was strengthened by the fact that a decrease in 
the gene expression level of PTPµ was observed in 34 AIS patients when compared to 17 
control subjects. Such a decrease was also confirmed at the protein level. We demonstrated 
that genetic deletion of PTPµ enhances the incidence and severity of scoliosis without 
affecting plasma levels of OPN or the expression of its receptors. In contrast, increased 
interaction of OPN with β1 integrin was noticed in cells depleted of PTPµ. Furthermore, 
reduction of Gi- protein coupled receptor GiPCR signaling by OPN was also enhanced in 
these cells, while their response to GiPCR stimulation was improved with siRNA of 
phosphatidylinositol-phosphate kinase type 1 gamma (PIPK1γ), a PTPµ substrate that 
favours ligand binding to integrins. These studies provide the first indication that the loss of 
PTPµ influences the nature of idiopathic scoliosis, possibly by amplifying the inhibitory 
effect of OPN on GiPCR signaling. 
This study allows a better understanding of AIS etiology and could have an impact 
for the future development of innovative diagnostic methods and eventual pharmacological 
approaches in order to prevent AIS and stop its progression in affected children. 
Keywords : Adolescent idiopathic scoliosis (AIS), G proteins, signaling, osteopontin and 
protein tyrosine phosphatase µ (PTP µ) 
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1 RATIONALE OF THE PROJECT 
Adolescent idiopathic scoliosis (AIS) is a complex spinal deformity of high 
prevalence and of extreme variability that occurs most commonly in girls rather than in 
boys, around the time of puberty. [3], [4], [5] Approximately 4 % of teenagers are affected 
worldwide and the disease demonstrates a rapid onset with a clinical course which is often 
unpredictable. In its extreme form, AIS is manifested by a pronounced lateral curvature 
accompanied by various co-morbidities and dangerous complications, such as 
cardiopulmonary failure which may cause death. [6], [7] Although this disease has been 
clinically recognized for centuries, the standard of care for patients has not changed during 
the last three decades in any significant manner. As a first approach, patients are treated 
with braces to limit the progression of the spinal deformity, and then as a last resort patients 
are faced with invasive spinal fusion surgery. However, constraints associated with bracing 
and complications from surgery, as well as changes in life style caused by these 
conservative treatments highlight the need for new therapeutic options. Efforts toward 
developing therapeutic options that could target the cause of AIS and offer a better outcome 
for patients are largely limited by the disease’s multifactorial origin. [8], [9], [10] Indeed, 
despite decades of intensive research, no unified cause has emerged, to explain the exact 
pathomechanism of AIS. Nevertheless, there is an emerging concept that Gi protein 
coupled receptor signaling Dysfunction via Gi, proteins, combined with high circulating 
osteopontin (OPN) levels, is a decisive event in the development and progression of AIS. 
Therefore, the identification of molecular determinants regulating such pathological 
process and a full understanding of the mechanistic aspect of Gi-mediated signaling under 
high plasma OPN conditions could provide a molecular platform for the development of 
innovative pharmacological options and personalized strategies for the treatment of AIS.    
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REVIEW OF LITERATURE 
Scoliosis: Definition and types of scoliosis 
Scoliosis can be defined as an abnormal lateral curvature of the spine (as defined in 
Webster’s College Dictionary), and is also known as a three-dimensional deformity of the 
spine with lateral  and vertebral rotation, where the Cobb angle is greater than 10 degrees 
as measured using the Cobb method on a standing radiography. Scoliosis can be classified 
as non-structural or structural.  
The non-structural scoliosis occurs in a structurally normal spine with a lateral 
curve, developed as a secondary response to a problem occurring elsewhere in the body. 
This type of scoliosis can arise due to differing leg lengths or a pelvic tilt. These flexion 
deformities of the hip or knee are often referred to as postural or compensatory scoliosis. 
The spinal curvature in non-structural scoliosis can be resolved while the patient is seated 
or lying down. [11]  
The structural scoliosis is the type where the spine has a lateral curve with a 
vertebral rotation. This form of scoliosis does not resolve when the patient lies down or sits 
upright and is the most known and familiar form. [12] Structural scoliosis is sub-classified 
to congenital, neurological, myopathic, traumatic and idiopathic. The congenital scoliosis 
refers to congenital vertebral anomalies occurring at birth and leads to a lateral curvature of 
the spine. The neurological and myopathic scoliosis are usually classified in a category 
called neuromuscular scoliosis. In this type of scoliosis, the spinal curvature is secondary to 
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a neurological or muscular disease, [13] like spina bifida and Duchenne muscular 
dystrophy. [12], [14] Idiopathic scoliosis is the most common form of spinal deformity for 
which the cause remains unknown. Idiopathic scoliosis is further classified according to the 
age of onset. The three subgroups of idiopathic scoliosis are infantile (1 day - 3 years), 
juvenile (4- 9 years) and adolescent (10-18 years). [15]  
Adolescent idiopathic scoliosis (AIS) 
AIS occurs during the time of puberty, when a child experiences a rapid growth. 
[15] AIS affects mainly females, both in number and severity, suggesting a possible 
contribution of estrogens.  
According to the Terminology Committee of the Scoliosis Research Society (SRS) 
(1976) and Online Mendelian Inheritance in Man (OMIM 181800), AIS represents 80% of 
all observed spinal deformities, affecting 3-4% of the global pediatric population. [16], 
[17], [18], [19] The annual estimation report of the National Scoliosis Foundation 
demonstrated that AIS incurs more than 600,000 visits to physicians in North America; 
with 30,000 children requiring a brace and 38,000 who undergo a spinal fusion surgery.  In 
the United States, the estimated cost of treating patients hospitalized with a diagnosis of 
idiopathic scoliosis in 2004 was over $3 billion dollars. [20], [21] According to the 
National Scoliosis Foundation statistics, there are six millions persons in the United States 
afflicted with scoliosis, and there is still no cure.  
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Diagnosis of AIS 
In order to diagnose AIS correctly, it is important for doctors to determine the 
nature and symptoms of the deformity. An initial evaluation is performed, which includes 
physical examination, risk assessment based on familial history of the disease, as well as 
imaging techniques if deemed necessary. This evaluation enables the physicians to 
determine if the spinal deformity is primary or secondary to other diseases or disorders.  
Physical examination 
For the screening of scoliosis in schools, physicians, still today, use the Adam's 
forward bend test (figure 1). This physical examination is also used in the offices of 
pediatricians and primary care physicians.  This test, which does not require any equipment 
whatsoever, has been used regularly since 1865 for the screening of spine curvature. 
Nevertheless, in 2005 the US Preventive Services Task Force determined that the test was 
ineffective for the detection of spinal curvatures and recommended against routine IS 
screening. [22] 
Another widely used method for the physical examination of scoliosis is the use of a 
scoliometer (figure 2). Using a scoliometer, a measurment of seven degrees equates to 
twenty degrees in Cobb angle [23], [24].  
These routine tests are not sufficient for the proper diagnosis of idiopathic scoliosis 
and often give rise to false positives, which can lead to incorrect treatment, such as 
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unecessary bracing or referral to specialty care. For accurate diagnosis, an imaging test is 
required.  
 
 
Figure 1: Adam's forward bend test, used for the evaluation of the spinal deformity 
(adapted from Reamy, et al). [25] 
 
 
Normal Spine Abnormal Spine 
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Figure 2: Scoliometer measures the spinal deformity. It is a simple instrument  for the 
detection the spinal curvature (adapted from Franko, et al). [26]  
Imaging test 
The imaging technique is a more  accurate and sensitive method for the detection of 
the disease, and allows the physicians to follow the progression of the spinal deformity. 
Additional tests are ordered, in the event of abnormal neurologic examinations, history of 
severe pain, or presence of rare left thoracic curves, to screen for other factors such as 
tumors. Additional tests may include X-rays, Computed Tomography (CT) scan or 
Magnetic Resonance Imaging (MRI). [27]  The x- rays are an effective method to establish 
the severity of the disease and follow its progression by measuring the Cobb angle. 
However, special precautions need to be taken to limit radiological exposure to avoid the 
development of tumors.  
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stage of observation. Treatment of IS usually begins when the deformity has developed to 
25° to 35°, using different types of braces. In cases where the spine continues to deform (≥ 
45°), spinal surgery is the only remaining solution. [31], [11], [32], [33], [34] Alternatively, 
other treatments such as biofeedback, electric stimulation, physical therapy or chiropractic 
care have not been shown to alter the natural history of scoliosis. [35], [36] Despite many 
studies on its etiology, the cause of AIS remains unclear. Therefore, a better understanding 
of the etiopathogenesis of the disease will enable us to better diagnose, prognose and 
facilitate treatment. 
 
  
 
Figure 4: Scoliosis treatment by bracing and surgery.  
The right panel (A) shows a brace which treats children with spinal deformities (25° to 35°) 
while the left panel (B) shows the surgery intervention to treat children with spinal 
deformities (≥ 45°) (adapted from Moe et al). [37] 
 
(A) (B) 
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Etiology of AIS 
Even though widespread research hypotheses have been proposed, and many 
studies undertaken to examine the roles of the nervous system, environmental factors, 
spinal growth abnormalities, endocrine system, connective tissue abnormalities, hormonal 
factors and genetic factors in the etiology of the AIS, none of these studies really explain 
the cause of IS. [38], [39] [40], [41]  
Many studies were undertaken to investigate the effects of the connective tissues on 
AIS. Researchers studied the collagen and the elastic fiber, the main structural elements of 
the spinal column. Others  showed that proteoglycan and collagen contents are abnormal in 
the intervertebral disc of AIS patients, [42], [43] which raised controversy. [44] Another 
study suggested that the abnormalities of these elements are secondary to AIS and not the 
main cause. [45] Furthermore, elastic fiber abnormalities were observed in the skin and in 
the spinal ligaments of AIS. [46], [47] As a whole, most researchers postulated that these 
abnormalities are secondary to the spinal deformity. [48], [49]  
Over the past years, the neurological abnormalities associated with AIS were 
investigated. It was thought that an abnormal sway pattern caused scoliosis but [50] the 
augmentation of the sway pattern now appears to be secondary to the scoliosis. [51] 
Machida and coworkers postulated that the development of the scoliosis in pinealectomized 
(PNX) chicken is due to somatosensory evoked potentials abnormalities. [52] On the other 
  
 
11
hand, another group postulated that PNX leads to melatonin reduction, in turn affecting the 
nervous system maturation. [53]  
Many studies were undertaken to assess the role of growth factors in AIS 
etiopathogenesis. These studies demonstrated that there is no difference between AIS and 
controls when growth hormone levels were increased. [54] Trontelj et al. demonstrated that 
the height of the vertebral bodies in girls is greater than in boys. [55] Further investigations 
are required to study the effects of these growth factors, hormones and their modulators.  
Biomechanical factors were also studied in AIS. The mechanical properties of the 
spinal tissues, the way that the spine is supported and the forces which lead to abnormal 
loading may also contribute to scoliosis. However, researchers postulated that these factors 
too, are rather secondary to AIS. [56] 
The similarity between the contractile systems of the platelets and the skeletal 
muscle led some researchers to postulate that the abnormalities of the contractile system 
could be involved in AIS etiology. The elevation of the platelet intracellular calcium and 
phosphorous in AIS patients was reported. [57] The elevation of calcium was observed in 
the dense bodies of platelets and they suggested that the defect of the calcium transport in 
the cell membrane or contractile complex could lead to spinal deformity. [57] Calmodulin, 
a well known calcium modulated protein, is a key player, which mediates calcium function 
and regulation in many processes in the eukaryotic organism. The calcium flux via the 
sarcoplasmic reticulum is mediated by the interaction of the calmodulin with (actin and 
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 Genetic Factors of AIS 
Extensive research is being done on the role of the genetic factors in the 
development of AIS. Indeed some studies indicate a higher prevalence of AIS among the 
relatives of AIS patients when compared to the normal unaffected population. [61], [62], 
]63[ , [64]  
The main conclusion of most genetic studies (table 1) regarding AIS is its multi-
factorial nature and possible crosstalk with environmental factors, which remain to be 
identified. However, for most, if not all of these studies, the number of patients and 
families needs to be increased and results replicated in distinct cohorts to confirm their 
validity and clinical utility. 
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Table 1: Summary of genetic studies for AIS 
Year Authors  Subjects Key finding 
1968 Wynne-
Davies 
114 IS patients with their 
family’s history 
IS has a dominant or a multiple-
gene pattern of inheritance. [65] 
1975 Robin and 
Cohen  
Five generations of one 
individual family with adolescent 
idiopathic  
IS has autosomal or multiple-
gene inheritance pattern. [66] 
2002 Chan et al Seven Chinese families with 25 
affected members 
Chromosome 19q13.3 
associated with the disease. [67] 
2005 
& 
2008 
Miller et al 
& L Ocaka, 
et al 
202 families with idiopathic 
scoliosis individuals & 25 multi-
generational British families  
Chromosomal regions on 
chromosome 6, 9, 16 and 17 
associated with the disease. 
[68], [69] 
2009 Gurnett et al 
& Raggio et 
al 
13 affected and 10 unaffected 
family members & 7 multiplex 
families  
Chromosome 18q is associated 
with IS, [70] another study 
showed that the disease is 
associated with Chromosome 
12p. [71] 
2010  Ward et al 
and Ogilvie J 
277 girls with low risk of AIS  
257 girls with higher risk of AIS 
163 boys with high risk of AIS 
All the boys and girls are Caucasian 
The genetic markers associated 
with the severity of the curve. 
[72], [73] 
2012 Gorman et al 50 studies reviewed, both 
pedigree (linkage) and population 
based (association)  
The association of some genes 
with the bone formation, 
metabolism puberty and growth, 
connective tissue structure and 
melatonin signaling pathways. 
[64] 
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 Animal models of AIS 
Animal models are important to enable us to understand many human diseases. 
These models help in the development of suitable treatments. The challenges are to find the 
suitable animal model representing the disease. In AIS, many animal models were 
investigated as shown in tables 2 and 3. These animal models were used to investigate 
many hypotheses like the role of melatonin, genetic, neurological and mechanical factors in 
AIS etiology. Most of the animal data collected supports the role of a melatonin deficiency 
as a cause of AIS. However the work of Cheung et al. [74] on monkeys raised controversy, 
suggesting that melatonin deficiency causes AIS only in lower animals. Gorman et al. 
demonstrated that guppies could be a relevant animal model for the study of scoliosis. In 
fact, this model is the only one that naturally develops scoliosis [75] while the curvature in 
all other scoliosis animal models is induced through surgical interventions. [2], [76]  
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Table 2: Summary of the surgical animal models for AIS  
Melatonin models 
Year Authors Animal 
model 
Experiment  Observation 
1959 Marie-
Jeanne 
Thillard 
Chickens 
 
Removal of pineal 
gland  
Pinealectomized chickens 
developed scoliosis. [77] 
1983 Dubousset 
et al 
Chickens Removal of pineal 
gland 
Pinealectomized chickens 
developed scoliosis, referring 
to the deficiency of the 
melatonin in these chickens. 
[78] 
1993 Machida et 
al 
Chickens Intramuscular 
implantation of the 
pineal body in 
pinealectomized 
chickens 
No scoliosis was observed in 
these chickens. [79] 
1994 Machida et 
al 
Scoliotic 
Chickens  
1-Treatment of PNX 
chicken with serotonin 
2- Treatment of PNX 
chicken with 
melatonin 
1- The group treated with 
serotonin developed scoliosis 
in 73.3 %.  
2- The group treated with 
melatonin developed scoliosis 
in 20 %. [53]   
1999 Machida et 
al 
Rat 1- Control  
2- Removal of pineal 
gland in quadrupedal 
rats 
3- Removal of pineal 
gland in bipedal rats 
implanted with 
melatonin pellet 
4- Removal of pineal 
gland in bipedal rats 
1- 0 % developed scoliosis,  
2- 0 % developed scoliosis, 
3- 10 % developed scoliosis, 
4- 100 % developed scoliosis. 
 
They concluded that the 
bipedal condition in rats is 
essential for the development 
of scoliosis like in chickens 
and humans. [80] 
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Year Authors Animal 
model 
Experiment  Observation 
2001 Bagnall et 
al 
Chickens Study of the 
relationship between 
melatonin levels and 
scoliosis in the 
chicken  
The decrease in melatonin 
levels in young chickens led 
to scoliosis development.[81] 
2005 Cheung et 
al 
Monkeys Removal of pineal 
gland 
None of the pinealectomized 
(PNX) monkeys developed 
scoliosis. They concluded 
that the melatonin deficiency 
leads to scoliosis in the lower 
animals only and not in 
humans. [36] 
2006 Machida et 
al and 
Oyama et 
al 
C57Bl/6j 
mice 
(naturally 
deficient 
in 
melatonin)
Removal of the 
forelimbs of these 
mice (bipedal model) 
Bipedal C57Bl/6j mice 
developed scoliosis; is 
considered a good model for 
the researchers who are 
working on scoliosis. [2], 
[82], [1] 
2009 Fagan et al Chickens Removal of the  pineal 
gland from one 
chicken group and 
used another group as 
a control without 
removal of pineal 
gland 
75% of pinealectomized 
chickens developed scoliosis. 
Chickens developed scoliosis 
naturally in 19%. [83] 
2011 Kono et al Chickens Removal of the  pineal 
gland from two groups 
of chicken, one treated 
with  melatonin 
Deficiency of melatonin is 
suggested to lead to the 
development of scoliosis and 
osteoporosis. [84] 
 
 
 
 
 
Table 2 cont’d 
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Year Authors Animal 
model 
Experiment  Observation 
1989 Suk et al Rabbits Removal of the 
anterior and 
posterior rhizotomies 
separately and together 
in different cohorts 
They postulated that anterior 
root paralysis and posterior 
root paralysis may induce 
scoliosis. [85] 
2009 Lambert et al Xenopus 
laevis 
(frog) 
At the larva stage, 
removal of the 
labyrinthine end organ 
The young frog after the 
metamorphosis developed 
spinal curvature similar to 
AIS. [86] 
 
 
 
Year Authors Animal 
model 
Experiment  Observation 
1980 Beguiristain et 
al  
Pigs Epiphysiodesis in 4 
to 5 consecutive 
vertebrae of 
neurocentral 
cartilage using 
cancellus screws 
Pigs developed structural 
scoliosis. [87] 
1991 Poussa et al Rabbits Use of an external 
splint to stimulate 
lordosis 
- Developed lordosis in the
  thoracolumbar junction    
- 53 % developed scoliosis  
- Lordosis is a precondition 
for development of scoliosis. 
[88] 
1997 Mente et al Rats Application of 
external ring fixators 
to check the 
mechanical effect 
(asymmetrical load) 
on the spine 
-Vertebral wedging is 
formed  
- Rats developed scoliosis. 
[89] 
2009 Zhang et al  Goat Tethering of the
goats unilaterally by 
pedicle screws and 
contralateral rib 
resections
The goats developed 
scoliosis and the curvature 
increased over time and is 
similar to the idiopathic 
deformity. [90] 
 
Mechanical models 
Neurological models 
  Table 2 cont’d 
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Table 3: Genetic models for AIS  
 
 
Year Authors Animal 
model 
Experiment  Observation 
2001 Blanco et al BDL 
mice 
Ky knockout mice  
 
Kyphoscoliosis and 
degenerative myopathy 
suggesting that this ky 
protein (muscle/ brain) is 
important for muscle 
growth, and myopathy 
should be checked in IS 
patients.  [91] 
2007,
2010 
& 
2011 
Gorman et al  Guppy Investigation of the 
spine curvature 
phenotype  through  
the different 
generations  
- Naturally developed 
scoliosis  
- Spinal curvature similar to 
IS in human 
- Suitable model to study the 
genetics associated with 
spinal curvature in IS 
patients. [92], [75], [93] 
 
 
 Clinical implication of melatonin deficiency  
Despite the fact that most of the animal data pointed to a crucial role of melatonin 
deficiency in spinal deformity formation, the majority of the clinical results (table 4) clearly 
demonstrated that melatonin levels were normal in AIS patients. 
  
Genetics models 
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Table 4: Clinical data representing the role of melatonin in scoliosis  
Year Authors Methodology Key finding  
1996 Machida et 
al 
Melatonin levels in AIS 
patients were measured 
during 24 hours and at night 
time compared to the 
controls.  
Melatonin levels in the AIS patients 
were lower than the controls. They 
concluded that melatonin plays a 
vital role in the curvature of the 
spine. [60] 
1996 Bagnall et 
al 
Melatonin levels in AIS 
patients and controls were 
measured. 
No difference among the AIS 
patients and the controls was 
observed. [94] 
1998 Fagan et al Melatonin in AIS patients 
and controls was measured. 
No difference among the AIS 
patients and the controls was 
observed. [95] 
2000 Brodner et 
al 
Melatonin in AIS patients 
and controls was measured. 
The levels of melatonin were similar 
in AIS patients and controls. [96] 
2003 Morcuende 
et al 
Association between the 
adolescent  idiopathic scoliosis 
and melatonin receptor MT2 
studied 
No association between the disease 
and chromosome 4 observed, and no 
mutation found in the coding region 
of the gene for the human melatonin 
receptor. [97] 
2004 Moreau et 
al 
cAMP was measured in 
osteoblast derived from 41 
AIS patients and 11 controls 
after stimulation with 
forskolin in presence of 
increasing doses of 
melatonin   
1- AIS patients were classified into 
three functional groups according to 
their functional responses to 
melatonin.  
2- Melatonin signaling dysfunction 
in AIS is caused by an impairment of 
Gi proteins. [1], [98], [99], [100] 
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Table 4 cont’d 
Year Authors Methodology Key finding  
2007 Suh et al Metabolism of the pineal 
gland in the AIS patients in 
comparison with the control 
subjects studied 
The pineal gland metabolism was 
normal in AIS patients. [101] 
2007  Qui et al Verification of the melatonin 
receptor in AIS patients 
Melatonin receptor MT1 was not 
associated with AIS occurrence but 
MT2 was.  Expression of the MT2 
receptor expressed asymmetrically in 
the AIS patients. [102], [103], [104] 
2007 Azeddine 
et al 
cAMP measured as a 
secondary messenger in 90 
AIS patients and 10 controls 
They confirmed what Moreau et al 
concluded in 2004. [105] 
2010 Akoume et 
al 
A new technique called cellular 
dielectric spectroscopy (CDS) 
was used to verify the 
melatonin signaling in the AIS 
patients  
Moreau et al. results confirmed.  AIS 
patients were classified into three 
different functional groups. Gi 
signaling defect found. [106] 
2013 Yim et al Expression of melatonin 
receptors MT1& MT2 verified. 
MT2 expression shown to be low in 
AIS girls. This abnormal expression 
shown to be associated to an 
abnormal systemic skeletal growth 
(abnormal arm span). [107] 
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 Melatonin signaling in AIS  
Melatonin is a neuro-hormone synthesized mainly by the pineal gland in the brain. 
[108], [109] Its secretion is stimulated by the dark and inhibited by the light, and is  an 
important regulator of the circadian rhythm. Melatonin is a highly important antioxidant 
molecule [110], [111] and its biological effects are through its receptors. In humans and 
other mammals, melatonin classically binds to two G protein-coupled receptors (GPCR) 
called melatonin receptor 1 (MT1 or MTNR1A or Mel1A) and melatonin receptor 2 (MT2 
or MTNR2B or Mel2B), whereas it binds to Xenopus melatonin receptors in non-
mammalian species. Melatonin acts through the activation of Gi protein coupled receptors 
which inhibits the adenylate cyclase activity and stops the conversion of adenosine 
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). [112], [113], [114] Chan 
et al. showed that in MCF-7 cells melatonin stimulates the Gs and increases the cAMP 
accumulation, suggesting a coupling between MT1 or MT2 and Gs, activating adenylate 
cyclase. [115] Melatonin receptor 1 (MT1) also binds to Gq protein, which activates 
phospholipase C (PLC), which in turn converts the phosphatidylinositol 4, 5-bisphosphate 
PIP2 into secondary messengers, IP3 and diacylglycerol (DAG) (figure 6). [116], [117] 
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G proteins 
G proteins represent small guanine nucleotide-binding proteins that play an 
important role in signal transduction of many membrane receptors termed G protein 
coupled receptor (GPCR). G proteins act as molecular switches, transferring the signal 
from the outside of the cell to the inside. The signal is transferred to the cell through several 
effectors such as enzymes, peptides, hormones or channel ions. G proteins are involved in 
many physiological processes and their malfunction has been found in many pathologies. 
[119] The G proteins are heterotrimeric proteins which consist of three subunits called 
alpha (α), beta (β) and gamma (γ). [120] The G proteins are classified according to their α 
subunit: Gαi/o, Gαq, Gα12 and Gαs.  There are 16 genes which encode α subunits, 5 genes 
encode β subunits and 12 genes encode γ subunits in humans. Each alpha subunit binds 
with one beta and one gamma subunit. [121], [122] This classification has gone under 
review following the discovery in recent years of the roles of the βγ subunits. [123] 
The largest subunit is the α subunit (33-55 kDa), which forms a complex with the β 
and γ subunits when it is linked to a guanosine diphosphate (GDP). This is called the 
inactive form of G proteins. Once the GDP converts to guanosine triphosphate (GTP), the α 
subunit dissociates from β and γ subunits and the G protein becomes active. It is in the 
GDP form that it is recognized by the proper receptor, which is activated by specific 
effectors and this receptor is called G protein coupled receptor (GPCR). During the 
interaction of the GPCR and the G protein, GDP is dissociated from the α subunit and is 
replaced by GTP, resulting in a conformational change and dissociation of the α subunit 
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from the βγ subunits. It is at this moment that the α and βγ subunits are able to bind to the 
effector proteins and control their respective functions. The alpha subunits have GTPase 
activity which regress the G protein to the inactive form. [124], [125], [126], [127], [125]  
G proteins play a key role in many biological processes. The impairment of G 
protein signaling is associated with several diseases. Albright’s hereditary osteodystrophy 
(Pseudohypoparathyroidism type 1) is an example and is associated with low serum 
calcium, high serum phosphate, high parathyroid hormone (PTH), bone abnormalities and 
mental retardation, due to the lack of response to the parathyroid hormone. This disease is 
caused by a mutation in Gαs protein leading to a loss of function. [128], [129] Conversely, 
the McCune–Albright syndrome, which is characterized by premature puberty as well as 
bone and skin pigmentation abnormalities, is caused by an activating mutation of the α 
subunit of Gs proteins. [130]  Gαi2 deficient mice were used as the animal model to study 
inflammatory bowel disease because they developed similar symptoms, and thus led to the 
discovery of pharmaceutical treatments. [131] There are two bacterial toxins impeding the 
G-protein inactivation-activation cycle and these toxins are associated with severe diseases. 
These toxins play a crucial role in understanding of G-protein signaling. Pertussis toxin 
(PTX) affects the respiratory system and causes severe coughing spells ending with 
Whooping cough. PTX catalyzes the ribosylation of adenosine diphosphate (ADP) of Gi 
proteins not Gs or Gq, and hinders the coupling of the GiPCR to the Gi proteins. 
Conversely, cholera toxin blocks the GTPase activity of Gs α- subunit through its internal 
ADP-ribosylation for the arginine receptors and Gs protein becomes constitutively 
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activated causing severe dehydration and diarrhea. [119], [132], [133] These toxins help 
researchers to study the specificity of agonists to G protein coupled receptors and their 
cognate G proteins. 
 Osteopontin (OPN) and AIS 
Osteopontin (OPN) is also known as secreted phosphoprotein 1 (SPP1), bone 
sialoprotein I (BSP-1 or BNSP) and early T-lymphocyte activation (ETA-1). [134], [135], 
[136], [137]  
The presence of OPN in skeletal muscle, proprioceptive sensory organs, postural 
control centers such as the cerebellum, and inner ear structures are of particular interest, 
since AIS patients also exhibit defects in postural control, proprioception and equilibrium. 
[138], [139], [140]  
OPN is an extracellular matrix protein with high negative charges. It is composed of 
approximately 300 amino acid residues. Among the mammalian species, OPN cDNA 
exhibits a high degree of homology.  OPN contains different binding sites, which includes a 
polyaspartic acid motif to be able to bind to the hydroxyapatite and the calcium channel. 
[141], [142] It includes two heparin binding domains and contains an arginine-glycine-
aspartic acid (RGD) motif. It also has sites for N – O glycosylation in addition to the serine 
– threonine phosphorylation sites. These sites generate functional forms of OPN in 
different tissues. Alternatively, OPN binds to different receptors like integrin beta 1 (β1), 
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integrin beta 3 (β3), integrin beta 5 (β5) and CD44 isoforms. This diversity of interactions 
gives OPN different functions in different tissues.  
OPN is expressed in different tissues like cartilage, dentin, cementum, skeletal 
muscle, sensory organ, cerebellum, inner ear, sweat and salivary gland, the pancreatic and 
bile ducts, the activated lymphocytes and macrophages, the gut and the kidney. [143],  
[144] OPN is expressed in the bone through osteoblast, osteocyte and osteoclast cells. [145] 
OPN is expressed by fibroblastic cells in the wound healing sites and the connective 
tissues. The secreted protein was observed in the biological fluids like blood, breast milk, 
urine and the seminal fluid. [143], [146],  [147], [148], [149] OPN expression is affected by 
many factors such as cytokines, hormones and growth factors, factors which affect OPN 
transcription, translation and its posttranslational modifications. The regulation of OPN 
expression is not completely understood. Vitamin D is known to stimulate OPN expression 
in bone cells. Conversely, Vitamin D deficient mice have low OPN mRNA expression. 
Platelet derived growth factor (PDGF), transforming growth factor βs (TGF-βs), 
inflammatory cytokines, bone morphogenetic proteins (BMPs), angiogensin II and 
epidermal growth factor (EGF) are factors that up-regulate OPN expression. [144] The 
tumor necrosis factor α (TNF α) and interleukin-1β (IL-1β) are strong stimulators of OPN 
expression.  On the other hand, OPN is down-regulated by bisphosphonates in the bone and 
by cGMP dependent protein kinase in the vascular smooth muscle cells. [142], [141]  
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Many studies have been undertaken to better understand the biological functions of 
OPN. OPN plays an important role in calcification, development, bone remodeling, 
immunoprotection and skeletal tissue homeostasis. OPN protects the cells from apoptosis 
and stimulates the proliferation and the survival of cells, especially smooth muscle and 
epithelial cells. This was shown by inducing apoptosis, by serum deprivation, in endothelial 
cells incubated in a plate coated with OPN. [150], [151], [152], [153] 
There are studies that show that OPN plays a crucial role in bone remodeling, a 
process in which osteoclasts remove old bone and osteoblasts form new bone. Both 
osteoblasts and osteoclasts express OPN and it is found in cement lines (bone formation 
sites) and at the bone surface. The migration of the osteoclasts is stimulated by OPN 
through its receptors, CD44 and integrin αvβ3, aside from the stimulation of CD44 
expression, which is important for motility. [154], [155] 
OPN protects endothelial cells through the activation of nuclear factor kappa B 
(NF-kB) when it binds with integrin alpha v beta 3 (integrin αvβ3) and this stimulates 
osteoprotegerin (OPG). OPG blocks apoptosis when it forms a complex with the TNF-
related apoptosis-inducing ligand (TRAIL). [156], [157] Non-adherent cells on the other 
hand, are protected against apoptosis by OPN through the CD44 receptor and the activation 
of the PI3K-Akt signaling pathway. [158] Taken together, we deduce that OPN can protect 
different types of the cells from apoptosis through different receptors and different 
pathways. 
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OPN is a multifunctional cytokine and is involved in many adult pathological 
conditions. [144], [141] Levels of OPN in the blood, OPN biosynthesis and OPN signaling 
are associated with different diseases. (Table 5) 
Table 5: OPN is associated with many diseases  
OPN abnormalities Pathogenesis 
Serum OPN elevation - Many types of cancer, such as breast cancer [159] 
- Associated to cancer severity [159] 
Plasma OPN elevation  - Coronary artery disease [160] 
- Systemic lupus erythematosus [161] 
- Osteoarthritis [162] 
- Prostate cancer, breast cancer and myeloma [163], [164], [165], 
[166] 
OPN biosynthesis 
stimulation 
- Cardiovascular disease 
- Renal disease (kidney stone - mineralization disorder) 
- Oncogenes association like Src and Ras [141] 
OPN signaling In autoimmune diseases:- 
A- Through integrin beta 3, IL-12 expression is stimulated 
B- Through CD44, IL-10 expression is attenuated [167], [168] 
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OPN receptors 
OPN exhibits different functions through its interactions with distinct receptors. 
This can be explained by the fact that OPN binds to its receptors through different binding 
sites. These receptors are mainly CD44 and integrin receptors. 
CD44 is the receptor for hyaluronic acid and also binds to OPN. CD44 is expressed 
in different types of the cells like osteocytes, fibroblasts, osteoblasts, epithelial and 
endothelial cells and smooth muscle cells. [142] There are many types of cancer like 
glioma, prostate, leukemia initiating cells and breast cancer that express the CD44 receptor. 
This receptor was shown to play a role in the stimulation of the invasion and metastasis in 
different types of cancer. [169], [170]  
Integrins are other known receptors for OPN. They are transmembrane 
heterodimeric receptors which contain alpha (α) and beta (β) subunits. Integrins play a role 
in cell adhesion, allowing the cell to attach to the extracellular matrix (ECM), as well as a 
role in cell signaling. [171], [172] 
The integrins have 18 α subunits and 8 β subunits, which associate together, to give 
no less than 24 heterodimers. [173] These heterodimers play a role in biological processes. 
One of the most widely expressed integrins is integrin β1 which has 12 complexes and 
invokes the binding of the cell with the matrix protein. [173] OPN and integrins can protect 
the cells from programmed cell death (apoptosis) and this was observed in solid cancers, 
for instance breast cancer. It was observed that integrin β1 inhibits apoptosis of cancer cells 
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normally induced by vincristine and paclitaxel, used as chemotherapy by stimulating 
apoptosis, leading to a drug resistance. [174] Other studies found that high expression of 
integrin β1 is associated with poor prognosis due to drug resistance in small cell lung 
cancer. [175], [176] 
 The integrin receptors play important roles in OPN-mediated cell adhesion through 
receptors like integrin beta 1, integrin beta 3 and integrin beta 5. [177], [178], [179] Some 
of these integrin receptors bind to OPN through the RGD motif like αvβ1, αvβ3,αvβ5 α5β1, 
and α8β1 but there are other integrin receptors interacting with OPN through a different  
amino acid sequence, like α4β1 and α9β1. CD44 binds to OPN in a RGD independent 
manner. [180], [181], [182], [183], [184], [185], [186], [187] 
The activation of the integrins requires an interaction with talin. Talin has the ability 
to bind to the cytoplasmic tail of the integrins leading to a conformational change of the 
latter by the separation of the heterodimer subunits of the cytoplasmic tails. This 
conformational change of the integrins allows their binding to cognate agonists. [188] Talin 
needs to be phosphorylated to bind and activate the integrins. The phosphorylation of the 
talin needs serine/ threonine kinases to be phosphorylated, and this process is regulated by 
protein tyrosine phosphatases (PTPases). [189], [190] 
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Protein tyrosine phosphatases (PTPases) 
Protein tyrosine phosphatases (PTPases) are enzymes removing the phosphate 
group from phosphorylated tyrosine residues. PTPases play a vital role in the regulation of 
the signal transduction, which controls many biological processes like differentiation, 
proliferation and apoptosis. [191] The human genome encodes approximately 112 PTPases. 
The specific function of these phosphatases is dependent on their substrate and their 
catalytic domain. [192]  
PTPases are classified according to their function, which mainly removes the 
phosphate from the tyrosine residues. However, other PTPases target the serine and 
threonine residues, and thus these PTPases have a dual function. PTPases work on the 
phospholipids as well as phosphoproteins. [193] 
The PTPases are further classified according to their localization: Non receptor 
PTPases, which are intracellular, and Receptor-like PTPases, which are transmembranous 
and contain PTPase domains, have an extracellular domain, a transmembrane region and 
catalytic cytoplasmic domain. In some cases, the extracellular domains of the receptor 
PTPases contain MAM domains, immunoglobulin-like domains and fibronectin type III 
(FN-III) repeats. While the cytoplasmic region contains two copies of the PTPase domain, 
only one has enzymatic activity while the other remains inactive. [194], [195] 
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PTPases and their roles in the pathogenesis 
Once the identification and classification based on function and location is defined, 
it is necessary to discuss the association between PTPases and the pathogenesis (table 6).  
Table 6: PTPases and their roles in diseases 
PTPase Pathogenesis  The mechanism  
Cell division 
cycle 25 
(cdc25) family 
members 
Overexpressed in  
malignant tumor 
- This family plays a role in DNA repair and 
apoptosis.  
- They allow the replication of DNA of the 
damaged cells 
- cdc25 A or B associated with the poor 
prognosis and not cdc25 C. [196], [197] 
Mitogen-
activated 
protein kinase 
phosphatase 1 
(MKP-1) 
Overexpressed in 
solid tumors like 
prostate cancer, 
pancreatic cancer, 
breast cancer and 
ovarian cancer 
- MKP-1 is PTPase with a dual specific activity. 
- MKP-1  plays a role in the protection of these 
solid tumors from apoptosis [198], [199], [200], 
[201], [202]  
- MKP-1 is associated with the early 
transformation and poor prognosis. [200], [202] 
 
The knockdown of the MKP-1 expression led to the reduction of the tumorigenicity 
in mice, the increase of programmed cell death and the decrease of cell growth in the 
cancer cells. [203], [204] 
 Src-homology 2 domain–containing PTPase 1 (SHP-1) is an example of a PTPase 
acting as a negative regulator. SHP-1 is a negative regulator for immune cell activation and 
cytokine signaling. [205], [206] 
  
 
35
 Hence, Protein tyrosine phosphatase mu (PTPµ) plays a crucial role in AIS; in the 
following section I will describe its structure and functions.    
 Protein tyrosine phosphatase mu (PTPµ): structure, function and role in diseases. 
In 1991 Gebbink et al, isolated 5.4 kb of mouse cDNA, which encodes for a protein 
called receptor protein tyrosine phosphatase mu (RPTPµ), which belong to the receptor-
like protein tyrosine phosphatases family. RPTPµ has an extracellular region [contains a 
meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain and four fibronectin type 
III-like repeats], a single transmembrane region, a long juxtamembrane domain and two 
tyrosine phosphatase domains, D1 and D2 (D1 is catalytically active, while D2 is not) 
(figure 8). Then in 1993, Suijkerbuijk RF et al. mapped the human receptor-like protein 
tyrosine phosphatase gene (PTPRM) to 18p11.2 using fluorescence in situ hybridization. 
[207], [208] 
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It was demonstrated that PTPµ regulates integrins through the dephosphorylation of 
the phosphatidylinositol-phosphate kinase type 1 γ (PIPK1γ). The integrin needs a 
phosphorylated talin to be activated, and PIPK1γ plays this role. PIPK1γ needs to be 
phosphorylated to be activated and this occurs in order to stimulate the formation of 
adherens junctions (AJs). Once integrin completes its role, PTPµ dephosphorylates 
PIPK1γ, inactivating it and indirectly inactivating β integrins. [189] [213], [190] Another 
group demonstrated that β integrins regulate the expression of PTPµ and cell-cell adhesion. 
[214] 
PTPµ also plays a role in the regulation of the neurite outgrowth. It was shown that 
the presence of PTPµ as a substrate in the dish led to neurite outgrowth stimulation. Also, 
the blocking of PTPµ in the developing retina affects the development of the neural retina. 
The dephosphrylation of the tyrosine residues, which is required for both temporal neurite 
repulsion and mediation of nasal neurite outgrowth, needs PTPµ. This tyrosine residue 
dephosphrylation is achieved through the main elements of the cadherin-catenin complex 
and this regulates the axonal migration. [215], [216], [217], [218], [219] Several related 
proteins were discovered such as protein kinase C delta (PKCδ), phospholipase C gamma 
1(PLCγ1) and others. The first two proteins were found to be important substrates for PTPµ 
and which participate in the regulation of neurite outgrowth and cell migration. [220], [221] 
PTPµ downregualtion was observed in the Glioblastoma multiform (GBM) and 
interestingly, the expression level of PTPµ diminished in breast cancer. It is also 
noteworthy, that PTPµ is important for cell invasion and migration through the control of 
ERK and JNK tyrosine phosphorylation. [222], [223]  
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GENERAL OBJECTIVE 
A series of studies from our laboratory initially demonstrated the occurrence of a 
melatonin signaling dysfunction in osteoblasts from progressive AIS patients, due to a 
hyperphosphorylation of Gi proteins. The differential degree of this defect among AIS 
patients allowed their classification into three functional subgroups. In addition, our studies 
have demonstrated that this defect occurs before the development of the spinal deformity. 
In parallel, analysis of plasma of AIS patients has revealed high levels of circulating OPN 
in both non-progressive and progressive AIS patients, as well as in asymptomatic children 
with a family history of AIS. Our general objective is to examine whether there is a cause-
and-effect relationship between these findings in order to gain more insights into the 
potential pathomechanisms leading to the development and progression of AIS. 
Key issues 
The pharmacological aspect of melatonin is not simple. Indeed, melatonin has been 
demonstrated to regulate and influence a variety of biological functions by initiating signal 
transduction through two high affinity receptors coupled to G proteins from the Gi and Gq 
families. [224], [225] Our demonstration that Gi protein-mediated melatonin signaling is 
reduced at different degrees among AIS patients is suggestive of a disparity in melatonin 
signaling pathways. This signaling disparity does not seem to be related to melatonin 
receptors, [97], [16] but rather lies at the Gi protein level. Indeed, we have attributed the 
reduced melatonin signaling to the phosphorylation of Gi proteins by demonstrating an 
increased phosphorylation of serine residues through the three Gi1, Gi2 and Gi3 isoforms in 
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osteoblasts from AIS patients. [16] However, a rational link between the 
hyperphosphorylation of Gi proteins and the different degrees of responses among AIS 
patient groups has not been established and many questions remain to be answered. 
Hypothesis 1 
Since Gi proteins interact with a variety of receptors expressed in many cell types 
throughout the body, we hypothesized that the reduced ability of Gi proteins to transduce 
extracellular signals from receptors is neither confined to osteoblasts nor specific to 
melatonin receptors, but constitutes a systemic and generalized defect in AIS. 
In the first manuscript the following working hypotheses were investigated:  
(1) The activity of melatonin receptor varies among functional groups of AIS patients, 
(2) The affinity of melatonin receptor for its ligands varies among functional groups of 
AIS patients, 
(3) The pattern of interaction between melatonin receptor and Gi proteins differs among 
functional groups of AIS patients, 
(4) The defect occurs in cells other than osteoblasts, 
(5) The defect is extended to other receptors coupled to Gi proteins, 
(6) The phosphorylation pattern of Gi protein isoforms varies among functional groups of 
AIS patients, 
(7) The hyperphosphorylation is due to increased kinase or decreased phosphatase 
activities, 
(8) The involved kinases or phosphatases differ among functional groups of AIS patients, 
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(9) The defect impacts the signaling of other G proteins such as Gs and Gq proteins, 
(10) The defect is a hereditary condition. 
Hypothesis 2 
Since deficient melatonin signaling through Gi proteins occurs before the spine 
deformity appears and given that OPN is elevated in plasma from asymptomatic children 
and patients affected with AIS, we hypothesized that OPN contributes to the onset and 
development of this disease by interfering with Gi protein-mediated signaling. 
 
The second manuscript focused mainly on the possible link between OPN and Gi-
coupled receptor signaling dysfunction occurring in AIS patients. In the second manuscript 
the following working hypotheses were investigated: 
 
(1) A link exists between this defect and the high circulating OPN levels associated with 
AIS, 
(2) OPN contributes to the development of AIS, 
(3) The receptors may or may not be required for the contribution of OPN, 
(4) The incidence and severity of AIS are influenced by changes in the interaction of OPN 
with its receptors. 
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Hypothesis 3 
Since the elevation of OPN was observed in AIS patients and correlates with 
disease severity and the occurrence of a Gi-coupled receptor signaling impairment. We 
hypothesized that, other molecules, like PTPµ, contribute to the AIS pathomechanism by 
modulation of OPN signaling activity. 
The third manuscript focused mainly on the identification and characterization of 
the molecular mechanisms governing the cellular response to OPN, and which cause the Gi 
signaling defect. In the third manuscript the following working hypotheses were 
investigated:- 
(1) A link exists between high circulating OPN levels associated with AIS and PTPµ, 
(2) PTPµ affects the Gi protein signaling defect caused by OPN, 
(3) PTPµ regulates the interaction of OPN with its receptors, 
(4) PTPµ leads OPN to favour α5β1 integrin and not the others integrins. 
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The first manuscript: Disrupted Gi-coupled receptor 
signaling occurs in adolescent idiopathic scoliosis 
Previously by using two different experimental methods we demonstrated that a 
melatonin signaling dysfunction occurs in AIS patients and involves an impairment of Gi 
proteins, leading to their stratification into three functional groups according to the 
variability of their cellular response. In this manuscript, we demonstrated the presence of 
systemic dysfunction of Gi-protein coupled receptor signaling in AIS patients by using 
different type of cells (osteoblasts, PBMCs and myoblasts) and varying concentrations of 
different agonists operating through distinct receptors coupled to Gi proteins. 
 
In this first manuscript, I contributed in the experimental design and in the generation of the 
results. More specifically I did the immunoprecipitation and western blots experiments and 
I have done siRNA transfections for some functional experiments. I reviewed and revised 
the manuscript, and approved the final manuscript as submitted. 
 
Dr. Marie-Yvonne Akoume conceptualized and designed the study, performed the 
CellKeyTM manipulations using CDS technique, some of the siRNA transfections carried 
out the initial analyses, drafted the initial manuscript, and approved the final manuscript as 
submitted. 
Mr. Maxime Veillette performed the CellKeyTM manipulation using CDS technique and 
approved the final manuscript as submitted. 
 Dr. Cedric Julien and Ms. Anita Franco performed the CellKeyTM manipulation using CDS 
technique reviewed and revised the manuscript, and approved the final manuscript as 
submitted. 
 Dr. Hubert Labelle, Dr. Benoit Poitras, Dr. Guy Grimard, Dr. Jean Ouellet, Dr. Stephan 
Parent, Dr. Giovanni Lombardi, Dr. Alessandra Colombini, Dr. Giuseppe Banfi and Dr. 
Marco Brayda-Bruno contributed in the diagnosis of the patients, donated us the bone 
specimens from the AIS patients and the controls subjects and approved the final 
manuscript as submitted. 
Dr. Alain Moreau contributed to the study conception, the analysis and interpretation of the 
data. He critically revised the manuscript for important intellectual content and approved 
the final manuscript as submitted. 
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Abstract 
 
We have previously stratified adolescent idiopathic scoliosis (AIS) patients into 
three functional groups (FG1, FG2 and FG3) representing distinct biological 
endophenotypes and have developed a cell-based assay evaluating melatonin signaling 
through Gi proteins. Here we report that the differential reduction of Gi protein activity 
among AIS groups contributes to a systemic and generalized signaling defect perturbating 
all Gi-coupled receptors due to a selective phosphorylation of Gi alpha subunit isoforms 
involving distinct kinases. AIS patients can be stratified into these three biological 
endophenotypes by any agonist that initiate Gi-mediated signaling, and represent an 
inheritable trait conserved among affected family members. Evaluation of the clinical 
outcomes of AIS patients according to their biological endophenotypes in Canadian and 
Italian cohorts revealed that those classified in FG2 endophenotype are more susceptible to 
developing severe scoliosis, while those in FG1 endophenotype present a much lower risk 
of disease progression. Early detection of scoliosis is not only critical to successful and less 
invasive clinical outcomes but broadens the range of treatment options for clinicians. 
Indeed, improving patients’ stratification and disease staging represent key steps to select 
AIS patients for minimally invasive surgeries before their spinal deformity is too advanced.   
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INTRODUCTION 
 
Adolescent Idiopathic Scoliosis (AIS) is one of the most frequent childhood 
deformities worldwide, characterized by a 3D spinal deformity with unknown cause, and 
represents both an immediate medical challenge and a chronic condition affecting 
individuals throughout their lives. It is the most common orthopedic condition requiring 
surgery in adolescents and affects 4% of this population. Most patients requiring treatment 
are females (90%) and AIS is extremely heterogeneous in its clinical course (Kane, 1977); 
(Weinstein, 1989); (Lonstein, 1994). Unfortunately, patients today are treated in a 
substantially manner to those of twenty or thirty years ago – observation (deformities 
between 10° to 25°), bracing (25° to 35°) and spinal surgery (≥ 45°) as last resort (Negrini 
et al., 2010); (Fazal and Edgar, 2006). Indeed, one of the challenges for orthopaedic 
surgeons is to identify this last category of patients so that appropriate treatment can be 
provided early to prevent surgical complications and cardiac and/or respiratory problems. 
Nowadays, the application of current treatments, such as bracing or surgical correction, is 
delayed until a significant deformity is detected or until a significant progression is clearly 
demonstrated, resulting in a delayed, less than optimal treatment and often important 
psychological sequellaes.  
The major limitation in developing prognostic tests that could facilitate treatment 
choices for patients is the heterogeneous nature of AIS. At the clinical level, the 
heterogeneity of AIS is clearly illustrated by the variability of curve patterns, localisations 
and curve magnitude even in families with multiple affected members. In absence of 
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reliable AIS phenotypes, we have undertaken a research program to understand the 
molecular changes associated with disease onset and spinal deformity progression. 
Molecular definition of disease is rapidly replacing traditional pathology-based disease 
descriptions in part because of its utility in identifying the optimal treatment regimen for 
patients.  It is clear that the same changes are coming for many common chronic diseases 
and scoliosis is no exception. Previously, we have reported the existence of a differential 
melatonin signaling dysfunction among AIS patients leading to their stratification into three 
functional groups or biological endophenotypes (Moreau et al., 2004); (Azeddine et al., 
2007); (Letellier et al., 2008). These results suggested a differential reduction of melatonin 
signaling through a hypofunctionality of Gi proteins among AIS patients. More recently, 
we provided further support to this hypothesis using cellular dielectric spectrometry (CDS) 
technique, which is a label-free method for the functional evaluation of G proteins and 
endogenous receptors coupled to those proteins (Verdonk et al., 2006). We found that the 
cellular response following melatonin receptor stimulation by melatonin was mainly Gi-
dependent in normal osteoblasts and was reduced at different extents in osteoblasts derived 
from AIS patients (Akoume et al., 2010). We have attributed this reduced melatonin 
signaling to posttranslational modifications of Gi alpha subunits by demonstrating an 
increased phosphorylation of serine residues of Gi1, Gi2 and Gi3 isoforms in osteoblasts 
from AIS patients (Moreau et al., 2004).  
 
In this study, we provide the first clinical evidence to our knowledge that a 
differential disruption of Gi alpha subunits occurs in AIS and demonstrate that such 
  
 
47
impairment is caused by a serine phosphorylation of distinct Gi isoforms leading to the 
classification of AIS patients into three biological endophenotypes representing inheritable 
traits. Heritability was clearly demonstrated with the detection of the same endophenotype 
in all family members affected by scoliosis. Evaluation of the clinical outcomes of AIS 
patients according to their biological endophenotypes reveals in two distinct cohorts 
(Canadians and Italians) that AIS patients classified in FG2 endophenotype are more 
susceptible to developing severe scoliosis, while those in FG1 endophenotype present a 
much lower risk of disease progression. In mechanistic in vitro studies, we further 
characterize that hypofunctionality of Gi proteins occurring in AIS led to (a) a systemic 
differential signaling defect affecting Gi-coupled receptors in different cell types, (b) an 
enhancement of Gs- coupled receptor signaling while Gq-coupled receptor signal 
transduction was not compromised, and (c) pharmacological inhibition of selected kinases 
rescued or improved Gi-signaling impairment at the cellular level and such response varied 
in function of each biological endophenotype. Our findings provided the first evidence to 
our knowledge that a differential disruption of Gi-signaling underscores AIS pathogenesis 
and represent a rational basis for the development of innovative prognostic tools and 
pharmacological therapies.      
Results 
Demographic and clinical characteristics of French-Canadian and Italian cohorts. The 
French-Canadian cohorts consisted of 956 consecutive adolescents with AIS and 240 aged-
matched controls without a family history of scoliosis. The absence of spine abnormalities 
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was confirmed in all control subjects, while a total of 162 AIS patients exhibited curvatures 
greater than 45° and 794 AIS patients had curvature between 10° and 44°. In the Italian 
cohort, the moderate curves (Cobb angle 10° - 44°) were apparent in 61 AIS patients and 
the severe curves (Cobb angle > 45°) in 78 AIS patients. All AIS patients were age-
matched with control subjects in both Canadian and Italian cohorts (Table 1).  
 
Clinical outcomes of AIS patients according to their functional classification. Patients were 
classified according to the response degree of their PBMCs to iodomelatonin stimulation as 
indicated in material and method section. Of 956 AIS patients from the Canadian cohort, 
243 were classified in functional group 1 (FG1), 353 in functional group 2 (FG2) and 310 
in functional group 3 (FG3). The prevalence of all three functional groups was comparable 
among low to moderate cases (Cobb angle 10° - 44°). However, the FG2 was predominant 
among severe cases (Cobb angle > 45°) with a proportion of 56 % compared to 31 % and 
13 % for FG3 and FG1, respectively. Similar profile of distribution was observed in the 
Italian cohort in whom surgery was required for 61 % of FG2, 36 % of FG3 and 3% of FG1 
AIS patients. Collectively, these results strengthen the view that clinical outcomes vary 
among AIS patients and suggest that the risk of severe progression is higher for FG2, 
moderate for FG3 and low for FG1 (table 2 and table 3).  
 
Each functional group represents a potential hereditary trait. Since the hereditary or 
genetic basis of AIS has consistently been claimed (Riseborough and Wynne-Davies, 
1973); (Blank et al., 1999); (Roach, 1999), we tested the possibility that the biological 
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defect characterizing each functional group may be a hereditary condition. For this purpose, 
25 individuals from 6 unrelated families were examined. Pedigrees are shown in 
supplementary figure S1. At least two individuals were affected in each family. The 
classification has revealed that all affected family members belonged to the same functional 
group and so displayed similar biological defect (Table 4). However, neither pattern nor 
severity of curve was group specific (Table 4). This suggests that each functional group 
represents a biological endophenotype that co-segregates within families independently of 
curve type and magnitude of spinal deformity. 
 
Deficit in cellular response to melatonin in AIS is associated with a generalized 
impairment of Gi protein-mediated receptor signaling. Melatonin is well known to regulate 
a variety of biological functions by initiating signal transduction through high affinity 
receptors coupled to Gi proteins (Hardeland, 2009). We hypothesized that the melatonin 
signaling dysfunction in AIS was possibly due to changes affecting the melatonin 
receptor/Gi protein coupling. Since the agonist binding to the receptor increases the 
efficiency of receptor/G protein coupling (Mukai et al., 1992), we first examined whether 
the affinity of melatonin for its receptors varies among AIS patients groups. For this 
purpose, concentration-response curves were generated for melatonin using osteoblasts 
from control subjects and compared with those of AIS patients of each biological 
endophenotype. As illustrated in Figure 1A, melatonin caused a concentration-dependent 
increase of response in all control and AIS groups reaching a plateau at 1µM, with the 
higher magnitude in control group and lower but at varying degree within the three AIS 
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groups. The order of magnitude of the maximum response from highest to lowest responses 
was control group, FG3, FG2 and FG1. Despite this apparent discrepancy in the maximum 
response between groups, the half-maximum response was observed at similar 
concentrations in control and AIS groups. These observations suggest that the affinity of 
melatonin receptor for its agonist is preserved in AIS. 
Then, we examined the possibility of changes in the activity of melatonin receptor 
by testing three agonists that have different efficacy to activate melatonin receptor. We 
compared the response produced with their maximum concentration (10 uM) in osteoblasts 
from control subjects and AIS patients of each functional group. Results illustrated in 
Figure 1B show that the three agonists, melatonin, idomelatonin and phenylmelatonin 
evoked various degree of response in osteoblats from control and AIS subjects. The 
response to each agonist was lower in all AIS groups compared to the control group. 
However, the magnitude and the reduction due to AIS in each group reflected the efficacy 
of agonists, the order of agonist potency being phenylmelatonin > iodomelatonin > 
melatonin, as previously reported by other investigators using different methods (Nonno et 
al., 1999). This suggests that the activity of melatonin receptor is comparable between 
control subjects and AIS patients and underscore that deficit is beyond the melatonin 
receptor. 
To examine the possibility that the deficit in melatonin signaling could be related to 
a decreased ability of agonist/receptor complex to activate Gi proteins, we used the G 
protein antagonist GPAnt-2. This hydrophobic peptide has been shown to inhibit 
receptor/Gi protein coupling by competing with the activated receptor for interaction with 
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G proteins (Mukai et al., 1992). Results illustrated in Fig 1C show that GPAnt-2 inhibited 
the response to melatonin stimulation in a concentration-dependent manner in control and 
AIS functional groups. At maximal concentration, the extent of reduction is similar in all 
groups, but at submaximal concentrations, the pattern is clearly different. Concentration-
response curves of all three AIS functional groups exhibited a left-shift compared to that of 
the control group, and the IC50 values were significantly decreased among AIS groups 
when compared to controls. Taking into a count that GPAnt-2 competes with receptors on 
various G proteins, we further selectively decreased the amount of Gi proteins by 
incubating osteoblasts with increasing concentration of pertussis toxin (PTX). We found 
that PTX treatment reduced the cellular response to melatonin in FG2 and FG3 osteoblasts 
exhibiting a pattern similar to the one obtained with GPAnt-2.  In contrast, PTX treatment 
enhanced the response to melatonin in FG1 osteoblasts at maximal concentration (Fig. 1D). 
These data show that the reduced melatonin signaling in AIS is most likely due to a 
decrease in the sensibility of Gi proteins for melatonin receptors, and indicate that the 
melatonin receptors may also interact with Gs in AIS patients classified in FG1. This later 
point is in agreement with a previous report showing that melatonin receptor MT2 
physically interacts with Gs alpha subunit in AIS patients classified in FG1 endophenotype 
(Letellier et al., 2008). 
To determine if the signaling dysfunction through Gi proteins as measured in AIS 
osteoblasts was restricted to melatonin receptors, we performed a comparative study with 
various synthetic compounds activating selectively other receptors coupled to Gi proteins. 
Five compounds were used including, apelin-17, BP554 maleate, lysophosphatidic acid 
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(LPA), UK14304 and somatostatin to activate endogenous APJ, serotonin 5-HT1A, LPA1, 
alpha2-adrenergic and somatostatin (sst) receptors, respectively. As illustrated in Fig. 2, all 
tested agonists caused a concentration-dependent increase of the cellular response, reaching 
a plateau at the same concentration in all control and AIS functional groups. In each case, 
the magnitude of the signaling response was lower in all AIS groups when compared with 
the control group, but the EC50 values were almost identical in all groups indicating that 
the affinity of all tested agonists for their respective receptors is not affected in AIS (Fig. 
2G).  Interestingly, inhibition curves of GPAnt-2 (Figure 3) or PTX (Figure 4) generated 
with any of the five synthetic agonists tested revealed curve patterns similar to those 
obtained with melatonin. In each case, GPAnt-2 reduced the IC50 values in AIS groups 
when compared to control group (Fig. 3G). Similar responses were also observed when 
GPAnt-2 was competed with mastoparan-7 (Fig. 3F), which directly activates Gi proteins 
by mimicking agonist-activated receptor (Higashijima et al., 1990) Moreover, response to 
mastoparan was almost abolished in all AIS and control groups following treatment with 
high concentrations of PTX, further pointing the abnormality at the level of Gi proteins. 
Collectively, these data strengthen the concept that agonist/receptor interaction is not 
affected in AIS, and reveal that AIS patients can be functionally stratified with any 
compounds that activate Gi protein-mediated signaling pathways. On the other hand, by 
extending our analysis to other cell types such as skeletal myoblasts and peripheral blood 
mononuclear cells (PBMCs) from the same set of controls and AIS patients, we found a 
pattern of response similar to that obtained in osteoblats for each agonist tested (Online 
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Supplementary Figures S2 and S3). Overall, these findings are strongly indicative of a 
systemic and generalized impairment of Gi protein-mediated receptor signaling. 
 
Reduction in Gi protein function selectively influences Gs protein function in AIS. Several 
studies using PTX treatment have revealed that abolition of Gi protein function enhances 
the function of Gs protein, presumably by removing the inhibitory input from Gi proteins 
(Itoh et al., 1984), (Anand-Srivastava et al., 1987), (Anand-Srivastava, 1989), (Wesslau 
and Smith, 1992). Accordingly, if Gi protein function is reduced in AIS, enhanced Gs 
protein function would be expected. This possibility was evaluated by screening osteoblasts 
from control and AIS patients for their response to isoproterenol and desmopressin, which 
activate beta-adrenergic and vasopressin (V2) receptors, respectively. Both receptors 
mediate signal transduction through Gs proteins. Results illustrated in (Fig. 5A-B) show 
that cellular responses initiated by both agonists were significantly enhanced in osteoblasts 
from AIS patients when compared with control osteoblasts. For each functional group, 
increased response to Gs stimulation inversely mirrored the reduced response induced after 
Gi protein stimulation, suggesting a functional imbalance between Gi and Gs proteins. To 
further illustrate this divergence, values of the responses to melatonin and isoproterenol 
were reported as differences (Δ) between response to Gi and Gs protein stimulation. As 
illustrated in Figure 5C, response to Gi stimulation predominated in a concentration-
dependent manner in control group. Similar pattern was observed in FG3 group, while no 
apparent imbalance was observed in FG2 group. In contrast, FG1 group exhibited 
predominance for response to Gs stimulation. These data indicate that Gs protein is 
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functionally affected in AIS according to the aberration degree of Gi protein function, 
revealing a profile of imbalance between Gi and Gs protein function specific to each AIS 
group.  
To extend our studies on the functional status of Gq protein, osteoblasts were 
stimulated with bradykinin and endothelin-1. Both agonists elicited similar responses at 
various concentrations in osteoblasts derived from control subjects and AIS patients, 
demonstrating that receptor signaling through Gq protein remains largely intact in AIS 
(Fig. 5D-E). It appears that reduction in Gi protein function in AIS exclusively influences 
Gs protein function.  
 
Divergences in the reduction degree of Gi protein function among AIS groups are not due 
to changes in expression of Gi protein isoforms. The three isoforms of Gi proteins, termed 
Gi1, Gi2 and Gi3 share the same proprieties and most membranous receptors that interact 
with Gi proteins are able to initiate signals via each of these isoforms. However, the 
amplitude of the response depends on the capacity of Gi isoforms to mediate the signal 
transduction while some Gi isoforms seem more efficient than other. We hypothesized that 
the differences in the degree of response characterizing the three AIS biological 
endophenotypes, is due to the differential alteration of Gi proteins isoforms. To address this 
hypothesis, we first sought to examine whether the functional changes observed are due to 
changes in the expression of G proteins. The qPCR analysis revealed no significant change 
in expression of any isoform of Gi proteins (Gi1, Gi2 and Gi3) and Gs protein between 
control and AIS osteoblasts (Fig. 6A). Assuming that PCR-amplification of the different 
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isoforms was equally efficient, it appears that Gi1 and Gi2 were the most abundant isoforms 
of Gi proteins in control and AIS osteoblasts, while the expression level of Gi3 isoform was 
less and quite similar to that of Gs protein. At the protein level, these isoforms have 
revealed no difference between control and any AIS group (Fig. 6B). These results indicate 
that the functional changes observed in osteoblasts from AIS patients were unlikely due to 
aberration in the expression levels of Gi protein isoforms.   
 
Differential phosphorylation patterns affect Gi protein isoforms in AIS. Activity of Gi 
proteins is acutely regulated by phosphorylation, a process that limits their ability to 
transduce signals (Casey et al., 1995); (Katada et al., 1985); (Kozasa and Gilman, 
1996); (Lounsbury et al., 1991); (Lounsbury et al., 1993); (Morishita et al. 1,995); 
(Morris et al., 1995); (Yatomi et al., 1992). We previously reported an increased 
phosphorylation of serine residues of the three Gi1, Gi2 and Gi3 isoforms of Gi proteins in 
osteoblasts from AIS patients (Moreau et al., 2004). To examine whether the functional 
disruption in Gi signaling occurring in AIS can be related to the differential pattern of Gi 
phosphorylated isoforms, we immunoprecipitated Gi isoforms from control subjects and 
AIS patients from each biological endophenotype and probed them with anti-phospho-
serine antibody (Fig. 7). Compared with control group, only Gi1 and Gi3 isoforms were 
phosphorylated in FG3 group, while Gi1 and Gi2 only were phosphorylated in FG2 group. 
However, the three Gi1, Gi2 and Gi3 isoforms were phosphorylated in FG1 group. These 
data provide evidence for a relationship between the phosphoprylation pattern of Gi 
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isofoms and the heterogeneous defect of Gi proteins in AIS and are undoubtedly indicative 
of a difference in the functional status of Gi protein isoforms among AIS groups 
We confirmed the identity of Gi isoforms responsible for the residual response in 
each AIS group using small interference RNA (siRNA) approach to knockdown 
individually or in combination the expression of Gi1, Gi2 Gi3 and Gs prior to stimulate 
osteoblasts with apelin, LPA or somatostatin. Silencing of each gene reduced by 75-85 % 
the expression of the corresponding mRNA in osteoblasts from control and the three AIS 
groups (Fig. 8E-H). In control group, response to any tested agonist was not significantly 
affected by Gi1, Gi2 Gi3 siRNA when transfected alone, but was almost abolished when 
transfected together (Fig. 8A). Response to each tested agonist was reduced by at least 75% 
by silencing Gi3 alone in FG2 osteoblasts, and by 90% by silencing Gi1 alone in FG3 
osteoblasts confirming that the residual response to Gi stimulation is mediated by Gi3 and 
Gi1 isoforms in FG2 and FG3 groups, respectively. In FG1 osteoblasts, response to each 
agonist was reduced by 50% following the depletion of all Gi isoform by siRNA, and was 
not affected by the knockdown of individual Gi isoform. In contrast, the depletion of Gs 
alone reduced the cellular response to any tested agonist by 50% in this AIS group, and was 
devoid of any effect in control, FG2 and FG3 AIS group. This agrees with the idea that Gi-
coupled receptors switch from Gi to Gs in FG1 group (Letellier et al., 2008), and indicates 
that the residual response to Gi stimulation in this functional group is an additive effect of 
Gi-receptors coupling simultaneously to Gs and Gi proteins. 
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Identification of serine/threonine kinases contributing to Gi proteins hypofunctionality in 
AIS. In order to identify putative serine/threonine kinases phosphorylating Gi isoforms in 
AIS, we treated control and AIS osteoblasts with a panel of serine/threonine kinase 
inhibitors prior to their stimulation with two distinct agonists (LPA and somatostatin). Of 
note, Gi stimulation induced via LPA or somatostatin receptor activation by their agonists 
in control osteoblasts was not affected by any kinase inhibitors (Fig. 9). In contrast, 
signaling response was significantly increased in FG1 osteoblasts by Gö8963, which 
inhibits several isoforms of PKC and also by STO-609 acetate, which inhibits three 
isoforms of calmodulin kinase (CaMK1, CaMK2, CaMK4), but was unaffected by KN93 
that inhibits selectively CaMK2. However, both CaMK inhibitors STO-609 acetate and 
KN93 increased the signalling response in osteoblasts from FG2 group, while Gö8963 was 
devoid of significant effect in this AIS group. Cellular response in FG3 osteoblasts was not 
improved by inhibition of neither of PKC nor CaMK. In contrast, the inhibition of Casein 
Kinase 2 (CK2) with D4476 increased response in osteoblasts from FG1 and FG3 groups, 
but not in FG2 osteoblasts, while the inhibition of PKA with H89 increased the signalling 
response in all AIS groups. Expression analysis had revealed a selective increase in the 
expression levels of PKCε, PKCη and CaMK1-δ in FG1 osteoblasts when compared to 
control group (Fig. 10). Neither FG2 nor FG3 osteoblasts have exhibited high expression 
levels of any examined kinase. In contrast, the expression level of CaMK2N1, a natural 
CaMK2 inhibitor, was significantly decreased in FG2 osteoblasts, suggesting that the 
regulatory system of CaMK2 activity is affected in this AIS group. Collectively, these 
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results show that selective functional alteration of Gi protein isoforms in AIS involves 
distinct kinases. 
DISCUSSION 
 Gi protein-mediated receptor signaling is impaired in AIS. Heterotrimeric G 
proteins play a pivotal role in signal transduction in a variety of cell systems by coupling 
many GPCRs types and subtypes to intracellular effectors. The increasing interest in 
clinical perspectives of altered G protein function has yielded important findings about the 
involvement of G proteins in processes leading to certain human diseases. In each case, 
abnormalities in G protein function have been associated with a signaling dysfunction. We 
have initially demonstrated, using two different experimental methods, the occurrence of a 
differential melatonin signaling dysfunction in AIS patients, leading to their stratification 
into three functional groups (Moreau et al., 2004); (Azeddine et al., 2007); (Moreau et 
al., 2009); (Akoume et al., 2010). In this study, we observed that osteoblasts, myoblasts 
and PBMCs from the same AIS patients displayed similar cellular responses in presence of 
varying concentrations of different agonists operating through distinct receptors coupled to 
Gi proteins. This demonstrates that the abnormality affecting Gi protein function in AIS is 
not specifically or exclusively related to melatonin receptors, and strongly argues for a 
generalized and systemic disturbance of Gi-mediated receptor signaling. This is further 
supported by the fact that EC50 values measured for each agonist remained comparable 
between control and AIS functional groups in different cell types, which strongly imply 
that agonist-receptor interactions are not impaired in AIS. Conversely, treatment with 
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GPAnt-2, an antagonist that competes with GPCRs for interaction with G proteins, showed 
also a differential response toward each agonist tested as evidenced by decreased IC50 
values in osteoblasts derived from AIS patients when compared to control ones. This 
reflects indirectly the level of residual Gi activity in each AIS functional group, FG1 being 
the most affected followed by FG2 and to a lesser extent FG3 group. Consistently, the 
result with mastoparan-7, which directly stimulates Gi proteins, further substantiates the 
hypothesis that the defect lies at the level of the Gi proteins because control and AIS 
functional groups were clearly distinguishable by the extent of their maximal response to 
mastoparan-7 stimulation with patterns similar to those observed with melatonin.  
 
 Functional status of Gi and Gs proteins are imbalanced in AIS. Classical paradigm has 
emerged from studies with PTX indicating that reduction in Gi protein function leads to 
increased Gs protein activity. Results presented here are in agreement with such paradigm 
and reveals a parallel relationship between reduced Gi and increased Gs protein functions 
in AIS it was interesting to note that profile of the functional imbalance between Gi and Gs 
protein was specific to each AIS groups, indicating that AIS patients can be clearly 
classified with respect to the profile of imbalance between response to Gi and Gs protein 
stimulation. Such approach advantageously eliminates the necessity to use control subjects 
and allows to monitoring patient responses over time. 
 
Differential alteration of Gi protein isoforms among AIS groups. Several lines of evidence 
support that events leading to the impaired function of G proteins are dependent on disease 
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and can involve altered G protein expression (Gawler et al., 1987); (Bushfield et al., 
1990). However, no significant changes were detected in Gi and Gs isoforms expression at 
the mRNA and protein levels in AIS. Subsequently, we focused our attention on serine 
phosphorylation of Gαi proteins since it inhibits Gαi activity (Houslay and Milligan, 
1997); (Moreau et al., 2004). It was interesting to observe distinct patterns of 
phosphorylation of Gi isoforms among AIS groups. Indeed, all Gi isoforms were 
phosphorylated on serine residues in FG1 osteoblasts, whereas only Gi1 and Gi2 in FG2 
group, and Gi1 and Gi3 in FG3 group were phosphorylated. The detection of 
unphosphorylated Gi3 and Gi2 isoforms respectively in FG2 and FG3 groups could explain 
their higher Gi signaling activity when compared to FG1 group. Nevertheless, FG2 
osteoblasts exhibit a much weaker residual Gi signaling activity when compared to FG3 
osteoblasts, which could be explained by the fact that Gi3 isoform is less abundant in 
human osteoblasts as demonstrated in the present study. The selective depletion of Gi3 and 
Gi1 isoforms in FG2 and FG3 osteoblasts respectively almost abolished their cellular 
responses to three distinct Gi-coupled receptors in a similar manner, further confirming the 
functional status of Gi3 and Gi1 isoforms in these two AIS groups. It is tempting to 
speculate that the loss of function of other Gi isoforms may be compensated by Gi3 isoform 
in FG2 and by Gi1 in FG3 group, which is consistent with the concept that each Gi isoform 
can partially rescue Gi signaling (Hurst et al., 2008). However, our previous data obtained 
with cAMP assays showed that FG2 osteoblasts were unable to inhibit cAMP production 
induced by forskolin stimulation (Moreau et al., 2004); (Azeddine et al., 2007). 
Accordingly, the identification of Gi3 as the remaining functional Gi isoform in this AIS 
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group is agreement with several reports indicating that Gi3 does not contribute to the 
inhibition of cAMP production (Chen and Manning, 2001); (McClue et al., 1992).  
It is of interest that depletion of all Gi isoforms by siRNA in control, FG2 and FG3 
osteoblasts translated in a 90% reduction in GPCR signaling activity elicited by three 
distinct agonists, while knockdown of Gs protein had no effect. More interestingly, 
depletion of the three Gi isoforms in FG1 osteoblasts reduced only by 50% the signaling 
activity of these distinct GPCRs. These findings, together with results from our 
experiments with high PTX concentrations, suggest the presence of a compensatory 
mechanism involving other G proteins in FG1 osteoblasts. Conceptually, it is possible that 
phosphorylation of all Gi isoforms allows or facilitates the coupling of Gs proteins to Gi-
coupled receptors in FG1 osteoblasts. Such possibility was clearly demonstrated by the 
simultaneous deletion of Gs and all Gi isoforms, which almost abrogated completely the 
signaling activity in FG1 osteoblasts. On the other hand, the three GPCRs tested did not 
activated Gs mediated signaling in FG2 and FG3 osteoblasts, which strongly suggest that 
Gs protein access to these receptors is limited by the presence of Gi3 and Gi2 isoforms, 
which are not phosphorylated in these groups. Of note, depletion of Gs proteins alone did 
not abolish the signaling activity in FG1 osteoblasts despite the fact that all three Gi 
isoforms were phosphorylated suggesting a possible heterogeneity in the number and 
position of serine residues phosphorylated among AIS functional groups. It is conceivable 
that phosphorylated Gi proteins in FG1 osteoblasts still exhibit some residual activity as 
opposed to phosphorylated Gi isoforms in FG2 and FG3 groups.  
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Contributions of PKC and CaMK in Gi-coupled GPCR signaling disruption in AIS. By the 
application of specific kinase inhibitors, PKC, PKA and CaMK were shown to be involved 
in the differential Gi agonists induced responses in AIS functional groups. It has been 
reported that PKC can phosphorylate Gi1 and Gi2, but not Gi3 in vitro leading to their 
inactivation activity (Murthy et al., 2000). Pharmacological inhibition of PKC with 
Gö6983 caused an increased signaling response to LPA and somatostatin agonists in FG1 
osteoblasts, but not in FG2 and FG3 osteoblasts. It is possible that phosphorylation of Gi1 
and Gi2 isoforms in FG2 and FG3 might be due to other serine/threonine kinases, such as 
PKA. Indeed, it has been shown that PKA phosphorylates Gi2 (Bushfield et al., 1991). Our 
observation of significant increase in response to Gi stimulation in all AIS groups 
following inhibition of PKA with H89 indicates that the Gi defect in AIS involves, at least 
in part, the action of PKA. A possible role for Calmodulin kinase (CaMK) as a contributor 
to Gi defect cannot be ruled out since the pre-treatment of AIS osteoblasts with STO-609 
acetate to inhibit three isoforms of Calmodulin kinase (CaMK1, CaMK2 and CaMK4), 
increases the response in FG1 and FG2 osteoblasts significantly. Interestingly, the fact that 
the selective inhibition of CaMK2 enhanced response in FG2, but not in FG1, suggests that 
this CaMK isoform as a specific player for FG2. Of particular interest was the different 
level of expression of PKC and CaMK isoforms among AIS groups. We noted that PKC-ε, 
PKC-η and CaMK1-δ isoforms were significantly up-regulated in FG1, but unchanged in 
FG2 and FG3. All other PKC and CaMK isoforms were not significantly altered in any of 
the AIS groups (Online Supplementary Figures S5 and S6). The increase in PKC-ε, PKC-η 
and CaMK1-δ expression in FG1 would be expected to enhance their activity, and 
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consequently their inhibitory effect, thus justifying the increased response observed in this 
AIS group following their inhibition. In contrast, the normal levels of CaMK2 was not 
consistent with the hyperresponsiveness obtained in FG2 following the inhibition of this 
kinase with KN93. However, its inhibitor, CaMK2N1, was significantly downregulated in 
this AIS functional group, suggesting that a possible dysregulation of CaMK2 activity in 
FG2. Collectively, these observations suggest a selective involvement of PKC-ε, PKC-η 
and CaMK1-δ for FG1 and CaMK2 for FG2, in the phosphorylation of serine residue of the 
concerned Gi protein isoforms. No evidence was obtained to suggest the involvement of 
these kinases in the phosphorylation of Gi proteins in FG3. In contrast, despite the presence 
of normal levels of casein kinase (CK) isoforms, we postulate that this serine/threonine 
kinase may be responsible for the phosphorylation of serine residue of Gi3 isoform. The 
increased response obtained in FG1 and FG3 following the inhibition of CK1 with D4476, 
but not in FG2 in which Gi3 is not phosphorylated, might offer support to this assumption. 
Nevertheless, further work is needed before this aspect can be clarified. 
 
Potential usefulness of Gi protein defect in predicting prognosis and treatment of AIS. The 
progression of AIS is often unpredictable and manifestations of this disease become life 
threatening when curve exceed 70 degrees, making surgery inevitable. Indeed, there is 
consensus about surgery treatment in a minority of patients with spinal curvature greater 
than 45 degrees. Gratifying results associated with this treatment when performed at early 
ages continually stimulate interests in the development of prognostic approaches to predict 
progressive disorders requiring surgery. Previously, we have validated classification of 
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individuals on the basis of Gi protein defect as prognostic test to identify sooner the 
asymptomatic children at risk of developing AIS. In the current study, we report that 
patients classified in FG2 are more susceptible of significant AIS progression as 
demonstrated by the higher prevalence of this endophenotype group among severe AIS 
cases. The similarity of this distribution pattern between Canadian and Italian cohorts 
strongly suggests that FG2 can serve as reference endophenotype to predict the type of 
patients at risk to require surgery in both Canadian and Italian populations. However, the 
application of this reference in other population needs to be validated. 
The current concept considers AIS as a multigene dominant condition with a strong pattern 
of inheritance (Riseborough and Wynne-Davies, 1973); (Blank et al., 1999); (Roach, 
1999). Results presented here support such concept as evidenced by the classification of all 
affected family members in the same endophenotype group. Interestingly, the genealogical 
information for one of six families enrolled in the study allowed us to detect the feature as 
far as the proband’s grandmother. Based on these finding, it can be envisaged that, besides 
the affected individuals, other at risk family members could also be classified before the 
development of spinal deformity and then, if required, surgery treatment could be provided 
in timely manner. Indeed, physicians commonly prescribe bracing to all patients at risk of 
progression. However, some patients still receive failure outcome and have often to be 
confronted with surgery when spine becomes more rigid or more deformed and 
consequently results are less fruitful. It could be very beneficial if evaluation of Gi protein 
defect could also predict the outcome of brace treatment. In this point, due to the small 
number of patients wearing brace among severe cases enrolled in the present study, we do 
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not have solid data to demonstrate that FG2 can also represent patients likely to be resistant 
to brace treatment. To address this issue, we have undertaken a study of large cohort of 
patients, followed in longitudinal, with the intention of determining if certain 
endophenotype groups will better respond to brace treatment and also if certain types of 
braces will provide more fruitful results to specific endophenotype groups. Nevertheless, 
the present study provides convincing evidences that evaluation of Gi protein defect can 
help clinicians in the decision regarding the surgery treatment. Overall, results confirm our 
functional classification test and demonstrate the potential usefulness of this classification 
in predicting clinical outcome of AIS patients. Furthermore, these data offer a molecular 
platform for developing the pharmacological options for the personalized treatments. 
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METHODS 
French-Canadian patients (Montreal’s cohort) 
This study was approved by the institutional review boards of The Sainte-Justine 
University Hospital, The Montreal Children’s Hospital, and The Shriners Hospital for 
Children. Three populations including children with AIS, families of children with AIS and 
control subjects were enrolled in the study. Healthy children recruited in Montreal’s 
elementary schools and Trauma cases were used as controls. The recruitment was approved 
by the Montreal English school Board, The Affluent School Board and all institutional 
review Board mentioned above. Parents or legal guardians of all participants with or 
without AIS gave their informed written consent, and minors gave their assent. All 
participants were examined by one of the seven orthopedic surgeons (H.L., B.P., C-H.R., 
G.G., J.O., M.B-B., S.P.) participating in this study.  
 
Italian patients (Milano’s cohort) 
A total of 139 consecutive AIS patients and 103 controls subjects were enrolled at 
the IRCCS Istituto Ortopedico Galeazzi (Milano, Italy) and represent a replication cohort. 
This replication study was approved by the institutional review board of IRSCC and The 
Sainte-Justine University Hospital. All patients were examined by one orthopedic surgeon 
(M.B-B).  
 
Cell preparation and culture 
Osteoblasts were isolated from bone specimens obtained intraoperatively from 
vertebras (varying from T3 to L4 according to the surgical procedure performed) and from 
other anatomical sites (tibia or femur) in AIS patients and trauma control cases, 
respectively as previously described (Moreau et al., 2004).  
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Myoblasts were isolated from biopsy specimen of skeletal muscle obtained from 
AIS and trauma control patients. Each biopsy specimen was cleared of remains fatty and 
connective tissue prior to be cut into smaller pieces. The tissue pieces were then transferred 
into PBS solution containing 0.01% collagenase, and digested for 45 min at 37 ºC. After 
dilution with culture media (1:1), the solution was filtered in sterile conditions through a 
nylon filter of 45 µm prior to the centrifugation at 280 x g for 5 min at room temperature. 
The pallet containing myoblasts was suspended in culture media (alpha-MEM) 
supplemented with 20% foetal bovine serum (certified FBS; Invitrogen, Burlington, ON, 
Canada), and 1% penicillin/ streptomycin (Invitrogen). After two weeks, culture media was 
replaced by fresh culture media supplemented with 10% FBS and 1% penicillin/ 
streptomycin and myoblasts were allowed to grow until confluence.  
Peripheral blood mononuclear cells (PBMC) were extracted from blood obtained 
from patients and control groups, as previously described (Akoume et al., 2010).  
 
Functional classification 
Patients were classified by evaluating the functional status of melatonin signaling in 
PBMC with cellular dielectric spectroscopy (CDS), using CellKeyTM apparatus, as 
previously described (Akoume et al., 2010). The impedance that reflects the cellular 
changes resulting from ligand/receptor interaction was measured for 15 minutes to monitor 
the cellular response to 14-4M iodomelatonin stimulation. The classification was achieved 
according to the following value ranges of impedance: between 0 and 40 ohms for FG1, 
between 40 and 80 ohms for FG2 and between 80 and 120 ohms for FG3. All control cases 
exhibiting the response extent less than 120 ohms were excluded from the study. 
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Functional evaluation of G proteins 
 The functionality of Gi, Gs and Gq proteins was evaluated by CDS assay in 
osteoblasts, myoblasts and PBMCs from the same individuals, using CellKeyTM apparatus, 
as previously described (Akoume et al., 2010).  
 
RNA interference 
 All Gi1, Gi2, Gi3, Gs and scrambled siRNA were obtained from Ambion (Ambion 
USA). The sequences used for gene silencing are shown in supplemental Table 3. 
Osteoblasts from control subjects and AIS patients were transiently transfected in serum-
free medium, using Lipofectamine RNAiMAX reagent (Invitrogen) according to the 
manufacturer’s instructions and functional experiments were performed 48h post 
transfection. The gene knockdown was evaluated by quantitative real-time PCR (qPCR).  
 
Quantitative real-time PCR  
RNA was isolated from osteoblasts using TRIzol reagent (Invitrogen) according to 
the manufactur’s protocol. Total RNA (1µg) was reverse-transcribed into cDNA using 
Tetro cDNA synthesis Kit (Bioline). Following cDNA synthesis, qPCR was performed 
using a PCR master mix containing QuantiTect SYBR Green PCR Master Mix (QIAGEN, 
Ontario, Canada). Transcript expression was assessed with the Stratagene Mx3000P 
(Agilent Technologies, La Jolla, CA) and calculations were performed according to the 
ΔΔCT method using β-actin as internal control. The sequences of the forward and reverse 
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primers used for identification of human mRNA of our interest genes are shown in 
supplemental Table 4. 
 
G protein expression in osteoblasts  
 Expression levels of Gi proteins isoforms and Gs protein were determined using 
standard western blotting technique. In brief, osteoblasts from AIS patients and trauma 
control cases were lysed in RIPA buffer (25 mM Tris.Hcl pH7.4, 150 mMNaCl, 1 % NP-
40, 1 % sodium deoxycholate, 0.1 % SDS) added with 5 mMNaVO4 and protease inhibitor 
cocktail (Roche molecular Biochemicals, Mannheim, Germany). Immunoblots were 
performed with primary antibodies directed specifically against Gi1, Gi2, Gi3 or Gs (Santa 
Cruz Biotechnology, Santa Cruz, CA) and peroxidase-conjugated secondary antibody. 
Bands were then visualized using SuperSignal chemilunescent substrate (Pierce, Rockford, 
IL) 
 
Assessment of phosphorylation of Gi protein isoforms in osteoblasts  
 Comparative studies were performed to examine the level of phosphorylation and to 
identify the phosphorylated Gi isoform with immunoprecipitated proteins using isoform 
specific antibodies and, subsequently, probing the level of phosphorylation with a phospho-
serine/threonine specific antibody (Santa Cruz Biotechnology). Whole cell proteins (1mg) 
were incubated with anti-Gi1, anti-Gi2 or anti-Gi3 (Santa Cruz Biotechnology), plus protein 
G beads for immunoprecipitation (IP) at 4 °C overnight. Purified proteins were loaded on 
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10 % gel after IP, then, processed for gel transferring to nitrocellulose membrane and 5 % 
BSA blocking. Membranes were exposed to phospho-serine/threonine specific antibody at 
4 °C overnight and, subsequently, treated with secondary antibody at room temperature for 
1 h. Bands were visualized using SuperSignal cheminescence, and quantified by 
densitometric scanning.  
 
 Statistical analysis 
Data are presented as mean ± SE, and were analyzed by ANOVA or Student’s t test 
using GraphPad Prism 4.0 software. Multiple comparisons of means were performed with 
one-way ANOVA followed by a post-hoc test of Dunnett. Only P values < 0.05 were 
considered significant. 
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Figure Legends 
Figure 1 The functionality of melatonin receptor is not impaired in AIS. (A) 
Comparison of concentration-response curves for melatonin between control and AIS 
functional groups. Data were normalised to maximal response in cells from control 
subjects. (B) Comparison of response to melatonin and its analogues. Cells were stimulated 
with the same concentration (1 uM) of melatonin, iodomelatonin or phenylmelatonin. The 
impedance represented in y-axis as dziec, indicates the resistance (ohms) of the cells 
toward the electric current applied by the Cellkey apparatus and represents the integrated 
cellular response. (C, D) Inhibition curves for response to melatonin following a treatment 
of (C) 4h with GPAnt-2 and (D) 16 hours with pertussis toxin. (E) EC50 and IC50 values of 
melatonin and GPAnt-2 in each functional group. Data are expressed as mean (± SE) of n = 
12 patients per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
 
Figure 2 The AIS functional groups are distinguished by the degree of response to 
various specific agonists of Gi-coupled receptors in osteoblasts. (A, B, C, D, E, and F) 
Agonists and targeted receptors are indicated in left corner of each panel. Data were 
normalised to maximal response in cells from control subjects. (G) EC50 values of tested 
compounds in each functional group. Data are expressed as mean (± SE) of n = 12 patients 
per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
Figure 3 Inhibition curves of GPAnt-2 on response to various selective agonists of Gi-
coupled receptors. (A, B, C, D, E, and F) Osteoblasts from control subjects or AIS 
patients of different groups were preincubated with varying concentrations of GPAnt-2 for 
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4h prior stimulation with 1 uM of specific synthetic agonist. The tested agonists and 
targeted receptors are indicated in left corner of each panel. Data were normalised to 
maximal response in cells from control subjects. (G) Table of IC50 values GPAnt-2 for each 
tested compound in each functional group. Data are expressed as mean (± SE) of n = 12 
patients per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
 
Figure 4 Inhibition curves of PTX on response to various selective agonists of Gi-
coupled receptors. (A, B, C, D, E, and F) Osteoblasts from control subjects or AIS 
patients of different groups were preincubated with varying concentrations of PTX for 16h 
prior stimulation with 1 uM of specific synthetic agonist. The tested agonists and targeted 
receptors are indicated in left corner of each panel. Data were normalised to maximal 
response in cells from control subjects. Data are expressed as mean ± SE of n = 12 patients 
per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
 
Figure 5 Functional status of Gs and Gq proteins in osteoblasts from control and AIS 
functional groups. The functionality of Gs protein was evaluated by challenging cells with 
(A) Isoproterenol or (B) Desmopressin. (C) The difference between response to Gi and Gs 
stimulation was calculated at various concentrations, and the functionality of Gq was 
assessed by challenging cells with Bradykinin (D) or Endothelin-1 (E). Receptor subtype 
targeted by the indicated agonist is put between parentheses. Data were normalised to 
maximal response in cells from control subjects. (F) EC50 values of tested compounds in 
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each functional group. Data are expressed as mean (± SE) of n = 12 patients per group. * P 
< 0.05, **P < 0.01, ***P < 0.001, vs control group. 
 
Figure 6 Expression of Gi and Gs proteins is similar between AIS functional groups. 
(A) Total RNA were extracted from osteoblasts and qPCR was used to compare mRNA 
expression levels of Gi1, Gi2, Gi3 and Gs genes in control relative to the AIS functional 
groups. β-actin was used as internal control. (B) Lysates were obtained from osteoblasts of 
each functional group. Equal amonut of proteins (40 ug) of each lysate was resolved by 10 
% SDS-PAGE and imminoblated for Gi1, Gi2, Gi3 or Gs proteins.  
 
Figure 7 Differential phosphorylation pattern of Gi protein isoforms in AIS functional 
groups.  Whole osteoblasts cells from control or AIS patients were subjected to 
immunoprecipitation with antibody of (A) Gi1, (B) Gi2 or (C) Gi3 and these precipitates 
were resolved by 10 % SDS-PAGE and immunoblotted for phospho-serine/threonine 
specific antibody. The bands were quantified by densitometric scanning. Values are 
expressed as mean ± SE, of n = 6 patients per group. * P < 0.05, **P < 0.01, ***P < 0.001, 
vs control group.  
Figure 8 Differential effects of Gi and Gs siRNA on response to Gi stimulation in AIS 
functional groups. Osteoblasts from (A) control subjects, (B) FG3, (C) FG2 and (D) FG1 
were transfectected with Gi1, Gi2, Gi3, Gs siRNA alone or in combination, or with 
scrambled siRNA, as indicated in Material and Method section.  Efficiency of siRNA was 
verified with qPCR in each functional group (B, D, and F) 48 hours after transfection, and 
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response to Gi stimulation was evaluated by challenging cells with Apelin-17, LPA or 
Somatostatin. Data were normalised to response in cells transfected with scrambled siRNA, 
and are expressed as mean ± SE, of n = 6 patients in each functional group. * P < 0.05, **P 
< 0.01, ***P < 0.001, vs control group. 
 
Figure 9 Effect of various serine/threonine kinase inhibitors on response to Gi 
stimulation in osteoblasts from control and AIS functional groups. Cells were treated 
with PKA inhibitor H89 (5 uM),PKC inhibitor Gö6983 (5 uM), CaMK (1,2,4) inhibitor 
STO-609 acetate (5 uM), CaMK-2 inhibitor KN93 (5 uM), CK1 inhibitor D4476 (5 uM) or 
vehicle for 1 hour prior to the stimulation with (A) LPA ( 10-6 M) or (B) Somatostatin (10-
6 M). Data were normalised to response in osteoblasts treated vehicle, and are expressed as 
mean ± SE, of n = 12 patients in each functional group.  * P < 0.05, **P < 0.01, ***P < 
0.001, vs control group. 
 
Figure 10 Expression of various serine/threonine kinases in AIS. (A) Total RNA were 
extracted from osteoblasts and qPCR was used to compare mRNA expression levels of 
PKC, PKA, CaMK and CK isoforms in control relative to the AIS functional groups. β-
actin was used as internal control. (B) Lysates were obtained from osteoblasts of each 
functional group. Equal amount of proteins (40 ug) of each lysate was resolved by 10 % 
SDS-PAGE and imminobloted for proteins of indicated kinase isoforms.   
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Supplemental figure S1 Representative pedigrees of families with a positive history of 
AIS. The circles represent females and the squares represent males. The symbol for 
affected individuals is filled in and the indicated numbers correspond to individuals listed 
in Table 4 that illustrates their functional groups and their clinical data 
 
Supplemental figure S2 The AIS functional groups are distinguished by the degree of 
response to various specific agonists of Gi-coupled receptors in myoblasts. (A, B, C, D, 
E, F) (A, B, C, D, E, and F) Agonists and targeted receptors are indicated in left corner of 
each panel. Data were normalised to maximal response in cells from control subjects. (G) 
EC50 values of tested compounds in each functional group. Data are expressed as mean (± 
SE) of n = 12 patients per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
 
Supplemental figure S3 The AIS functional groups are distinguished by the degree of 
response to various specific agonists of Gi-coupled receptors in PBMCs. (A, B, C, D, 
E, F) (A, B, C, D, E, and F) Agonists and targeted receptors are indicated in left corner of 
each panel. Data were normalised to maximal response in cells from control subjects. (G) 
EC50 values of tested compounds in each functional group. Data are expressed as mean (± 
SE) of n = 12 patients per group. * P < 0.05, **P < 0.01, ***P < 0.001, vs control group. 
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Figure 1
E
Control FG1 FG2 FG3
Melatonin
EC50 (nM) 68.46 ± 0.36 66.68 ± 0.91 70.6 ± 0.43 69.89 ± 0.51
GPAnt-2
IC50 (uM) 13 ± 0.19 0.16 ± 0.03*** 0.54 ± 0.03*** 1.37 ± 0.46***
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Figure 2
Control FG1 FG2 FG3G
EC50 EC50 EC50 EC50
(nM) (nM) (nM) (nM)
Apelin-17 34.37 ± 0.30 34.07 ± 2.64 36.07 ± 0.93 35 ± 0.39
BP554 69.57 ± 0.65 71.78 ± 0.28 70.45 ± 0.64 70.12 ± 0.49
LPA 8.762 ± 0.49 10.13 ± 0.63 9.85 ± 0.44 9.35 ± 0.23
Somatostatin 24.32 ± 0.25 23.93 ± 1.01 24.75 ± 0.62 24.35 ± 0.27
UK14304 15.46 ± 0.22 16.19 ± 1.18 15.34 ± 0.55 15.88 ± 0.28
Mastoparan 18.98 ± 0.29 19.14 ± 1.90 18.35 ± 0.52 18.84 ± 0.33
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Figure 3
Control FG1 FG2 FG3
G
IC50 IC50 IC50 IC50
(uM) (uM) (uM) (uM)
Apelin-17 12.8 ± 0.27 0.07 ± 0.01*** 0.13 ± 0.23*** 1.76 ± 0.30***
BP554 19.6 ± 0.19 0.09 ± 0.02*** 0.35 ± 0.3*** 2.76 ± 0.27***
LPA 7.86 ± 0.17 0.11 ± 0.03*** 0.89 ± 0.22*** 1.58 ± 0.23***
Somatostatin 13.7 ± 0.15 0.08 ± 0.02*** 0.45 ± 0.27*** 1.76 ± 0.30***
UK14304 17.1 ± 0.19 0.05 ± 0.02*** 0.71 ± 0.31*** 1.76 ± 0.30***
Mastoparan 51.3 ± 0.20 0.08 ± 0.02*** 0.99 ± 0.15*** 9.63 ± 0.27***
 
 
 
 
  
 
84
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120   Apelin
 (APJR)
A
Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120 UK14304
(α2-ADR)
E
Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120 Somatostatin
(SSTR)
D
Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120   PB554
(5-HT1R)
B
Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120    LPA(LPAR)
C Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0
0
20
40
60
80
100
120 Mastoparan-7
 (Gi proteins)
F
Control
AIS FG1
AIS FG2
AIS FG3
 PTX, Log[μg/mL]
%
 m
ax
im
um
 r
es
po
ns
e
Figure 4
 
 
  
 
85
-11 -10 -9 -8 -7 -6 -5
0
50
100
150
200
250
300
350 Isoproterenol
   (β2-ADR)
A
Control
AIS FG1
AIS FG2
AIS FG3
Log[M]
%
 m
ax
im
um
 r
es
po
ns
e
-11 -10 -9 -8 -7 -6 -5
0
50
100
150
200
250
300
350 Desmopressin
        (V2R)
B
Control
AIS FG1
AIS FG2
AIS FG3
 Log[M]
%
 m
ax
im
um
 r
es
po
ns
e
-11 -10 -9 -8 -7 -6 -5
-20
-10
0
10
20
30
C Control
AIS FG1
AIS FG2
AIS FG3
 Log[M]
ΔG
-11 -10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120 Bradykinin
   (B2R)
D
Control
AIS FG1
AIS FG2
AIS FG3
Log[M]
%
 m
ax
im
um
 r
es
po
ns
e
-11 -10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120 Endothelin-1
    (ETR)
E
Control
AIS FG1
AIS FG2
AIS FG3
 Log[M]
%
 m
ax
im
um
 r
es
po
ns
e
Figure 5
Control FG1 FG2 FG3
F
EC50 EC50 EC50 EC50
(nM) (nM) (nM) (nM)
Isoproterenol 2.79 ± 0.59 2.7 ± 0.23 2.77 ± 0.46 2.94 ± 0.32
desmopressin 6.98 ± 0.37 6.6 ± 0.25 6.82 ± 0.25 6.5 ± 0.33
Bradykinin 18.92 ± 0.29 20.91 ± 0.27 19.87 ± 0.23 22.42 ± 0.27
Endothelin-1 11.67 ± 0.49 18.58 ± 0.30 14.41 ± 0.26 12.56 ± 0.26
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Canadian Cohort Italian Cohort
N Mean Age (years) N Mean Age (years)
Healthy control subjects 240 12.4 ± 3.2 103 11.0 ± 1.6
AIS patients
Cobb Angle < 44 % 794 13.0 ± 2.6 78 13.6 ± 2.8
Cobb Angle > 45 % 162 15.1 ± 2.1 61 13.8 ± 2.2
Table 1
Demographic data of AIS patients and healthy control subjects
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Table 2
Clinical data of AIS patients classified into functional groups
Canadian Cohort
Cobb Angle < 44 ° Cobb Angle > 45 ° Curve type
N (%) Cobb Angle (°) N (%) Cobb Angle 
(°)
Single 
N (%)
Double 
N (%)
Triple 
N (%)
FG1 222 (28) 20.0 ± 10.1 24 (13) 60.8 ± 12.4 97 (51) 85 (45) 7 (4)
FG2 262 (33) 21.5 ± 9.5 45 (56) 60.0 ± 10.8 144 (48) 140 (46) 19 (6)
FG3 310 (39) 18.9 ± 9.4 26 (31) 60.7 ± 12.6 206 (54) 157 (41) 19 (5)
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Table 3
Clinical data of AIS patients classified into functional groups
Italian Cohort
Cobb Angle < 44 ° Cobb Angle > 45 ° Curve type
N (%) Cobb Angle (°) N (%) Cobb Angle 
(°)
Single 
N (%)
Double 
N (%)
Triple 
N (%)
FG1 222 (28) 20.0 ± 10.1 24 (13) 60.8 ± 12.4 97 (51) 85 (45) 7 (4)
FG2 262 (33) 21.5 ± 9.5 45 (56) 60.0 ± 10.8 144 (48) 140 (46) 19 (6)
FG3 310 (39) 18.9 ± 9.4 26 (31) 60.7 ± 12.6 206 (54) 157 (41) 19 (5)
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Table 4: Functional groups and clinical data of affected members from studied families
Functional
subgroup Family ID Case Number Gender Age Cobb Angle Curve Pattern
FG1 2 3004 Female 12,8 8 - 8 -
FG1 2 3005 Female mother NA Scoliosis
FG1 2 3006 Male 9,4 12 Left thoracolumbar
- 2 3007 Male father 0 -
FG2 11 3027 Female 16,5 16 Left Lumbar
FG2 11 3028 Female NA NA Scoliosis
- 11 3213 Male NA 0 -
- 33 3095 Male 14,4 0 -
FG2 33 3096 Female 12,3 15 Right thoracolumbar
FG2 33 3097 Female mother NA Scoliosis
- 33 3215 Male father 0 -
FG3 38 3111 Male 14,0 0 -
FG3 38 3112 Female 16,5 14 Right Thoracic
FG3 38 3113 Female mother NA Scoliosis
- 38 3114 Male father 0 -
FG2 42 3123 Female 13,3 8 – 14 Double major
- 42 3124 Male 17,5 4 -
FG2 42 3125 Male father NA Scoliosis
FG2 73 3191 Female 9,5 10 Left thoracolumbar
- 73 3192 Male father 0 -
FG2 73 3193 Female mother NA Scoliosis
FG2 73 3194 Female aunt NA Scoliosis
FG2 73 3195 Female grand-mother NA Scoliosis
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Supplementary Figure S1
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Supplementary Figure S2
Control FG1 FG2 FG3
G
EC50 EC50 EC50 EC50
(nM) (nM) (nM) (nM)
Apelin-17 82.62 ± 0.17 80.16 ± 0.73 81.5 ± 0.54 82.83 ± 0.29
BP554 37.01 ± 0.22 37.63 ± 0.98 36.87 ± 0.48 36.26 ± 0.28
LPA 25.91 ± 0.19 25.38 ± 0.32 25.9 ± 0.55 26.61 ± 0.36
Somatostatin 48.06 ± 0.19 49.19 ± 1.06 49.56 ± 0.18 48.35 ± 0.35
UK14304 59.85 ± 0.22 60.65 ± 0.73 61.27 ± 0.39 60.76 ± 0.25
Mastoparan 58.08 ± 0.26 59.66 ± 0.82 57.65 ± 0.13 58.85 ± 0.33
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Supplementary Figure S3
Control FG1 FG2 FG3
G
EC50 EC50 EC50 EC50
(nM) (nM) (nM) (nM)
Apelin-17 11.12 ± 0.26 11.61 ± 0.54 11.46 ± 0.79 11.3 ± 0.47
BP554 13 ± 0.28 13.58 ± 0.45 13.13 ± 0.26 13.43 ± 0.45
LPA 13.04 ± 0.64 12.17 ± 0.39 12.17 ± 0.34 11.75 ± 0.39
Somatostatin 8.45 ± 0.11 8.34 ± 1.34 8.34 ± 0.47 8.5 ± 0.46
UK14304 16.28 ± 0.45 16.5 ± 0.42 16.5 ± 0.36 16.26 ± 0.31
Mastoparan 12.48 ± 0.43 13.11 ± 0.47 13.11 ± 0.37 12.97 ± 0.50
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Supplementary Table S1: siRNA sequences used in this study
Gene symbol siRNA sequence Cat. Number
GNAi1 GAGAUUGUGGAAAGAUAGUGGUGUA 1299003
GNAi2 GAGGACCUGAAUAAGCGCAAAGACA
1299003
GNAi3 UCAGCUCAAUGAUUCUGCUUCAUAU
1299003
GNAS ACAACAUGGUCAUCCGGGAGGACAA
1299003
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 Forwards Reverses  
Gi1 AGGGCTATGGGGAGGTTGAAGAT ACTCCAGCAAGTTCTGCAGTCA 
Gi2 AGGGAATACCAGCTCAACGACTCA TGTGTGGGGATGTAGTCACTCTGT 
Gi3 GAGAGTGAAGACCACAGGCATT CGTTCTGATCTTTGGCCACCTA 
Gs GAGACCAAGTTCCAGGTGGACA GATCCACTTGCGGCGTTCAT 
Gq ATCAGAACATCTTCACGGCC AAAGCAGACACCTTCTCCAC 
PKC-α (PKCA) CGGAATGGATCACACTGAGAAG  ACATAAGGATCTGAAAGCCCG  
PKC-β (PKCB) TTCCCGATCCCAAAAGTGAG  GTCAAATCCCAATCCCAAATCTC  
PKC-δ (PKCD) GCTTCAAGGTTCACAACTACATG  ACCTTCTCCCGGCATTTATG  
PKC-ɛ (PKCE) CCTACCTTCTGCGATCACTG  TACTTTGGCGATTCCTCTGG  
PKC-η (PKCHt) GTAAATGCGGTGGAACTTGC  ACCCCAATCCCATTTCCTTC  
PKC-Ι (PKCI) GAGAAGCATGTGTTTGAGCAG  GGAAGTTTTCTTTGTCGCTGC  
PKC-γ (Gamma) ACGAAGTCAAGAGCCACAAG  GTCGATGAACCACAAAGCTG  
PKC-θ (PKCQ) CGGATTTTGGAATGTGCAAGG  CATAAAGGAGAACCCCGAAGG  
PKC-ζ (PKCZ) TGCTTACATTTCCTCATCCCG  CGCCCGATGACTCTGATTAG  
CaMK1-δ (CaMK1D)  AATGGAGGGCAAAGGAGATG  AAGATGTAGGCAATCACTCCG 
CaMK1-γ (CaMK1G)  CTTGAGAAGGATCCGAACGAG TTGCCTCCACTTGCTCTTAG 
CaMK2-α (CaMK2A)  CAGTTCCAGCGTTCAGTTAATG  TTCGTGTAGGACTCAAAATCTCC  
CaMK2-β (CaMK2B)  CTCTGACATCCTGAACTCTGTG  CCGTGGTCTTAATGATCTCCTG 
CaMK2-δ (CaMK2D  GGCACACCTGGATATCTTTCTC  AGTCTGTGTTGGTCTTCATCC  
CaMK2-γ (CaMK2G)  AAACAGTCTCGTAAGCCCAG ATCCCATCTGTAGCGTTGTG 
CaMK4 TCGCCTCTCACATCCAAAC  CATCTCGCTCACTGTAATATCCC 
CaMK2n1  AGGACACCAACAACTTCTTCG  GGTGCCTTGTCGGTCATATT  
 
Supplementary Table S2: List of the forward and reverse 
sequences used in this study  
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 Forwards Reverses 
PKA-α1 CTCAGTTCCTGGAGAAAGATGG  CCCAGTCAATTCATGTTTGCC  
PKA-α2 ATGGAATATGTGTCTGGAGGTG  TGGTTTCAGGTCTCGATGAAC  
PKA-β1 GAGTAAACTTCCCCTCACCAG  TCCACTGACCATCCACAAAG  
PKA-β2 CACTGTTATCCGCTGGTCTG  CTTGTATTGGTGCTCTCCCTC  
PKA-cα CAAGGACAACTCAAACTTATACATGG   CAGATACTCAAAGGTCAGGACG  
PKA-cβ  CCTTTCCTTGTTCGACTGGAG  TGAGCTGCATAGAACCGTG  
PKA-cγ CCGGATCTCCATCAATGAGAAG  TTCAATCCAACCCTCCCATC  
PKA-γ1 GCGCATTCTGAAGTTCCTCA  AAAATCCCCAGAGCCACATAG  
PKA-γ2 TTGCCCGTTATTGACCCTATC   CGTTCCTATTCCAAGCTCATCC  
PKA-γ13 TGACTGCACTGGACATCTTTG  TGGTTGTAGGTTTGCTGGG  
CK-1α TGTCGGAGGGAAATATAAACTGG  GGCCTTCTGAGATTCTAGCTTC  
CK-1γ1  AGGTGGAGGTAGTGGAGG  GTACAATTGAGTCAGAGTCCCC  
CK-1γ2 GTGATGTTCTAGCCACAGAGG  CCCTTTCCCTCCTTTCTTGTC  
CK-1γ3 GTTCAAATGCACCCATCACAG AGTAACTCCCCAGGATCTGTC 
CK-2α1 GTATGAGATTCTGAAGGCCCTG  CCAAACCCCAGTCTATTAGTCG  
CK-2α2 CGATACGACCATCAACAGAGAC  TCGCTTTCCAGTCTTCATCG  
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The second manuscript: Osteopontin contributes to the 
development of idiopathic scoliosis 
We previously observed the elevation of circulating OPN levels in patients affected 
with adolescent idiopathic scoliosis (AIS) or asymptomatic children at risk of developing 
AIS. This observation supports our hypothesis that OPN plays a crucial role in the 
pathogenesis of AIS. In this manuscript we demonstrated how OPN plays an important role 
in the development of spinal deformity through its interaction with α5β1 integrin. We took 
the advantage of C57Bl/6 bipedal mouse model which developed scoliosis after amputation 
of forelimbs and tails and we found that these bipedal scoliotic mice exhibited higher 
plasma osteopontin and lower response to GiPCR stimulation when compared to non-
scoliotic quadrupedal mice. The genetic depletion of OPN prevented spinal deformities in 
bipedal mice and improved the response to GiPCR.  
 
In this second manuscript, I contributed in the experimental design and in the 
generation of the results. More specifically I did the immunoprecipitation and western blots 
experiments and I have done siRNA transfections for some functional experiments. I 
reviewed and revised the manuscript, and approved the final manuscript as submitted. 
 
Dr. Marie-Yvonne Akoume conceptualized and designed the study, performed the 
CellKeyTM manipulation using CDS technique, some of the siRNA transfections carried out 
the initial analyses, drafted the initial manuscript, and approved the final manuscript as 
submitted 
Mr. Saadallah Bouhanik contributed in the generation of the bipedal mice and their 
phenotypic characterization and approved the final manuscript as submitted.  
Ms. Anita Franco contributed to the ELISA experiments and approved the final manuscript 
as submitted. 
Dr. Alain Moreau contributed to the study conception, the analysis and interpretation of the 
data. He critically revised the manuscript for important intellectual content and approved 
the final manuscript as submitted. 
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ABSTRACT  
Idiopathic scoliosis is a three-dimensional spinal deformity of unknown origin. We 
have previously associated this condition with a defective Gi protein-coupled receptor 
(GiPCR) signaling and reported increased circulating osteopontin (OPN) levels in affected 
individuals. Here we provide the first evidence that lack of OPN leads to improvement in 
GiPCR signaling and confers a protection against the development of spinal deformity. We 
further showed that OPN reduces GiPCR signaling in vitro via α5β1 integrin engagement. 
Our extensive investigation revealed that the mechanism by which OPN interferes with 
signaling of GiPCR is likely a depletion of functional Gi proteins necessary for these 
receptors. We propose a scenario that includes the sequestration of a part of Gi proteins by 
integrin β1 subunit and the inactivation of the remaining Gi proteins following their 
phosphoryaltion by various kinases engaged in the signaling cascade of α5β1 integrin. For 
the first time, a critical role for OPN is demonstrated in the development of idiopathic 
scoliosis. 
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INTODUCTION  
Osteopontin (OPN) is a multifunctional glycoprotein greatly synthesized in variety 
of cell types and secreted into body fluids in response to injury (Sodek et al., 2000); 
(Denhardt et al., 2001a). OPN is also abundantly produced in pathological conditions 
(Chiba et al., 1999); (Fitzpatrick et al., 1994); (Katagiri et al., 1999); (Liaw et al., 
1998); (Ophascharoensuk et al., 1999); (Reinholt et al., 1990) and has been implicated in 
the pathogenesis of numerous diseases (Denhardt and Guo, 1993); (Giachelli et al., 
1993); (Giachelli et al., 1994); (Giachelli et al., 1995); (Murry et al., 1994); (O’Brien et 
al., 1995); (Oates et al., 1997). We have previously reported high circulating levels of 
OPN in patients with idiopathic scoliosis. However, whether OPN is involved in the 
development of idiopathic scoliosis has not been explored in depth. 
Idiopathic scoliosis is generally defined as a three-dimensional deformity of the 
spine characterized by lateral curvature combined with vertebral rotation. Despite extensive 
research, the aetiology and pathophysiology of this disease remain largely unknown. 
Current view maintains that many factors are involved in the genesis of idiopathic scoliosis 
and practically every structure of the body has been incriminated, while no single 
biological process driving the pathogenesis has been identified. Nevertheless, recent works 
from our laboratory suggest that this unsolved mystery may implicate the deficiency in Gi 
protein-mediated signal transduction. Indeed, we have demonstrated that various 
compounds activating Gi proteins, either directly or via receptors failed to efficiently 
induce cell signaling in cells from scoliotic patients and asymptomatic children as 
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measured by cellular dielectric spectroscopy (CDS) and cAMP assay (Moreau et al., 
2004); (Azeddine et al., 2007); (Akoume et al., 2010). Moreover, approximately 33 % of 
asymptomatic children diagnosed with a defective Gi protein function have developed 
scoliosis many years later (Akoume et al., 2010). 
It is commonly accepted that the development of scoliosis is influenced by a 
postural mechanism. The bipedal condition, naturally present in humans or experimentally 
induced in animals seems to play an important role in the manifestation of scoliotic 
deformities (Machida et al., 1999). Importantly, it has been reported that mice on a 
C57Bl/6 or C3HHe background develop scoliosis closely similar to human idiopathic 
scoliosis when they gain bipedal posture for 40 weeks following amputation of their 
forelimbs and tails (Machida et al., 2006a); (Oyama et al., 2006). Hence, to address the 
question of whether OPN contributes to the development of idiopathic scoliosis we took 
advantage of the availability of OPN-deficient mice on a C57Bl/6 background. Our 
findings reveal that OPN is of key importance in the development of idiopathic scoliosis 
likely by disrupting Gi protein-mediated signaling via a dual mechanism requiring β1 
integrin engagement. 
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MATERIALS AND METHODS 
Derivation of primary osteoblast cultures 
Bone specimens from mice were obtained from the spine after euthanasia. Bone 
fragments were reduced to smaller pieces with a cutter in sterile conditions. The small bone 
pieces were incubated in αMEM medium containing 10% fetal bovine serum (FBS; 
certified FBS, Invitrogen, Burlington, ON, Canada) and 1% penicillin/ streptomycin 
(Invitrogen) at 37°C in 5% CO2, in a 10-cm2 culture dish. After one month, osteoblasts 
emerging from the bone pieces were separated from the remaining bone fragments by 
trypsinization. RNA was extracted from the osteoblasts using the TRIzol method, 
(Invitrogen). Expression profiles were studied by qPCR. Transcript expression was 
assessed with the Stratagene Mx3000P (Agilent Technologies, La Jolla, CA). 
 
Functional evaluation of G proteins 
 The functional evaluation of Gi, Gs and Gq proteins was assessed by CDS assays 
using osteoblasts cells derived from C57Bl/6j WT and C57Bl/6j OPN-/- mice (bipedal and 
quadrupedal) using CellKeyTM apparatus, as previously described (Akoume et al., 2010).  
 
Osteopontin enzyme-linked immunosorbent assays  
Peripheral blood samples were collected in EDTA-treated tubes and then 
centrifuged. Plasma samples were derived then aliquoted and reserved frozen at -80°C until 
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thawed and analyzed. The concentrations of plasma OPN were measured by enzyme-linked 
immunosorbent assays (ELISA) as said by protocols provided by the manufacturer (IBL, 
Hamburg, Germany). This OPN ELISA kit measures total concentration of both 
phosphorylated and non-phosphorylated forms of OPN in plasma. All ELISA tests were 
performed in duplicate and the optical density was measured at 450 nm using an DTX880 
microplate reader (Beckman Coulter, USA). 
 
Generation of bipedal C57Bl/6j OPN-null mice and bipedal C57Bl/6j 
CD44-null mice 
Breeding pairs of C57Bl/6j mice devoid of either OPN (OPN-null mice) or CD44 
(CD44-null mice) were obtained from Dr. Susan Rittling (Rutger University, NJ, USA) and 
were backcrossed for more than 10 generations in C57Bl/6j background to establish our 
own colonies, while C57Bl/6j mice were used as wild-type control mice (Charles-River, 
Wilmington, MA, USA). C57Bl6/6j mouse strain was used because it is naturally deficient 
in melatonin (Von Gall et al., 2000) and exhibits high circulating OPN levels (Aherrahrou 
et al., 2004) . These mice develop scoliosis when they are maintained in a bipedal state. 
(Machida et al., 2006b). Bipedal surgeries were performed after weaning (5-weeks after 
birth) by amputation of the forelimbs and tail under anesthesia as reported previously. 
(Machida et al., 2006b). Similarly bipedal C57Bl/6j-CD44-null mice were generated.  
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Cell line and transfections 
MC3T3-E1 cells were used to check the effect of the knockdown of OPN and its 
receptors. MC3T3-E1 osteoblasts cells were transiently transfected in serum-free medium, 
using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer’s 
instructions and functional experiments were performed 48h post transfection. The 
sequence of RNA oligo used for the knockdown of different genes are, ssp1 (encode OPN) 
(CCA CAG CCA CAA GCA GUC CAG AUU A), integrin β1 (CCU AAG UCA GCA 
GUA GGA ACA UUA U), integrin β3 (CCU CCA GCU CAU UGU UGA UGC UUA U), 
integrin α5 (CCG AGU ACC UGA UCA ACC UGG UUC A), integrin α8 (GAG AUG 
AAA CUG AAU UCC GAG AUA A), integrin αv (GAC UGU UGA GUA UGC UCC 
AUG UAG A) and CD44 (GAA CAA GGA GUC GUC AGA AAC UCC A). 
Quantitative reverse transcription-polymerase chain reaction (qPCR) 
Thermo-Script reverse transcriptase (Invitrogen) was used to reverse mRNA into 
cDNA (1mg total concentration). Several dilutions were tested to choose the concentration 
that yielded the most efficient amplification. The human primers used were the following:  
β-actin forward  5'-GGAAATCGTGCGTGACAT-3',  
β-actin reverse  5'-TCATGATGGAGTTGAAGGTAGTT-3',  
CD44 forward  5'(AGCATCGGATTTGAGACCTG)3',  
CD44 reverse   5'(TGAGTCCACTTGGCTTTCTG)3', 
β1 integrin forward  5'(ATGTGTCAGACCTGCCTTG)3', 
β1 integrin reverse  5'(TTGTCCCGACTTTCTACCTTG)3', 
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αv integrin forward  5'(GTCCCCACAGTAGACACATATG)3', 
αv integrin reverse  5'(TCAACTCCTCGCTTTCCATG)3'.  
Each amplification was performed in duplicate using  5ml of diluted cDNA, 7,5ml 
of 3mM primer solution and 12,5ml of  2X QuantiTect SYBR Green PCR Master Mix 
(QIAGEN Inc, Ontario, Canada). All reaction mixes were run on Mx3000P system from 
Stratagene (Agilent Technologies Company, La Jolla, CA) and analyzed with MxPro 
QPCR Software also from Strata-gene. Relative quantification was calculated with the delta 
CT method using β-actin as the endogenous control. 
 
The evaluation of the effect of OPN on GPCR and Gi proteins expression 
Gi proteins isoforms expression levels were determined using western blot 
technique. MC3T3-E1 cells were treated with PBS or rOPN 0.5µg/ml overnight (R&D 
systems Inc., Minneapolis, USA). These cells were washed with cold PBS 1x then lysed in 
RIPA buffer (25 mM Tris.Hcl pH7.4, 150 mMNaCl, 1 % NP-40, 1 % sodium 
deoxycholate, 0.1 % SDS) added with 5 mMNaVO4 and protease inhibitor cocktail (Roche 
molecular Biochemicals, Mannheim, Germany). Immunoblots were performed with 
primary antibodies directed specifically against Gi1, Gi2, Gi3, Gs, Phosphoserine, integrin 
β1 (Santa Cruz Biotechnology, Santa Cruz, CA), Mu opioid receptor (MOR) (abcam 
Toronto, ON, Canada), Lysophosphatidic acid receptor 1 (LPAR1) (assaybiotech Inc., 
USA), melatonin receptor 2 (MT2) and peroxidase-conjugated secondary antibody. Bands 
were then visualized using SuperSignal chemiluminescent substrate (Pierce, Rockford, IL). 
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Effect of OPN on interaction of Gi proteins with GPCR and β1 integrin  
MC3T3-E1 cells were treated with PBS or rOPN (0.5µg/ ml) then the whole cell 
proteins (1mg) were incubated with anti- MOR (Abcam Toronto, ON, Canada), anti-MT2 
or anti- β1 integrin (Santa Cruz Biotechnology), plus protein G beads for 
immunoprecipitation (IP) at 4 °C overnight. Purified proteins were loaded on 10 % gel after 
IP, then, processed for gel transferring to PVDF membrane and 5 % BSA blocking. 
Membranes were exposed to antibodies specific for Gi1, Gi2, Gi3, MOR, MT2 and β1 
integrinat 4 C overnight and, subsequently, treated with secondary antibody at room 
temperature for 1 h. Bands were visualized using SuperSignal chemiluminescent (Pierce, 
Rockford, IL) and quantified by densitometric scanning.  
 
Statistical analysis 
Data are presented as mean ± SE.  Multiple comparisons of means were performed 
with one-way analysis of variance (ANOVA) followed by a post-hoc test of Dunnett, using 
GraphPad Prism 4.0 software.  Only P values < 0.05 were considered significant. 
 
RESULTS  
Genetic deletion of OPN protects bipedal C57Bl/6 from scoliosis  
The bipedal C57Bl/6 mice are widely used as animal model to study the 
pathophysiological events leading to idiopathic scoliosis. To determine whether OPN is 
involved in the development of idiopathic scoliosis, female wild-type (WT) and OPN 
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knockout (OPN-/-) C57Bl/6 mice were amputated from forelimbs and tails at 1 month of 
age and subjected to bipedal ambulation for 36 weeks to induce scoliosis. Representative 
radiographs of the spine as taken at the end of the experiment period are shown in (Fig. 1, 
A-D). As expected, scoliosis did not develop in any of the WT or OPN-/- quadrupedal mice. 
However, lateral curvature was apparent in 55 % of bipedal WT mice. The convexity of 
curve was directed to either side, with no consistent preference. In contrast, analysis of 
radiographs yielded no evidence of scoliosis in bipedal OPN-/- mice. All bipedal OPN-/- 
mice had straight spine indistinguishable from the quadrupedal mice. These data strongly 
emphasize that genetic OPN deletion protects bipedal C57Bl/6 mice from scoliosis and 
suggest a role for OPN in the development of scoliosis.  
To provide further evidence for this hypothesis, OPN was measured in plasma from 
bipedal mice at 12, 24 and 36 weeks after surgery (Fig. 1 E), and compared with plasma 
OPN levels in age-matched quadrupedal mice. Whereas OPN could be detected neither in 
quadrupedal nor in bipedal OPN-/- mice (data not shown), bipedal WT showed significantly 
higher plasma OPN than quadrupedal WT mice at all indicated time points. The maximum 
values were observed at the thirty-sixth postoperative week. 
 
OPN deficiency improves Gi protein-mediated receptor signal 
transduction 
 Since we have previously associated idiopathic scoliosis with defective Gi protein 
function, it was of interest to examine whether lack of OPN can influence Gi protein-
mediated signaling. For this purpose, osteoblasts from WT and OPN-/- mice were screened 
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for their response to DAMGO, somatostatin, oxymethazolin and apelin to activate opioid, 
somatostatin, alpha2-adrenergic and APJ receptors, respectively. These receptors are well 
known to mediate signal transduction through Gi proteins. Results illustrated in (Fig. 1, F-
I) show that all four compounds caused a concentration-dependent increase of response in 
osteoblasts from WT and OPN-/- mice. However, in each case, the magnitude of response 
was greater in OPN-/- than WT osteoblasts, which may suggest that the activation of Gi 
proteins is facilitated in OPN-/- osteoblasts. On the other hand, while the magnitude of 
response was similar in osteoblasts from quadrupedal and bipedal OPN-/- mice, a significant 
difference was observed in response between those from quadrupedal and bipedal WT 
mice. The extent of response was much lower in osteoblasts from bipedal WT mice. 
To corroborate these results with the function of Gi proteins, we treated osteoblasts 
with pertussis toxin (PTX), which ADP-rybosylates Gi proteins and disrupts their 
interaction with receptors (Gilman, 1987); (Moss et al., 1984). Results illustrated in (Fig. 
1, J-M) show that cellular responses to each of the four tested agonists, were largely 
reduced by PTX pre-treatment in osteoblasts from either phenotype. However, the extent of 
reduction was high in OPN-/- osteoblasts. Notably, the differences in the magnitude of 
response between WT and OPN-/- osteoblasts were completely abrogated by PTX treatment. 
Collectively, these data indicate that OPN deficiency enhances Gi protein-mediated 
receptor signal transduction in osteoblasts cells. 
 To determine whether loss of OPN specifically enhances Gi protein signaling, we 
examined the effect of loss of OPN on signaling initiated by other G proteins such as Gs 
and Gq. We used isoproterenol and desmopressin to activate Gs through beta-adrenergic 
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and vasopressin receptors, respectively; while bradykinin and endothelin-1 were used to 
activate Gq through their cognate receptors. Results in (Fig. 1, N and O) show that 
osteoblasts from OPN-/- mice were less responsive to Gs stimulation than those from WT 
mice, whereas the Gq stimulation elicited in WT and OPN-/- osteoblasts with comparable 
magnitude. These findings are strongly indicative that OPN deficiency exclusively 
improves Gi protein-mediated signaling. 
 
Extracellular OPN disrupts Gi protein-mediated receptor signal 
transduction   
To further investigate the role of OPN in Gi protein-mediated receptor signaling, 
several lines of experiments were performed using MC3T3-E1 osteoblastic cell line. Since 
these cells express OPN, we first examined whether depletion of OPN by siRNA influences 
the capacity of GiPCR ligands to induce cell signaling as measured by CDS in MC3T3-E1 
cells. Results illustrated in (Fig. 2 A) show that the integrated response to DAMGO was 
significantly greater in cells depleted of OPN. Similar results were obtained when cells 
were stimulated with oxymethazolin. Interestingly, blockade of secreted OPN, by exposing 
cells to neutralizing OPN antibody, also increased response to both compounds (Fig. 2 B). 
These results suggest that the extracellular OPN disrupts GiPCR signaling. To confirm this 
hypothesis, cells were treated with exogenous recombinant OPN (rOPN) prior to DAMGO 
and oxymethazolin stimulation. In each case, rOPN caused decrease in the integrated 
response in a concentration-dependent manner, which was prevented by OPN antibody 
(Fig. 2, C-D).  
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CD44 is not involved in the inhibition of GiPCR signaling by extracellular 
OPN   
OPN is well known to function by interacting with a variety of cell surface 
receptors, including CD44 and many integrins (Weber et al., 1996); (Rangaswami et al., 
2006). Since CD44 is considered as a key receptor for OPN, we first explored whether 
CD44 is responsible for the inhibitory effect of OPN on GiPCR signaling. For this purpose, 
we first interfered the interaction between OPN and CD44, using CD44 antibody. As 
shown in (Fig. 3 A), OPN reduced the integrated response to DAMGO in cell pre-treated 
with IgG control or CD44 antibody. Similar results were obtained when cells were 
stimulated with oxymethazolin (Fig. 3 A), suggesting that the blockade of CD44 did not 
prevent the GiPCR signaling reduction induced by OPN. To exclude the possibility that the 
lack of prevention by CD44 antibody was due to its inefficacy, the cells pre-treated with 
IgG control or CD44 antibody were stimulated with increasing concentrations of 
hyaluronic acid (HA), a high affinity ligand of CD44.  As shown in (Fig. 3 B), the 
integrated response induced by HA was completely abrogated by pre-treatment with CD44 
antibody. Moreover, the effect of CD44 antibody on response to HA stimulation was 
concentration-dependent (Fig. 3 C). These data clearly indicate that CD44 antibody was 
active.  
We further used the small interfering RNA (siRNA) approach to knockdown the 
expression of CD44, and the efficiency of siRNA transfection was demonstrated by 
quantitative real-time PCR and western blot analysis (Fig. 3, D and E). We found that the 
deletion of CD44 by siRNA did not prevent the inhibitory effect of OPN on response to 
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DAMGO or oxymethazolin (Fig. 3, F). Consistent with these findings, rOPN treatment 
caused a concentration-dependent decrease in response to both DAMGO and 
oxymethazolin in osteoblasts from bipedal CD44 knockout (CD44-/-) mice (Fig. 3, G and 
H). Moreover, these osteoblasts were less responsive to DAMGO or oxymethazolin when 
compared with osteoblasts from quadrupedal (CD44-/-) mice (Fig. 3, I and J).  
Collectively, these data indicate without ambiguity that CD44 is not involved in the 
inhibition of GiPCR signaling by OPN and support the view that there is a relationship 
between deficient GiPCR signaling and the development of scoliosis 
 
RGD-dependent integrins mediate the inhibitory effect of OPN on GiPCR 
signaling 
We next examined the possible requirement of integrins. Given that OPN contains 
an arginine-glycine-aspartate (RGD)-motif that engages a subset of cell surface integrins 
and a serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing 
domain that interacts with other integrins, it was of interest to examine whether OPN action 
required a specific domain-dependent integrins. For this purpose, small synthetic peptides 
were used to compete with integrin binding of the RGD or SVVYGLR sequences in OPN.  
We used BIO1211 to selectively inhibit α4β1 integrin, the only SVVYGLR-containing 
integrin present in osteoblasts. As shown in (Fig. 4 A), OPN action on GiPCR signaling 
was not significantly influenced by BIO1211 in MC3T3-E1 cells. Response to DAMGO or 
oxymethazolin was reduced by rOPN in the absence or presence of BIO1211, suggesting 
that integrins with SVVYGLR recognition specificity is not entailed in this process. In 
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contrast, coincubation of cells with rOPN and RDG peptide completely prevented the 
inhibitory effect of rOPN on response to DAMGO and oxymethazolin. (Fig. 4, B and C) 
illustrate that this preventive effect of RDG was concentration-dependent. Increasing 
concentrations of RGD resulted in a progressive attenuation of the inhibitory effect of 
OPN, reversing the effect of OPN when concentrations went beyond 10µg/ml. Similarly, 
incubation of osteoblasts from WT mice with high concentrations of RGD demonstrated 
significant increase of response to DAMGO or oxymethazolin (Fig. 4, D), suggesting 
efficient inhibition of the effect of secreted OPN by RGD. Consistent with this view, RGD 
was without effect when osteoblasts from OPN-/- mice were used (Fig. 4, E), indicating that 
the effect of RGD is strictly dependent on the presence of OPN. 
Collectively, these data suggest that the inhibitory effect of OPN on GiPCR 
signaling is mediated by one or more RGD-dependent integrins expressed in osteoblasts.  
 
Identification of integrins involved in the inhibition of GiPCR signaling 
by OPN  
 Having established a probable role for RGD-dependent integrins in the inhibitory 
effect of OPN on GiPCR signaling in osteoblasts, we attempted to examine specific 
integrins that could mediate this effect. For this purpose, we used antibodies to selectively 
neutralize the subunits of αvβ1, αvβ3, αvβ5, α5β1, and α8β1, the RGD-dependent integrins that 
have been shown to be expressed in osteoblasts (Hughes et al., 1997); (Gronthos et al., 
1997); (Grzesik and Robey, 1994); (Clover et al., 1992); (Moursi et al., 1997); (Pistone 
et al., 1996). (Fig. 5, A and B) show that the inhibitory effect of rOPN on response to 
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DAMGO and oxymethazolin was attenuated at different degrees, but not abolished, by β3, 
β5, αv and α8 antibodies. Conversely, antibodies against α5 or β1 reversed the inhibitory 
effect of rOPN on response to both DAMGO and oxymethazolin. Cells pre-treated with 
these antibodies showed an increase in the magnitude of the integrated response in the 
presence of rOPN compared to untreated cells, in sharp contrast to the decrease induced by 
rOPN in cell pre-treated with IgG. These results suggest that α5 and β1 integrins are the 
primary mediators of the inhibitory effect of OPN on GiPCR signaling. 
 To further support this hypothesis, we used siRNA approach. When compared with 
untreated cells, MC3T3-E1 transfected with scrambled siRNA demonstrated less response, 
while cells transfected with α5 or β1 integrins siRNA demonstrated high response in the 
presence of rOPN. Cells transfected with both α5 and β1 integrin siRNA demonstrated a 
further increase (Fig. 5 C). Also, silencing of both integrin subunits simultaneously 
resulted in increased response to DAMGO and oxymethazolin in osteoblasts from bipedal 
WT and CD44-/- mice (Fig. 5, D and E). Effective silencing of integrin expression was 
supported by q-RT-PCR (Fig. 5, F).  In all cases, transfection of cells with other integrins 
resulted in a partial attenuation of the inhibitory effect of OPN on GiPCR signaling (data 
not shown). Taken together, these results are the convincing evidence that α5β1 is the main 
integrin dimmer involved in mediating the inhibitory effect of OPN on GiPCR signaling in 
osteoblasts. 
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OPN is without effect on expression of Gi proteins and their cognate 
receptors 
Given that the level of GPCRs is critical for their signaling, it was of interest to 
examine whether the defective GiPCR signaling induced by OPN is the consequence of a 
quantitative reduction of these receptors. For this purpose, MC3T3-E1 cells were treated 
with PBS or rOPN and the cell lysates were analyzed by western blot for the expression of 
three different GPCRs; including mu-opioid (MO), lysophosphatidic acid type 1 (LPA1) 
and melatonin type 2 (MT2) receptors. As showed in (Fig. 6 A), all three receptors were 
immunodetected in MC3T3-E1 cells and the level of each receptor was not modified by 
rOPN treatment. Consequently, we examined the effect of rOPN on the expression of Gi 
proteins. Relative to PBS-treated cells, there was no significant effect of rOPN treatment on 
the quantity of Gi proteins as determined by immunoblotting using antibodies against Gi1, 
Gi2 and Gi3 isoforms (Fig. 6 B). The qPCR analysis also revealed no significant difference 
in expression of any of these isoforms between PBS- and rOPN-treated cells (Fig. 6 C). 
These results exclude the possibility that rOPN reduces the expression of receptors or Gi 
proteins. 
 
OPN reduces the availability of Gi proteins for their cognate receptors 
 Gi proteins have been shown to be recruited by β1 integrins via an adaptor molecule 
and to mediate integrin signaling (Green et al., 1999). It is notable that when different 
receptors signal through the same subfamily of G proteins, they share the same limited pool 
of G proteins. Therefore, if OPN enhances the recruitment of Gi proteins in the β1 integrin 
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complex, reduction in the amount of Gi proteins in GiPCR complex would be expected. To 
evaluate this possibility, cells lysates were immunoprecipitated with antibodies against 
MO, MT2 or β1 integrin receptors, and the presence of Gi proteins in each precipitate was 
examined by western blot using antibodies specific for Gi1, Gi2 or Gi3 isoform. (Fig. 6 D, E 
and F) shows that the relative amount of Gi1 isoform immunoprecipitated with MO or 
MT2 receptor was reduced in rOPN-treated cells compared to PBS-treated cells. Similar 
observations were noted for Gi2 and Gi3 isoforms. In contrast, the amount of each of these 
Gi protein isoforms was elevated in the β1 integrin precipitates following rOPN treatment. 
These results suggest that OPN causes a kidnapping of Gi proteins and reduces their 
availability for GiPCRs. 
 
OPN enhances the phosphorylation of Gi proteins  
 Given that the defective GiPCR signaling associated with idiopathic scoliosis has 
causatively been related to increased phosphorylation of Gi proteins (Moreau et al., 2004), 
it was of interest to examined whether OPN influences the phosphorylation status of Gi 
proteins. Accordingly, MC3T3-E1 cells were treated with rOPN, then cell lysates were 
immunoprecipitated with antibodies against Gi1, Gi2 or Gi3 protein isoforms, and the 
phosphorylation level was examined by western blot using anti-phospho serine/threonine or 
anti-tyrosine antibodies. Results revealed the presence of phosphorylated serine and 
tyrosine residues in Gi1 precipitates obtained from cells treated with PBS or rOPN. 
However, band density was higher in OPN-treated cells. Similar observations were noted in 
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Gi2 and Gi3 precipitates (Fig. 7 A). These results show that OPN enhances the 
phosphorylation of Gi proteins at serine and tyrosine residues.  
To support the involvement of α5β1 integrin in this process, cells were pre-treated 
with antibody against α5β1 integrin prior to rOPN treatment. Western blot analysis revealed 
that the Gi phosphorylation induced by rOPN treatment was attenuated by anti-α5β1 
integrin blocking antibody (Fig. 7 A).   
To further associate these findings with the decreased GiPCR signaling in scoliosis, 
we examined directly whether Gi proteins undergone increased phosphorylation in 
osteoblasts from scoliotic mice. We probed the immunoprecipitated of Gi1, Gi2 and Gi3 
proteins with an anti-phospho-serine/threonine or an anti-phospho-tyrosine specific 
antibody and found that the level of phosphorylation of each Gi isoform was significantly 
greater in osteoblasts from scoliotic bipedal WT or CD44-/- mice compared with those from 
quadrupedal control mice (Fig. 7B). Importantly, phosphorylation levels were attenuated 
by anti-α5β1 integrin blocking antibody (data not shown). These results provide 
convincing evidence that GiPCR signaling in scoliotic mice is associated with Gi protein 
phosphorylation induced by OPN via α5β1 integrin engagement. 
 
Phosphorylation of Gi proteins induced by OPN involves various kinases 
 To identify which kinases are involved in the phosphorylation of Gi proteins 
induced by OPN, we pharmacologically inhibited FAK, MEK, ERK1/2, P38, JNK, PI3K, 
Src, PKC and CaMKII, which were described to be activated by OPN (Denhardt et al., 
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2001a; Denhardt et al., 2001c) (Denhardt et al., 2001b) Cell extracts prepared from 
MC3T3-E1 that had been treated with rOPN in the presence or absence of inhibitor specific 
for each kinase were subjected to immunoprecipitation and western blot analysis. Results in 
(Fig. 7 C-E) show that inhibitor of PKC (Gö6983) attenuated level of serine 
phosphorylation in the Gi protein precipitates, but was without effect on tyrosine 
phosphorylation levels. However, both serine and tyrosine phosphorylation were attenuated 
by inhibitors of FAK (FAK inhibitor-14), Scr (PP2), CaMKII (KN93), PI3K (wortmannin), 
MEK (PD98059), ERK1/2 (FR180204), JNK (SP60125) and P38 (SB203580). These 
results indicate that various kinases are directly or indirectly involved in the 
phosphorylation of Gi proteins induced by OPN. 
 
The effects of OPN on Gi and Gs proteins favour GsPCR signaling  
Several reports indicate that inhibition of Gi proteins disrupts signal from GiPCR 
and enhances GsPCR signaling (Itoh et al., 1984); (Katada et al., 1985); (Katada et al., 
1985); (Wesslau and Smith, 1992); (Wesslau and Smith, 1992). On the other hand, it has 
been demonstrated that the tyrosine phosphorylation of Gs protein by Src also enhances 
GsPCR signaling, presumably by increasing activity of Gs protein and its association with 
receptor (Hausdorff et al., 1992); (Chakrabarti and Gintzler, 2007).  
 Taken into account these considerations and having observed that genetic deletion 
of OPN inversely influenced response to Gi and Gs stimulation (Fig. 1 ), it was of interest 
to examine the effect of OPN on the functional and phosphorylation status of Gs protein 
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and on its interaction with receptors. For this purpose, cells were subjected to isoproterenol 
and desmopressin in the presence of rOPN or PBS. As expected, response to isoproterenol 
was higher in rOPN than in PBS-treated cells. Similar results were obtained when cells 
were stimulated with desmopressin, indicating that OPN increases response to GsPCR 
stimulation (Fig. 8 A). Interestingly, immunoprecipitates of Gs protein probed with anti-
tyosine antibody exhibited higher intensity in rOPN-treated cells compared to PBS-treated 
cells (Fig. 8 B). More interestingly, rOPN treatment enhances the presence of Gs protein in 
the immunoprecipitates of MT2 and MO receptors (Fig. 8 C-D). 
Collectively, these results demonstrate that OPN enhances not only the GsPCR signaling, 
but also the tyrosine phosphorylation of Gs protein and its association with receptors.  
Assuming that inhibition of Gi protein and phosphorylation of Gs protein are 
responsible for the increased GsPCR signaling associated with rOPN, our next experiments 
aimed to determine the contribution of each parameter. For this purpose, cells were treated 
with PTX to mimic disruption action of rOPN and compared to cells treated with rOPN 
alone or in combination with Src inhibitor (PP2) to prevent tyrosine phosphorylation. 
Results in (Fig. 8 E) show that rOPN-treated cells were more responsive to isoproterenol 
stimulation than PTX-treated cells by 30 %. This modest difference was abolished by Src 
inhibitor (PP2). Similar observations were notified when cells were stimulated with 
desmopressin. These results indicate that Gs phosphorylation contributes only part of the 
stimulatory effect of rOPN on GsPCR signaling and that disruption of the inhibitory signal 
from GiPCR represents the main cause of this phenomenon. 
  
 
125
Discussion 
The consideration of OPN as a potential contributor in the pathophysiologic process 
underlying idiopathic scoliosis is a concept relatively recent that has emerged from the 
observation of high circulating OPN levels in patients affected with idiopathic scoliosis or 
asymptomatic children at risk of developing this disease. Results presented in the present 
study support such concept and demonstrate that OPN plays an important role in the 
development of spinal deformation by interfering with GiPCR signaling via a dual 
mechanism involving α5β1 integrin. 
 Research involving idiopathic scoliosis has focused on many potential mechanisms, 
but in most cases, the demonstration of a direct link with development of the disease has 
been hampered by lack of appropriate animal models. A well-established model and largely 
utilized to explore the pathogenesis of idiopathic scoliosis is bipedal C57Bl/6 mice. These 
mice rapidly develop spinal deformity following 40 weeks of bipedal ambulation (Oyama 
et al., 2006). A major observation of the present study is that the genetic depletion of OPN 
prevented spinal deformation in these mice and enhanced the response to GiPCR 
stimulation in their osteoblasts, suggesting a role for OPN. Consistent with this, we found 
that scoliotic bipedal mice exhibited higher plasma OPN than non-scoliotic quadrupedal 
mice and responded less efficiently to the activation of GiPCR. Given these results and the 
demonstration by in vitro assay that OPN reduces response to GiPCR activation; our 
findings establish a causative relationship between, spinal deformation, GiPCR dysfunction 
and OPN. 
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It is well known that OPN functions by binding to CD44 or integrin receptors 
(Weber et al., 1996); (Rangaswami et al., 2006). We found that the inhibitory effect of 
OPN on GiPCR signaling is mediated by RGD-dependent integrins. There was no evidence 
for the involvement of CD44 receptor in the effects related to circulating OPN. Indeed, 
bipedal mice depleted from CD44 exhibited high circulating OPN levels and have 
developed spinal deformity. Interestingly, the inhibition of the expression of CD44 or of its 
interaction with OPN resulted in an exacerbated reduction in GiPCR signaling by OPN. 
These findings suggest that the ability of OPN to bind CD44 may interfere with the 
activation of integrins. It is possible that the blockade or the absence of CD44 causes a 
greater access to integrins. 
Among the five RDG-dependent integrins characterized in osteoblasts, including 
αvβ1, αvβ3, αvβ5, α5β1, and α8β1 (Hughes et al., 1997); (Gronthos et al., 1997); (Grzesik 
and Robey, 1994); (Clover et al., 1992); (Moursi et al., 1997); (Pistone et al., 1996), we 
identified α5β1 integrin to mediate the inhibitory effect of OPN on GiPCR signaling. This 
integrin appears to be of particular importance in GiPCR signaling, since it coprecipitates 
with Gi proteins (Brown and Frazier, 2001); (Berg et al., 2007). In the present study, we 
found that the amount of Gi proteins increases in the immunoprecipitates of β1 integrin 
while it decreases in those of GiPCRs following rOPN treatment. This suggests that rOPN 
reduces response to GiPCR activation by favouring the kidnapping of Gi proteins by β1 
integrin. However, the modest amount of Gi proteins in β1 integrin precipitates contrasts 
with the strong reduction in response to GiPCR activation, suggesting an additional 
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parameter. In this regard, phosphorylation of Gi proteins has been demonstrated to 
contribute to diminishing GiPCR signaling in various cell types (Katada et al., 1985); 
(Bushfield et al., 1991); (Strassheim and Malbon, 1994); (Murthy et al., 2000); 
(Shangguan et al., 2003). Interestingly, we found that OPN caused an increase in the 
phosphorylation of Gi proteins. The fact that this increase was prevented by the inhibition 
of β1 integrin is strongly suggestive of involvement of the β1 integrin downstream events 
being given that integrins do not have intrinsic activity. Consistent with this notion, we 
found that the rOPN effect on Gi protein phosphorylation was prevented by the inhibition 
of various molecular intermediates engaged in integrin signaling pathways. 
Several reports indicate that integrin activation promotes various signaling 
pathways, many of which are mediated by tyrosine kinases, which in turn phosphorylate 
other kinases (Illario et al., 2003). Using several inhibitors, our results suggest that FAK, 
Src, MAPK, PI3K, PKC and CamK participate in the signaling cascade linking β1 integrin 
activation by rOPN to Gi protein phosphorylation. Whether each of these kinases directly 
or indirectly phosphorylates was not examined in the present study. To date, Kinases that 
have been associated with direct phosphorylation of Gi proteins include the 
serine/threonine kinase PKC and the tyrosine kinase Scr. It has been shown that Src can 
phosphorylate most of members of the Gi protein family (Hausdorff et al., 1992), whereas 
PKC phosphorylates only Gi1 and Gi2 proteins (Murthy et al., 2000). Our observation that 
OPN causes increased phosphorylation of the three tested (Gi1, Gi2 and Gi3) Gi proteins 
isoforms indicates that, beside PKC, other serine/threonine kinases may be involved. 
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Although our findings suggest that Akt in PI3K downstream as well as MAPK and CaMKII 
could be good candidates, more definitive studies are required to identify the exact kinases 
responsible for the phosphorylation of each Gi protein isoform following OPN binding to 
β1 integrin. 
Nevertheless, on the basis of our collective findings and the available evidences, we 
present the hypothetical scenario schematized in (Fig. 9), to explain the mechanism by 
which OPN reduces GiPCR signaling and contributes to the development of spinal 
deformity. We propose that upon OPN binding, α5β1 integrin recruits a part of Gi proteins 
from the common pool, then promotes different signaling pathways leading to the 
activation of various kinase, which directly or indirectly phosphorylate a part of the 
remaining Gi protein in the common pool. These events simultaneously cause depletion of 
pool and inactivation of different isoforms, leading to the reduction in the amount of the 
functional Gi proteins necessary for the efficient GiPCR signaling. This would reduce the 
inhibitory control on Gi protein and favour GsPCR signaling, which is exacerbated by 
phosphorylation of Gs protein by Src. The exaggerated GsPCR signaling increases bone 
formation (Hsiao et al., 2008) and reduce myoblast proliferation (Marchal et al., 1995), 
leading to an imbalance between bone mass and muscular strength around the spine. Thus, 
spine will be throwing out of the balance and the lateral curvature will appear. Since signal 
transduction through Gs proteins enhances OPN mRNA and protein levels (Nagao et al., 
2011), the exaggerated GsPCR signaling would sustain the high production of OPN and 
amplify events driving the development of spinal deformity. Although additional 
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mechanisms could be operable, the contribution of GsPCR signaling is further supported by 
the addition of spinal deformity to the constellation of orthopaedic problems commonly 
associated with Fibrous Dysphasia of bone, an uncommon disease caused by congenital 
mutation in Gs protein (Leet et al., 2004). 
In conclusion, we show here for the first time that OPN plays a crucial role in the 
pathogenesis of idiopathic scoliosis, at least by reducing Gi protein-mediated receptor 
signaling via a mechanism involving α5β1 integrin. 
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Figures Legends 
Figure 1 Genetic deletion of OPN protects bipedal C57BL6 from scoliosis by 
improving Gi protein-mediated receptor signal transduction. (A-D) Female C57Bl/6 
wild-type (WT) and OPN knockout (OPN-/-) mice were amputated from forelimbs and tails 
at 1 month of age and subjected to bipedal ambulation for 36 weeks to induce scoliosis. X-
ray radiographs of the spine as taken at the end of the experiment period. OPN-/- mice did 
not develop scoliosis in the quadrupedal or even bipedal while WT developed in the 
bipedal mice. (E) Plasma OPN was detected in C57Bl/6 (WT) and the bipedal showed 
higher plasma OPN than quadrupedal WT mice. (F-I) GiPCR signaling was checked in 
osteoblasts from WT and OPN-/- mice using DAMGO, somatostatin, oxymethazolin and 
apelin. The response was greater in OPN-/- than WT osteoblasts. On the other hand, bipedal 
WT mice showed lower response than the quadrupedal WT. (G-J) The pre-treatment of 
osteoblasts from WT and OPN-/- mice with PTX blocked the Gi coupling for their cognate 
receptors in these cells, response to each of the previous agonists. This is indicating that 
these compounds evoked typical CDS response profiles of GiPCR in WT and OPN-/- 
osteoblasts. (N-O) Isoproterenol and desmopressin were used to activate Gs while 
bradykinin and endothelin-1 were used to activate Gq through their cognate receptors. 
Osteoblasts from OPN-/- mice were less responsive to Gs stimulation than those from WT 
mice, whereas no difference in the Gq stimulation elicited in WT and OPN-/- osteoblasts. 
 
Figure 2 Extracellular OPN causes Gi protein-coupled receptor signaling dysfunction. 
(A) OPN was knockdown by siRNA in MC3T3-E1 osteoblastic cell line and the capacity of 
GiPCR ligands to induce cell signaling as measured by CDS. Cellular response to DAMGO 
and oxymethazolin was significantly greater in cells depleted of OPN (B) OPN was 
blocked by OPN specific antibody in MC3T3-E1 osteoblastic cell line gave the same 
results as (A). (C-D) MC3T3-E1 osteoblastic cells were treated with exogenous 
recombinant OPN (rOPN) prior to DAMGO and oxymethazolin stimulation. In each case, 
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rOPN caused decrease in the integrated response in a concentration-dependent manner, 
which was prevented by OPN antibody. 
 
Figure 3 CD44 is not involved in the inhibition of GiPCR signaling caused by 
extracellular OPN. (A) The blockage of CD44 by CD44 specific antibody in MC3T3-E1 
osteoblastic cell line and cells treated with rOPN 0.5µg/ml did not affect the Gi signaling 
defect cause by OPN. DAMGO and oxymethazolin were used as agonist for GiPCR. (B-C) 
To validate the activity of anti-CD44 antibody, the cells pre-treated with IgG control or 
CD44 antibody were stimulated with increasing concentrations of hyaluronic acid (HA), a 
high affinity ligand of CD44.  The integrated response induced by HA was completely 
abrogated by pre-treatment with CD44 antibody. Moreover, the effect of CD44 antibody on 
response to HA stimulation was concentration-dependent. (D-E) CD44 was knockdown in 
MC3T3-E1 osteoblastic cell line by siRNA the efficiency of siRNA transfection was 
demonstrated by qPCR and western blot analysis. (F) The knockdown of CD44 led to 
similar results as (A) and CD44 knockdown did not affect the Gi signaling defect cause by 
OPN. (G-H) rOPN treatment caused a concentration-dependent decrease in response to 
both DAMGO and oxymethazolin in osteoblasts from bipedal CD44 knockout (CD44-/-) 
mice. (I-J) Osteoblasts cells form bipedal (CD44-/-) mice were less responsive to DAMG or 
oxymethazolin when compared with osteoblasts from quadrupedal (CD44-/-) mice. 
 
Figure 4 RGD-dependent integrins mediate the inhibitory effect of OPN on GiPCR 
signaling. (A- B & C) OPN binds to integrins through RGD motif and this was clear when 
we inhibit the (SVVYGLR) by bio1211 which selectively inhibits α4β1 integrin, the only 
SVVYGLR-containing integrin present in osteoblasts and did not affect on the OPN 
signaling while coincubation of cells with rOPN and RDG peptide completely prevented 
the inhibitory effect of rOPN in response to DAMGO and oxymethazolin. (D-E) Incubation 
of osteoblasts from WT mice with high concentrations of RGD demonstrated significant 
increase of response to DAMGO or oxymethazolin while no change in osteoblasts from 
OPN-/- mice was observed. 
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Figure 5 Identification of integrins involved in the inhibition of GiPCR signaling by 
OPN. The blockage of the different integrins in MC3T3-E1 osteoblastic cells (A-B-C) 
using specific antibodies and (D-E-F) the knockdown of these integrins in C57Bl/6 bipedal 
WT and CD44-/- was reversed the inhibitory effect of rOPN in response to both DAMGO 
and oxymethazolin through α5β1 integrin. 
 
Figure 6 OPN reduces the availability of Gi proteins for their cognate receptors. (A- B 
& C) MC3T3-E1 osteoblastic cells were treated with PBS or rOPN. Cell lysates were 
analyzed by western blot for the expression of three different GPCRs; including mu-opioid 
(MO), lysophosphatidic acid type 1 (LPA1) and melatonin type 2 (MT2) receptors while 
Gi1, Gi2 and Gi3 proteins isoforms expression was detected by western blot and qPCR. 
There was no significant effect of rOPN treatment on the quantity of Gi proteins or GiPCR. 
(D-E-F) Cells lysates were immunoprecipitated with antibodies against MO, MT2 or β1 
integrin receptors, and the presence of Gi proteins in each precipitate was examined by 
western blot using antibodies specific for Gi1, Gi2 or Gi3 isoform. The amount of each of 
these Gi protein isoforms was elevated in the β1 integrin precipitates following rOPN 
treatment.  
 
Figure 7 OPN enhances the phosphorylation of Gi proteins. (A) MC3T3-E1 cells were 
treated with rOPN, or pre-treated with antibody against α5β1 integrin prior to rOPN 
treatment and then cell lysates were IP by antibodies against Gi1, Gi2 or Gi3 protein 
isoforms, and WB by anti-phospho serine/threonine or anti-tyrosine antibodies. (B) 
Osteoblasts from scoliotic bipedal WT or CD44-/- mice and quadrupedal control mice IP by 
antibodies against Gi1, Gi2 and Gi3 proteins then WB by antibodies against anti-phospho-
serine/threonine or an anti-phospho-tyrosine. (C-E) Cell extracts prepared from MC3T3-E1 
that had been treated with rOPN in the presence or absence of Kinases inhibitors then IP by 
antibodies against Gi1, Gi2 or Gi3 protein isoforms, and WB by anti-phospho 
serine/threonine or anti-tyrosine antibodies. 
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Figure 8 The effect of OPN on GsPCR proteins. (A) MC3T3-E1 cells were treated with 
rOPN or PBS (A) stimulated by isoproterenol and desmopressin or (B) IP by antibodies 
against Gs then WB by antibodies against anti-phospho-serine/threonine or (C-D) IP by 
antibodies against MOR or MT2R then WB by antibodies against Gs. (E) MC3T3-E1 cells 
were treated with PTX to mimic disruption action of rOPN   and compared to cells treated 
with rOPN alone or in combination with Src inhibitor (PP2) to prevent tyrosine 
phosphorylation. 
 
Figure 9 OPN reduces GiPCR signaling and contributes to the development of spinal 
deformity. OPN binding, α5β1 integrin recruits a part of Gi proteins from the common 
pool, then promotes different signaling pathways leading to the activation of various 
kinase, which directly or indirectly phosphorylate a part of the remaining Gi protein in the 
common pool 
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The third manuscript: PTPµ deficiency aggravates the 
harmful role of osteopontin in Idiopathic Scoliosis  
 
We recently demonstrated how OPN played a vital role in the development of the 
spinal deformity through its interaction with α5β1 integrin. In this manuscript we 
demonstrated that the Gi protein coupled receptor (GiPCR) signaling dysfunction mediated 
by the elevation of plasma OPN in AIS patients is exacerbated by the depletion of PTPµ. 
The knockout of PTPµ in C57Bl/6 bipedal mice stimulates the incidence and severity of the 
spinal deformity without affecting plasma levels of OPN or the expression of its receptors. 
PTPµ is also downregulated in AIS patients. Interestingly, this downregualtion of PTPµ is 
more prevalent in the severe AIS cases classified in FG2 group when compared to the two 
other groups and healthy subjects. Although, OPN causes GiPCR signaling dysfunction 
through binding to α5β1 integrin in scoliotic bipedal mice, PTPµ potentiates the binding of 
OPN to α5β1 integrin when compared to others OPN receptors. This mechanism mediated 
by PTPµ is regulated through phosphatidylinositol-phosphate kinase type 1 γ (PIPK1γ).  
 
In this third manuscript, I conceptualized and designed the study, performed the 
immunoprecipitation and western blots experiments and I have done siRNA transfections, 
CDS analysis and carried out the initial analyses, drafted the initial manuscript and 
approved the final manuscript as submitted. 
 
Dr. Marie-Yvonne Akoume contributed in the experimental design and in the generation of 
the results. More specifically she did CellKeyTM experiments for some functional 
experiments, reviewed and revised the manuscript, and approved the final manuscript as 
submitted. 
Mr. Saadallah Bouhanik contributed in the generation of the bipedal mice and their 
phenotypic characterization and approved the final manuscript as submitted. 
Ms. Anita Franco contributed to the ELISA experiments and approved the final manuscript 
as submitted. 
Dr. Alain Moreau contributed to the study conception, the analysis and interpretation of the 
data. He critically revised the manuscript for important intellectual content and approved 
the final manuscript as submitted. 
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ABSTRACT 
 
Recent studies suggest that osteopontin (OPN) plays a critical role in the 
development of idiopathic scoliosis by reducing Gi protein-coupled receptor (GiPCR) 
signaling via β1 integrin engagement. Here, we establish a link between severity of 
scoliosis associated with OPN action and lack of protein tyrosine phosphatase µ (PTPµ), a 
negative regulator of integrin activation. We demonstrate that genetic deletion of PTPµ 
enhances the incidence and severity of scoliosis without affecting plasma levels of OPN or 
the expression of its receptors. In contrast, increased interaction of OPN with β1 integrin 
was notified in cells depleted of PTPµ. Furthermore, reduction of GiPCR signaling by OPN 
was also to the higher extent in these cells, while their response to GiPCR stimulation was 
improved with siRNA of phosphatidylinositol-phosphate kinase type I gamma (PIPK1γ), a 
PTPµ substrate that favours ligand binding to integrin. These studies provide the first 
indication that the loss of PTPµ exacerbates spinal deformity progression, possibly by 
amplifying the inhibitory effect of OPN on GiPCR signaling. 
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INTRODUCTION 
Idiopathic scoliosis is a three-dimensional deformity of the spine with lateral 
curvature accompanied by a vertebral rotation (1). Despite considerable advances in 
research involving this disease, the aetiology and pathogenesis remain unclear (2), (3), (4). 
From the current understanding, it is generally accepted that the cause of idiopathic 
scoliosis is multifactorial (2), (3), (4) and an emerging concept indicate that biological 
process driving the pathogenesis may implicate defective GiPCR signaling (5), (6), (7).  
Recently, we have identified OPN, a multifunctional cytokine, as a potentially key 
pathophysiologic contributor in the development of idiopathic scoliosis (Akoume et al., 
2013a, 1st manuscript of the thesis). Particularly, we have documented increased plasma 
OPN levels in patients with idiopathic scoliosis and in bipedal mice, a well-established 
animal model of this disease. Furthermore, using OPN knockout mice, we demonstrated 
that a lack of OPN, protects bipedal mice against scoliosis. We further showed that OPN 
reduces GiPCR signaling in vitro via a dual mechanism involving β1 integrin engagement. 
It is known that the engagement of integrins by ligands is facilitated by the binding 
of talin that allows integrins to switch from the low affinity to the high affinity form for 
ligands (8), (9), (10). Previously, talin binding to integrin was shown to be modulated by 
PIPK1γ. This enzyme generates the lipid second messenger phosphatidylinositol-4,5 
biphosphate (PI4,5P2), which promotes the interaction of talin with integrin (11). Tyrosine 
phosphorylation of PIPK1γ upon FAK-dependent Src activation is essential for this 
interaction since it stimulates the catalytic activity of this enzyme, resulting in enhanced 
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PI4,5P2 production in the vicinity of  integrin and further promotion of talin binding to 
integrin (12), (13). Termination of this process occurs following dephosphorylation by 
various tyrosine phosphatases among which PTPµ has been identified as the most 
promising for maintaining PIPK1γ in a hypophosphorylated state (14).  
Based on these considerations, we hypothesized that lack of PTPµ may exacerbate 
the inhibitory effect of OPN on GiPCR signaling and stimulate spinal deformity 
progression. Our results show that the genetic deletion of PTPµ enhances the incidence and 
severity of scoliosis, possibly by enhancing the interaction of OPN with β1 integrin. This 
study highlights the importance of the inhibitory effect of OPN on GiPCR signaling in the 
pathogenesis of idiopathic scoliosis.  
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Materials and Methods 
Patient recruitment 
The Institutional Review Board of The Sainte-Justine Hospital, Montreal, Quebec 
approved this study. Parents or legal guardians of all participants gave their written 
informed consent, and minors gave their assent. One of the orthopedic surgeons at the 
Saint-Justine Children’s hospital clinically assessed each patient, and all bone biopsies 
were collected during corrective surgeries. For AIS patients, bone specimens were obtained 
intra-operatively from vertebrae (varying from T3 to L4 according to the surgical procedure 
performed), while with trauma cases (used as non-scoliotic controls), bone specimens were 
obtained from other anatomical sites (tibia, femur or iliac crest).  
Experimental animal models 
The Institutional Review Board for the care and handling of animals used in 
research (CHU Sainte-Justine) has approved the protocol in accordance with the guidelines 
of the Canadian Council of Animal Care. 
 The bipedal mouse model has been generated as described by Oyama et al (2006) 
(15). Amputation of the forelimbs and tail was performed under anesthesia after weaning 
(5-weeks after birth), as reported by Oyama et al. (2006) (15). A Faxitron X-ray instrument 
(Faxitron MX20- Faxitron Co., Arizona, USA) was used to image and examine the spine of 
these mice monthly post-weaning, up until their sacrifice at nine months of age. Bipedal 
surgeries were performed on 120 mice from each wild type, PTPµ knockout (a gift from 
Dr. Gebbink MF, Laboratory of Thrombosis and Haemostasis, Department of Clinical 
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Chemistry and Haematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 
CX Utrecht, The Netherlands), and OPN knockout mice (a gift from Dr. Susan R. Rittling 
and Dr. David T. Denhard, Department of Cell Biology and Neuroscience, Rutgers 
University, Piscataway, New Jersey 08854, USA).  
 
Derivation of primary osteoblast cultures 
In human subjects, we derived primary osteoblast cell cultures from AIS and 
control patient biopsies that were obtained intra-operatively. Bone specimens from mice 
were obtained from the spine after euthanasia. Bone fragments were reduced to smaller 
pieces with a cutter in sterile conditions. The small bone pieces were incubated in αMEM 
medium containing 10% fetal bovine serum (FBS; certified FBS, Invitrogen, Burlington, 
ON, Canada) and 1% penicillin/ streptomycin (Invitrogen) at 37°C in 5% CO2, in a 10-cm2 
culture dish. After one month, osteoblasts emerging from the bone pieces were separated 
from the remaining bone fragments by trypsinization. RNA was extracted from the 
osteoblasts using the TRIzol method, (Invitrogen). Expression profiles of the PTPµ gene 
was studied by qPCR. Transcript expression was assessed with the Stratagene Mx3000P 
(Agilent Technologies, La Jolla, CA).  
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Quantitative reverse transcription-polymerase chain reaction (qPCR) 
Thermo-Script reverse transcriptase (Invitrogen) was used to reverse mRNA into cDNA 
(1mg total concentration). Several dilutions were tested to choose the concentration that 
yielded the most efficient amplification. The human primers used were the following:  
β-actin forward  5'-GGAAATCGTGCGTGACAT-3',  
β-actin reverse 5'-TCATGATGGAGTTGAAGGTAGTT-3',  
PTPµ forward  5'-GGCCGGACTTTTGCTAACT-3',  
PTPµ reverse  5'-TGTGCTATACGGCTCATCAAA-3',  
CD44 forward  5'-AGCATCGGATTTGAGACCTG-3',  
CD44 reverse   5'-TGAGTCCACTTGGCTTTCTG-3'  
β1 integrin forward 5'-ATGTGTCAGACCTGCCTTG-3',  
β1 integrin reverse 5'-TTGTCCCGACTTTCTACCTTG-3',  
β3 integrin forward  5'-GGAAAGTCCATCCTGTATGTGG-3'  
β3 integrin reverse  5'-GAGTTTCCAGATGAGCAGGG-3'  
αv integrin forward 5'-GTCCCCACAGTAGACACATATG-3', 
αv integrin reverse 5'-TCAACTCCTCGCTTTCCATG-3',  
α1 integrin forward  5'-GACATTTGGATGAACTTTAGTCACC-3', 
α1 integrin reverse  5'-GGCAATGGAATTCACGACTTG-3', 
α4 integrin forward  5'-GGATGAGACTTCAGCACTCAAG-3', 
α4 integrin reverse  5'-GGTGAAATAACGTTTGGGTCTTTG-3', 
β3 integrin forward 5'-GGAAAGTCCATCCTGTATGTGG-3', 
β3 integrin reverse  5'-GAGTTTCCAGATGAGCAGGG-3', 
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β5 integrin forward 5'-CTTGCACTCCTGGCTATCTG-3', 
β5 integrin reverse  5'-TGCGTGGAGATAGGCTTTC-3', 
β8 integrin forward  5'-GATTGGGTTGCTTAAAGTCCTG-3',  
β8 integrin reverse  5'-GGTAGGTGACTGCT CTTGTG-3'. 
Each amplification was performed in duplicate using  5ml of diluted cDNA, 7,5ml 
of 3mM primer solution and 12,5ml of  2X QuantiTect SYBR Green PCR Master Mix 
(QIAGEN Inc, Ontario, Canada). All reaction mixes were run on Mx3000P system from 
Stratagene (Agilent Technologies Company, La Jolla, CA) and analyzed with MxPro 
QPCR Software also from Strata-gene. Relative quantification was calculated with the delta 
CT method using β-actin as the endogenous control. 
 
Isolation of plasma membrane (PM) protein from cell culture 
Osteoblasts from human subjects were washed the cell monolayer 3 times with cold 
PM (plasma membrane) buffer [0.25 M Sucrose, 1mM EDTA and 20 mM Tricine] and 2 
ml of cold PMC buffer (PM buffer plus 1X protease inhibitors, 1mM PMSF, 0.4 mM 
Sodium Orthovanadate) was added. The cells were scraped from the petri dishes and 
centrifuged at 1000xg for 5 min. The pellet (5 cm) was dissolved in 600 μl of cold PMC 
buffer. The pellet was then homogenized using ceramic beads (Precellys) 3x 5500xg for 
20″ with 2 min between each cycle, and then centrifuged at 1000xg for 10 min at 4°C. The 
Post-Nuclear Supernatant (PNS) was kept on ice. The pellet was resuspended in 300 μl 
PMC buffer, the homogenization step was repeated once more and then centrifuged at 
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1000xg for 10 min at 4°C. The protein concentration was measured; PNS was layered on 
the top of 15 ml of 30% percoll with PMC buffer (in 25x 89 mm tubes). The samples were 
centrifuged in a fixed angle rotor at 84,000xg (50.2Ti rotor) for 30 min at 4°C. PM fraction 
was visible as a band at a distance of 5.7 cm from the bottom of tube. To remove any trace 
of percoll, the samples were centrifuged in a S45-A rotor in a sorval M150 micro-
ultracentrifuge at 105,000xg (TLA100.4 rotor) for 90 min. A tightly packed pellet was 
formed by the percoll and PM fraction was carefully removed and stored at -80°C for 
immunoprecipitation and western blot methods. The concentration of protein was measured 
using, Protein Bio Rad, (Bio-Rad laboratories, California, U.S.A). 
 
 Immunoprecipitation and western blot  
A pre-clearing step was done to reduce the non-specific binding of proteins to 
agarose or sepharose beads. Briefly, 25 μl of protein sepharose (A) beads (GE Healthcare 
Bioscience AB, Canada) were added to the PM protein solution (1.0mg). The mix was 
incubated for 30 minutes at 4°C with gentle agitation. The solution was then centrifuged at 
16,200 xg at 4°C for 1 minute. The pellet was discarded and the supernatant was kept for 
immunoprecipitation. To immunoprecipitate the PTPµ we added 1μg of anti-PTPµ 
antibody (SC-25433), (Santa Cruz Biotechnology Inc., Santa Cruz, CA) /1 mg protein. The 
sample was incubated with the antibody overnight at 4°C with agitation. To each sample, 
50μl of protein sepharose (A) beads were added and then mixed gently using wide-
mouthed pipette tips. The lysate-beads mixture was incubated at 4°C with agitation for 2 
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hours. After incubation the tubes were centrifuged, the supernatant was removed and the 
beads were washed in PM buffer three times (each time centrifuging at 4°C and removing 
the supernatant). Finally, the supernatant was removed and 50 μl of 3x loading (Laemmli) 
buffer was added. Samples were boiled at 100°C for 5 minutes to denature the protein and 
separate it from the protein a beads, then samples were centrifuged and the supernatant was 
kept for the protein marker. Samples were subjected to 5%-12% gradient SDS–PAGE, 
transferred to PVDF (polyvinylidene fluoride) membrane and immunoblotted using anti- 
PTPµ anti-mouse (1:500 dilution of primary antibodies; Santa Cruz Biotechnology Inc., 
Santa Cruz, CA; 1:10,000 dilution of horseradish peroxidase-conjugated secondary 
antibodies, BioSource Inc. Camarillo, CA). Reactive bands were visualized using an 
enhanced chemiluminescent kit (BM Chemiluminescent blotting substrate POD) according 
to the manufacturer’s specifications (Roche Diagnostic Corp., Indianapolis, IN). Similarly, 
in order to validate the interaction between OPN and its cognate receptors, the different 
receptors for OPN were immunoprecipitated using different antibodies. For each receptor 
1μg was added per 1 mg protein these antibodies, integrin β1 (SC-6622), integrin β3 (SC-
6627), integrin β5 (SC-5401), integrin α4 (sc- 6589), integrin α5 (sc-166681), integrin α8 
(sc-30983) (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and integrin αv (4711) (Cell 
signaling technology, Ontario, Ca). This Immunoprecipitation was followed by western 
blot using anti-OPN anti mouse (1/2000) (courtesy of Dr. Marc D. McKee, McGill 
University). The previous antibodies were used for western blot detection (1/ 1000).  
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Analysis of G protein signaling  
The signaling capacity of G proteins was assessed from osteoblast cultures using 
cellular dielectric spectroscopy (CDS) performed on a CellKey™ apparatus (MDS Sciex, 
San Francisco, CA), as described in Akoume, et al., 2010.  To determine the precise class 
of G protein activated, we used specific agonists that bind to GPCR and regulate either Gi, 
Gs or Gq proteins: Lysophosphatidic acid (LPA) (Sigma Aldrich, Canada),  Melatonin 
(Mel) (Sigma Aldrich, Canada) and Somatostatin (Som) (Tocris Bioscience, Canada) were 
used to test Gi protein coupled receptors;  Isoproterenol (Iso) and Vasopressin (Vaso) (both 
from Tocris Bioscience, Canada) to test Gs protein coupled receptors, and finally  
Bradykinin (BK) and Endothelin-1 (both from Tocris Bioscience, Canada) to test Gq 
protein coupled receptors. 
Furthermore, Pertussis toxin (PTX) (Sigma Aldrich, Canada) was used to determine 
if the effect of the agonists was related to G αi proteins.  This toxin is produced by 
Bordetella pertussis and it catalyzes the adenosine diphosphate (ADP)-ribosylation of some 
G-proteins at a cysteine residue near the C-terminus resulting in uncoupling of receptor and 
G-protein.  
siRNA transfection 
  Primary osteoblast cell cultures from C57Bl/6 WT and PTPµ-/- were cultured (as 
described above). Lipofectamine RNAimax (Invitrogen) was applied for DNA transfection 
according to the manufacturer’s instructions. The sequence of RNA oligo used for the 
knockdown of OPN is (CCA CAG CCA CAA GCA GUC CAG AUU A). The cells were 
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harvested for RNA extraction after 48hrs. The same procedure was followed for 
phosphatidylinositol-phosphate kinase type I gamma (PIPK1γ). The sequence of RNA 
oligo used for the knockdown of PIPK1γ is (CCU CCA CAU CGG GAU UGA UAU U). 
Osteopontin immunosorbent assays 
Peripheral blood samples from mice were collected in EDTA-treated tubes and then 
centrifuged. Derived plasma samples were aliquoted and kept frozen at -80°C until thawed 
and analyzed. Plasma concentrations of OPN were measured by capture enzyme-linked 
immunosorbent assays (ELISA) according to protocols provided by the manufacturer (IBL, 
Hamburg, Germany). The OPN ELISA kit measures total concentration of both 
phosphorylated and non-phosphorylated forms of OPN in plasma. All ELISA tests were 
performed in duplicate and reading were performed at 450 nm 
Statistical analysis 
Data are presented as mean ± SE, and were analyzed by ANOVA or Student’s t test 
using GraphPad Prism 4.0 software. Multiple comparisons of means were performed with 
one-way ANOVA followed by a post-hoc test of Dunnett. Only P values < 0.05 were 
considered significant. 
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RESULTS 
Lack of PTPµ influences the nature of scoliosis associated with high 
plasma OPN in bipedal mice       
Amputation of forelimbs and tails induces scoliosis in mice after 40 weeks of 
bipedal ambulation (16), (15) and increases their plasma OPN levels. Consistent with this 
approach, scoliosis was induced in female wild type (WT) and PTPµ knockout (PTPµ-/-) 
mice to examine the impact of PTPµ deficiency on the development of scoliosis under high 
plasma OPN conditions. Measurements of OPN in plasma from PTPµ-/- mice were 
performed each 12 weeks during the experimental period. Results presented in (Figure 1 
A), have revealed no significant difference in plasma OPN level between normal scoliotic 
C57Bl/6 bipedal mice and PTPµ ko ones. At all time points, levels of plasma OPN in WT 
and PTPµ-/- mice were similar. Of all mice examined by radiography at the final time point 
36th postoperative week, lateral curvature was apparent in 55 % of WT and 85 % of PTPµ-/- 
mice, indicating a higher incidence of scoliosis in PTPµ-/- than in WT mice (Figure 1 B). 
The lateral curvature was also more pronounced in PTPµ-/- mice, as illustrated by 
representative radiographs in (Figure 1 C and D), suggesting that scoliosis is more severe 
in PTPµ-/- than in WT mice. These data emphasize that lack of PTPµ exacerbates spinal 
deformity progression and support a link between development of scoliosis and high 
plasma OPN in bipedal mice.  
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Lack of PTPµ amplifies the defective GiPCR signaling in bipedal mice  
 We have recently provided evidences for the occurrence of defective GiPCR 
signaling in bipedal mice by demonstrating a reduced ability of various GiPCR selective 
agonists to promote cell signaling as measured by CDS using mouse (Akoume et al., 
2013b, 2nd manuscript of the thesis). To examine the impact of PTPµ-/- deficiency on this 
defect, osteoblasts from WT and PTPµ-/- mice were screened for their response to three 
GiPCR selective agonists identified in (Figure 2). In agreement with our previous results, 
all three compounds evoked typical CDS response profiles of GiPCR in WT osteoblasts. 
Consistent with Gi coupling for their cognate receptors in these cells, response to each of 
the three tested compounds was blocked by pre-treatment with PTX (Figure 2 A-F). 
Similar results were obtained with PTPµ-/- osteoblasts (Figure 2 G-L). Results illustrated 
in Figure 3 show that all three compounds increased response in a concentration-dependent 
manner in osteoblasts from WT and PTPµ-/- mice. However, in each case, osteoblasts from 
PTPµ-/- mice were less responsive than those from WT mice, but EC50 values were similar 
in both groups (Figure 3 A-C). These results suggest that lack of PTPµ affects Gi protein 
activity independently of the receptor. 
 To relate these findings to the OPN action, we used the small interference RNA 
(siRNA) approach to knockdown the expression of OPN in WT and PTPµ-/- osteoblasts. 
The efficiency of siRNA in these osteoblasts was demonstrated by qPCR and western blot 
analysis (Figure 3 D and E). We found that the deletion of OPN enhanced response to 
GiPCR stimulation in WT and PTPµ-/- osteoblasts and abrogated the difference in the 
degree of their responses (Figure 3 F-H). These results support a role for OPN in the 
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defective GiPCR signaling in bipedal mice and suggest that lack of PTPµ exacerbates the 
inhibitory effect of OPN on GiPCR signaling. 
 To test this hypothesis, WT and PTPµ-/- osteoblasts were treated with varying 
concentrations of exogenous recombinant OPN (rOPN) prior to GiPCR stimulation with 
agonists identified in (Figure 4 A-C) in each case, rOPN caused decrease in the integrated 
response in a concentration-dependent manner, as well in WT as in PTPµ-/- osteoblasts. 
However, IC50 values were lower in PTPµ-/- compared to WT osteoblasts, suggesting that 
osteoblasts from PTPµ-/- mice are more sensitive to the inhibitory effect of OPN on GiPCR 
signaling 
 
Lack of PTPµ influences the interaction of OPN with integrin in 
osteoblasts 
 We have previously demonstrated that OPN inhibited GiPCR signaling in 
osteoblasts cells via a dual mechanism involving α5β1 integrin (Akoume et al., 2013b, 2nd 
manuscript of the thesis). Since OPN interacts with various receptors among which 
osteoblasts have been shown to express αvβ1, αvβ3, αvβ5, α4β1, α5β1 and α8β1 integrins and 
CD44 (17), (18), (19), (20), (21), (22), it was of interest to examine whether α5β1 integrin is 
also the unique receptor responsible for the effects associated with PTPµ deficiency. For 
this purpose, we first examined the expression levels of all these mentioned receptors, 
using a qPCR analysis. As illustrated in (Figure 5A), we found no significant difference in 
expression of integrin at the mRNA levels between WT and PTPµ-/- osteoblasts. Similar 
profiles were obtained when protein levels of these receptors were determined by western 
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blot (Figure 5 B). These results exclude the possibility that the effects associated with 
PTPµ deficiency implicate changes in receptor expression. 
 Then, we sought to examine if the interaction of OPN with receptor is influenced by 
PTPµ deficiency. For this purpose, cell lysates from WT and PTPµ-/- osteoblasts were 
immunoprecipitated with antibodies against OPN receptors and the interaction with OPN 
was revealed by western blot using antibody specific for OPN indicated in (Figure 5 C). 
Results showed that OPN was co- immunoprecipitated with all receptors in WT and PTPµ-/- 
osteoblasts. However, levels of OPN in the β1 and α5 integrins immunoprecipitates were 
increased by more than 30 fold in PTPµ-/- osteoblasts compared to WT osteoblasts, while 
there was only a moderate difference (0,8 to 2,3 fold) in the levels of other integrins 
between both cell groups. In contrast, levels of OPN in CD44 immunoprecipitates were 
similar in WT and PTPµ-/- osteoblasts. These results suggest that loss of PTPµ favours the 
interaction of OPN with integrins in osteoblasts and indicate that α5β1 integrin is possibly 
the most promising receptor responsible for the effects associated with PTPµ deficiency. 
 
  
  
 
166
Silencing of PIPK1γ selectively enhances GiPCR signaling in  PTPµ-/- 
osteoblasts 
To understand the molecular basis of the interaction of OPN with integrin in the 
absence of PTPµ, we gave special attention to PIPK1 because the catalytic activity of 
PIPK1γ by tyrosine phosphorylation is essential for enhancing the affinity of integrin for 
ligands, and this enzyme has been shown to be dephosphorylated by PTPµ-/-. Therefore, we 
hypothesized that loss of PTPµ amplifies the reduction in GiPCR signaling through the 
sustained activation of PIPK1γ. To test this hypothesis, we first examined the 
phosphorylation status of PIPK1γ in WT and PTPµ-/- osteoblasts. Accordingly, cell lysates 
were immunoprecipitated with PIPK1γ antibody and probed with phospho-tyrosine 
antibody. As expected, phosphorylation levels of PIPK1γ were higher in osteoblasts from 
PTPµ-/- than those from WT mice, while levels of PIPK1γ total form were comparable 
between both phenotypes (Figure 6 A). To examine whether FAK and Src are responsible 
for the increased phosphorylation of PIPK1γ observed in osteoblasts from PTPµ-/- mice, 
cells were treated with inhibitor of Src (PP2) and FAK (inhibitor-14) prior to 
immunoprecipitation assay. As expected, levels of PIPK1γ phosphorylation were 
attenuated by both treatments.  This suggests that the activity of PIPK1γ is abnormally 
elevated in osteoblasts from PTPµ-/- mice upon FAK and Src action.  
To further provide the implication of PIPK1γ in the mechanism of action behind 
PTPµ deficiency, we used SiRNA approach to knockdown the expression of PIPK1γ in 
WT and PTPµ-/- osteoblasts prior to initiate GiPCR signaling with somatostatin stimulation. 
Efficiency of siRNA in WT and PTPµ-/- osteoblasts was confirmed by qPCR and western 
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blot analysis (Figure 6 B and C). Representative index curves illustrated in (Figure 6 D-
H) show that impedance signatures were not affected in WT and PTPµ-/- osteoblasts 
depleted of PIPK1γ. Both cells exhibited typical CDS response of GiPCR following 
somatostatin stimulation. In contrast, the screening at varying concentrations of 
somatostatin revealed that depletion of PIPK1γ enhanced response to somatostatin 
stimulation in osteoblasts from PTPµ deficiency mice, but not in those from WT mice. In 
addition, PTPµ-/- osteoblasts depleted of PIPK1γ exhibited similar degree of response to 
somatostatin stimulation than WT osteoblasts, indicating that depletion of PIPK1γ 
abrogates the difference in their ability to respond to GiPCR stimulation. 
Collectively, these results suggest that the amplified reduction in GiPCR signaling 
observed in osteoblasts from PTPµ-/- deficient mice is due to the dysregulation of PIPK1γ 
activity resulting from loss of PTPµ. 
 
PTPµ is downregulated in osteoblasts from patients with idiopathic 
scoliosis 
 To explore the clinical relevance of the loss of PTPµ in the development of 
idiopathic scoliosis, we first investigate PTPµ expression level in patients with idiopathic 
scoliosis and healthy control subjects. We found that PTPµ expression was clearly detected 
in osteoblasts from control subjects but was decreased in those from patients with 
idiopathic scoliosis, whereas expression levels of β-actin were similar between both groups 
(Figure 7 A and B). We found at least a 50 % decrease in PTPµ mRNA in osteoblasts 
from scoliotic patients relative to control subjects. Similar results were obtained when cell 
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lysates were analysed by western blot to examine protein levels of PTPµ (Figure 7C). 
These data clearly indicate that PTPµ is downregulated in patients with idiopathic scoliosis. 
DISCUSSION 
 We have recently established a causative role between circulating OPN and the 
development of scoliosis using bipedal mice, a well-established model of idiopathic 
scoliosis. These mice exhibit high plasma OPN levels and are protected from scoliosis by 
the genetic deletion of OPN (Akoume et al., 2013b, 2nd manuscript of the thesis). Our study 
has also revealed a defective GiPCR signaling in their osteoblasts and suggested that OPN 
contributes to pathogenesis of scoliosis in this model by interfering with GiPCR signaling. 
Results of the present study support such notion and provide the first evidence that severe 
manifestations of scoliosis under high plasma OPN conditions may implicate decrease in 
PTPµ protein. Indeed, the present study reveals that bipedal PTPµ-/- mice displayed greater 
incidence of scoliosis and exhibited more pronounced lateral curvature than bipedal WT 
mice. There was, however, no association between OPN concentrations and disease 
severity, since WT and PTPµ-/- mice exhibited similar plasma OPN levels. This observation 
was strongly suggestive that the relationship between OPN and PTPµ deficiency in bipedal 
mice extends beyond the OPN production and lies probably at the level of OPN action. In 
this regard, an earlier study from our laboratory has demonstrated that OPN has an 
inhibitory effect on GiPCR signaling via a mechanism that requires β1 integrin engagement. 
Here, we add to these findings that the PTPµ deficiency leads to the amplification of the 
inhibitory effect of OPN on GiPCR signaling. We further provided the mechanistic insights 
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by demonstrating that lack of PTPµ favours the interaction of OPN with β1 integrin via 
PIPK1γ action. 
 It should be noted that the association of integrins with theirs ligands can be 
regulated by the tyrosine phosphorylation of PIPK1γ upon FAK-dependent Src activation 
(12), (13) and a recent study has shown that PIPK1γ is dephosphorylated by PTPµ (14). 
Consistent with these observations, we found increased tyrosine phosphorylated PIPK1γ in 
osteoblasts from PTPµ-/- mice, and this increased phosphorylation was attenuated by the 
inhibition of FAK and Src with pharmacological inhibitors. Thus, our data demonstrate that 
PIPK1γ can be viewed as a key player in the increased reduction of GiPCR signaling 
observed in the absence of PTPµ. This is further supported by the observation that silencing 
of PIPK1γ by siRNA abrogated the difference in the degree of response between WT and 
PTPµ-/- osteoblasts. Collectively, these results suggest that loss of PTPµ causes a 
dysregulation of PIPK1γ activity, which in turn leads to the amplification of the inhibitory 
effect of OPN on GiPCR signaling and the subsequent severe lateral curvature. 
 It was particularly interesting to observe that osteoblasts from PTPµ-/- mice were 
more sensitive to the inhibitory effect of OPN on GiPCR signaling. This finding together 
with the fact that PTPµ-/- mice exhibited more severe lateral curvature, support the notion 
that repression of GiPCR signaling is an important event in biological process driving the 
development of scoliosis and indicate that decrease of PTPµ protein could underlie the 
major changes in the pathobiology of scoliosis and play an important role in severe 
progression of scoliosis in bipedal mice. 
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 Our findings may have important clinical implications since by extending our study 
to humans, we found that all scoliotic patients examined exhibited lower levels PTPµ 
protein than control individuals. However, a disparity in PTPµ protein levels was observed 
among scoliotic patients. Therefore, it is tempting to speculate that patients exhibiting very 
low PTPµ protein levels will be more sensitive to OPN effect and more likely at risk for 
severe progression of idiopathic scoliosis. 
 Early prediction of clinical outcome in individuals affected with idiopathic scoliosis 
could be crucial to improve the treatment of severe scoliosis. Thus, the expression levels of 
PTPµ could potentially be used as a marker for predicting the clinical outcome of affected 
individuals. However, future studies will be necessary to correlate PTPµ expression levels 
with the risk of scoliosis progression and to better define the thresholds below which PTPµ 
expression could become rate limiting for severe progression of scoliosis. In this context, 
we have previously categorized three groups of scoliotic patients according to their degree 
of alteration in GiPCR signaling (5), (7), (Akoume et al., 2013a. 1st manuscript of the 
thesis)  
 On the other hand, we have suggested a genetic factor in the defective GiPCR 
signaling associated with idiopathic scoliosis, by demonstrating that affected individuals 
from the same family exhibited the same degree of GiPCR signaling defect and belonged to 
the same functional group (Akoume et al., 2013a, 2nd manuscript of the thesis). Therefore, it 
should be expected that loss of PTPµ protein could also contribute to genetic predisposition 
for sensitivity to the OPN action on GiPCR signaling and to the development of severe 
idiopathic scoliosis in children of affected parents. Thus, identifying and targeting the 
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genetic and epigenetic mechanisms underlying PTPµ downregulation in individuals with 
idiopathic scoliosis will be a first step toward identifying strategy for preventing PTPµ 
repression. 
 
CONCLUSION 
 To our knowledge, the present study provides the first evidence that lack of PTPµ 
can exacerbate spinal deformity progression, possibly by amplifying the inhibitory effect of 
OPN on GiPCR signaling. In addition, this study identifies dysregulation of PIPK1γ due to 
the loss of PTPµ as a unique mechanism underlying development of severe lateral 
curvature under high plasma OPN conditions. 
 
 
 
  
  
 
172
References  
1. Kane, W. J. (1977) Scoliosis prevalence: a call for a statement of terms. Clinical 
orthopaedics and related research, 43-46 
2. Dickson, R. A. (1992) The etiology and pathogenesis of idiopathic scoliosis. Acta 
orthopaedica Belgica 58 Suppl 1, 21-25 
3. Machida, M. (1999) Cause of idiopathic scoliosis. Spine 24, 2576-2583 
4. Burwell, R. G. (2003) Aetiology of idiopathic scoliosis: current concepts. Pediatric 
rehabilitation 6, 137-170 
5. Moreau, A., Wang, D. S., Forget, S., Azeddine, B., Angeloni, D., Fraschini, F., 
Labelle, H., Poitras, B., Rivard, C. H., and Grimard, G. (2004) Melatonin signaling 
dysfunction in adolescent idiopathic scoliosis. Spine 29, 1772-1781 
6. Azeddine, B., Letellier, K., Wang da, S., Moldovan, F., and Moreau, A. (2007) 
Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic 
scoliosis. Clinical orthopaedics and related research 462, 45-52 
7. Akoume, M. Y., Azeddine, B., Turgeon, I., Franco, A., Labelle, H., Poitras, B., 
Rivard, C. H., Grimard, G., Ouellet, J., Parent, S., and Moreau, A. (2010) Cell-
based screening test for idiopathic scoliosis using cellular dielectric spectroscopy. 
Spine 35, E601-608 
8. Tozer, E. C., Hughes, P. E., and Loftus, J. C. (1996) Ligand binding and affinity 
modulation of integrins. Biochemistry and cell biology 74, 785-798 
9. Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 
673-687 
10. Calderwood, D. A. (2004) Integrin activation. Journal of cell science 117, 657-666 
11. Martel, V., Racaud-Sultan, C., Dupe, S., Marie, C., Paulhe, F., Galmiche, A., Block, 
M. R., and Albiges-Rizo, C. (2001) Conformation, localization, and integrin 
binding of talin depend on its interaction with phosphoinositides. The Journal of 
biological chemistry 276, 21217-21227 
  
  
 
173
12. Di Paolo, G., Pellegrini, L., Letinic, K., Cestra, G., Zoncu, R., Voronov, S., Chang, 
S., Guo, J., Wenk, M. R., and De Camilli, P. (2002) Recruitment and regulation of 
phosphatidylinositol phosphate kinase type 1γ by the FERM domain of talin. Nature 
420, 85-89 
13. Ling, K., Doughman, R. L., Iyer, V. V., Firestone, A. J., Bairstow, S. F., Mosher, D. 
F., Schaller, M. D., and Anderson, R. A. (2003) Tyrosine phosphorylation of type Iγ 
phosphatidylinositol phosphate kinase by Src regulates an integrin–talin switch. The 
Journal of cell biology 163, 1339-1349 
14. Sakamoto, Y., Ogita, H., Komura, H., and Takai, Y. (2008) Involvement of nectin 
in inactivation of integrin αvβ3 after the establishment of cell-cell adhesion. Journal 
of Biological Chemistry 283, 496-505 
15. Oyama, J., Murai, I., Kanazawa, K., and Machida, M. (2006) Bipedal ambulation 
induces experimental scoliosis in C57BL/6J mice with reduced plasma and pineal 
melatonin levels. Journal of pineal research 40, 219-224 
16. Machida, M., Dubousset, J., Yamada, T., Kimura, J., Saito, M., Shiraishi, T., and 
Yamagishi, M. (2006) Experimental scoliosis in melatonin-deficient C57BL/6J 
mice without pinealectomy. Journal of pineal research 41, 1-7 
17. Hughes, P. E., Renshaw, M. W., Pfaff, M., Forsyth, J., Keivens, V. M., Schwartz, 
M. A., and Ginsberg, M. H. (1997) Suppression of integrin activation: a novel 
function of a Ras/Raf-initiated MAP kinase pathway. Cell 88, 521-530 
18. Gronthos, S., Stewart, K., Graves, S. E., Hay, S., and Simmons, P. J. (1997) 
Integrin Expression and Function on Human Osteoblast‐like Cells. Journal of 
Bone and Mineral Research 12, 1189-1197 
19. Grzesik, W. J., and Robey, P. G. (1994) Bone matrix RGD glycoproteins: 
immunolocalization and interaction with human primary osteoblastic bone cells in 
vitro. Journal of bone and mineral research : the official journal of the American 
Society for Bone and Mineral Research 9, 487-496 
  
 
174
20. Clover, J., Dodds, R. A., and Gowen, M. (1992) Integrin subunit expression by 
human osteoblasts and osteoclasts in situ and in culture. Journal of cell science 103 
( Pt 1), 267-271 
21. Moursi, A. M., Globus, R. K., and Damsky, C. H. (1997) Interactions between 
integrin receptors and fibronectin are required for calvarial osteoblast differentiation 
in vitro. Journal of cell science 110 ( Pt 18), 2187-2196 
22. Pistone, M., Sanguineti, C., Federici, A., Sanguineti, F., Defilippi, P., Santolini, F., 
Querze, G., Marchisio, P. C., and Manduca, P. (1996) Integrin synthesis and 
utilization in cultured human osteoblasts. Cell biology international 20, 471-479 
  
 
175
Figures Legends 
 
Figure 1 Lack of PTPµ influences the nature of scoliosis associated with high plasma 
OPN in bipedal mice. (A) Plasma OPN was detected in C57Bl/6j Wild type (WT) and 
PTPµ-/- each 12 weeks during the experimental period. No difference was detected at all 
time points in the plasma OPN levels of WT and PTPµ-/- mice. The higher values were 
notified at the 36th postoperative week in both phenotypes. (B, C & D) All the mice were 
examined by radiography the PTPµ-/- showed increase in the incidence and severity 
comparing to wild type mice. 
 
Figure 2 Specificity of the agonists to GiPCR signaling. The pre-treatment of osteoblasts 
from WT and PTPµ-/- mice with PTX blocked the Gi coupling for their cognate receptors in 
these cells, response to each of the three tested compounds (Apelin- 17 (APJR), 
Oxymethazolin (α2-ADR) & Somatostatin (SSTR)). (A-B-C) C57Bl/6j Wild type (WT) 
cells treated with vehicle (D-E-F) C57Bl/6j Wild type (WT) cells treated with PTX (G-H-I) 
C57Bl/6j (PTPµ-/-) cells treated with vehicle (J-K-L) C57Bl/6j (PTPµ-/-) Cells treated with 
PTX. This is indicating that these compounds evoked typical CDS response profiles of 
GiPCR in WT and PTPµ-/- osteoblasts. 
 
Figure 3 Lack of PTPµ exacerbates the defective GiPCR signaling in bipedal mice. 
(A-C) Osteoblasts from PTPµ-/- mice were less responsive than those from WT mice to 
Apelin-17 (APJR), Oxymethazolin (α2-ADR) & Somatostatin (SSTR). Different 
  
 
176
concentrations for each agonist were used leading to increased response in a concentration-
dependent manner in osteoblasts from WT and PTPµ-/- mice. (D-E) OPN was knockdown 
in WT and PTPµ-/- osteoblasts cells and knockdown efficiency was determined by qPCR 
and western blot. (F-G-H) The lack of PTPµ exacerbates the inhibitory effect of OPN on 
GiPCR signaling using the same three agonists which mentioned above. 
 
Figure 4 Lack of PTPµ exacerbates the defective GiPCR signaling caused by OPN. 
(A-B-C) Osteoblasts from WT and PTPµ-/- osteoblasts were treated with varying 
concentrations of exogenous recombinant OPN (rOPN) prior to GiPCR stimulation with 
different concentrations of the agonists identified. 
 
Figure 5 Lack of PTPµ influences the interaction of OPN with integrin in osteoblasts. 
(A-B) The expression of OPN receptors was determined in WT and PTPµ-/- osteoblasts 
using qPCR and western blot. (C) Osteoblasts cell lysates of WT and PTPµ-/-were 
immunoprecipitated with antibodies against OPN receptors followed by western blot 
specific for OPN.  
 
Figure 6 Silencing of PIPK1γ selectively enhances GiPCR signaling in PTPµ-/- 
osteoblasts. (A) Osteoblasts from PTPµ-/- mice, cells were treated with inhibitor of Src 
(PP2) and FAK (inhibitor-14) prior to immunoprecipitation assay. Phosphorylation levels 
of PIPK1γ were attenuated by both treatments while Phosphorylation levels of PIPK1γ 
were higher in osteoblasts from PTPµ-/- than those from WT mice.  (B-C) PIPK1γ was 
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knockdown using siRNA approach in WT and PTPµ-/- osteoblasts cells and it is approved 
by the qPCR and western blot. (D-H) PIPK1γ was knockdown in WT and PTPµ-/- 
osteoblasts cells Osteoblasts depleted of PIPK1γ exhibited similar degree of response to 
somatostatin stimulation than WT osteoblasts. 
 
Figure 7 PTPµ is downregulated in osteoblasts from patients with idiopathic scoliosis. 
(A-B-C) The expression of PTPµ was determined in osteoblasts from scoliotic patients 
relative control subjects using RT-PCT, qPCR and western blot. PTPµ is downregulated in 
idiopathic scoliosis patients comparing to control subjects. 
 
 
 
 
  
  
 
178
Figure 1 
 
 
 
 
 
 
 
PTPµ-/- WT 
Time after surgery 
  
 
179
Figure 2 
 
 
 
 
WT 
PTPµ-/- 
  
 
180
Figure 3 
 
 
 
 
Bipedal WT 
Bipedal PTPµ-/- 
  
 
181
Figure 4 
 
 
 
 
 
 
 
 
  
Bipedal WT 
Bipedal PTPµ-/- 
Bipedal WT 
Bipedal PTPµ-/- 
Bipedal WT 
Bipedal PTPµ-/- 
Apelin-17 Oxymethazolin 
Somatostatin
  
 
182
Figure 5 
 
  
PTPµ-/- 
PTPµ-/-WT 
WT 
IP- OPN receptors 
WB- OPN 
  
 
183
Figure 6 
 
 
 
 
 
 
 
 
PTPµ-/-PTPµ
-/- 
PTPµ-/-
  
 
184
 
Figure 7 
 
 
 
 
 
  
 
PTPµ 
Na/ K-ATPase 
PTPµ 
β-actin 
  
 
185
 
    
 
 
 
GENERAL DISCUSSION 
 
  
  
 
186
GENERAL DISCUSSION 
The major challenge for orthopaedic surgeons regarding the management of AIS is 
the identification of patients at risk of progression and to determine, at an early stage, the 
best suitable therapeutic option. Due to the limited knowledge concerning the 
etiopathophysiology of AIS, no approach has yet been developed to address those issues 
with certainty. Nevertheless, through the various studies performed in our laboratory, we 
have discovered a systemic Gi protein coupled receptor signaling dysfunction as a decisive 
factor for the pathogenesis of AIS. Our interest in identifying molecular determinants of 
AIS and to better understand the mechanistic aspect of Gi-mediated signaling defect under 
high plasma OPN conditions may lead to a more comprehensive molecular concept to 
explain the pathomechanism implicated in the development and progression of AIS. This 
may thereby provide a molecular basis for the development of innovative pharmacological 
options and personalized treatments for AIS. 
The CDS method within this project was chosen because it allowed the 
simultaneous Gi, Gs and Gq-mediated signaling measurement and also allowed for the 
testing of many receptor agonists in various cell types, all within the same assay. The use of 
bipedal mouse model for scoliosis helped to discover a direct link between Gi-mediated 
signaling under high plasma OPN conditions and the development of scoliosis. In the 
following text, I will discuss the overall results of my Ph.D. projects and present a potential 
mechanism exacerbating Gi-mediated signaling dysfunction in AIS and the relationship of 
the disease progression under high OPN conditions. 
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Methodological considerations  
The significance of any experimental results is mainly dependent on the relevance 
of analytical methods and/or animal models utilized. In this regard, the first question 
addressed in the context of the present PhD project, was the choice of appropriate 
techniques to rapidly assess GPCR signaling as well as the suitable animal models.  
 
Choice of analytical methods 
Most of the common cell-based assays to assess GPCR signaling primarily rely on 
the measurement of a specific cellular response, including the generation of a second 
messenger, the dynamic relocalization of a target tagged with a fluorescent molecule, and 
the expression of a reporter gene. [226] Generally, these technologies require 
manipulations or engineering of cells, such as loading of fluorescent molecules into cells or 
over-expression of a target with or without a fluorescent tag. These manipulations may alter 
the cellular physiology of the target receptor. Together with the possible interference of 
many compounds with the detection technology, these common cell-based assays suffer 
imperative limitations.  
To overcome these limitations, a non-invasive cell-based assay technology, termed 
cellular dielectric spectroscopy, or CDS, that measures whole-cell response in a label-free 
manner, has been developed. This technology yields information regarding the total 
integrated response of the cell to external stimuli and is based on applying electrical current 
to the cells within a microplate and measuring the changes in impedance. Precisely, the 
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CDS technology employs the application of alternating voltages at set frequencies to 
cellular components and intact cells and monitors the resulting currents generated from the 
dipoles within the sample. At each frequency, the difference in magnitude of the reflected 
signal, is compared to the incident wave, and is measured. In this electrical detection 
method, cells are cultured on small gold electrodes arrayed onto a substrate, and the 
system's electrical impedance is followed over a period of time. The impedance is a 
measure of changes in electrical conductivity of the cell layer. The latest generation of 
systems, such as the CellKeyTM system (MDS Sciex, San Francisco, CA) has been created 
to overcome high assay variability usually associated with the classical impedance systems, 
which use small detection electrodes and large reference electrodes. [227] 
 The CellKeyTM system consists of an environmentally controlled impedance 
measurement system, a 96-well electrode-embedded microliter plate, an onboard 96-well 
fluidics system, and a custom acquisition and analysis software. [228] The cells are seeded 
in the culture wells; each well has an integrated electrode array. The system operates using 
a small amplitude alternating voltage at 24 frequencies, from 1 KHz to 10 MHz. The 
resultant current is measured at an update rate of 2 seconds. The system is thermally 
regulated and experiments can be conducted between 28°C and 37°C. A 96-well head fluid 
delivery device handles fluid additions and exchanges onboard. In a single assay format, 
the cellkey system monitors the activation of different classes of endogenous GPCR and 
simultaneously differentiates among subtypes coupled to Gi, Gs and Gq proteins. In this 
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regard, this system has a large advantage over other universal technologies that do not 
distinguish among responses to these different GPCR subtype stimulations. 
 Particularly, the application of the CellKeyTM system to any receptor subtype 
coupled to Gi proteins (GiPCR) is very noteworthy for the benefits it holds over other 
systems using [35S] GTPγS binding or modulating of cAMP production. [35S] GTPγS 
binding requires radioactivity and uses isolated plasma membrane fragments. cAMP 
production is a viable whole-cell assay alternative that we have initially used to achieve our 
previous studies. [229], [105], [230] However, this classical cAMP assay is limited to 
marginal precision due to the need to first stimulate adenylate cyclases with forskolin and 
then measure a reduction in this response by GiPCR agonists.  
Based on these considerations, we have introduced the CellKeyTM system in our 
laboratory and developed a cell-based assay to classify AIS patients and asymptomatic 
children according to the degree of maximum response to melatonin stimulation. [231] 
Indeed, we have demonstrated that the deficient melatonin signaling in AIS and the 
disparity of this defect among patients can be detected by the CellKeyTM system. Moreover, 
relatively to the classical cAMP assay, we found that the CellKeyTM system is more 
accurate and more reproducible to classify AIS patients or asymptomatic children by 
targeting the melatonin receptor. Recently, we have published a procedure for our cell-
based assay as currently performed in our laboratory using the CellKeyTM system. [231] 
The highest specificity, reproducibility and accuracy of our assay combined with the 
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remarkable simplicity of experimental and analytical procedures, the possibility of 
analysing a large number of samples under various conditions in the same assay, and the 
fact that this assay is applicable to any receptors coupled to any G proteins within any cell 
type, including adherent and suspension cell lines and primary cells, make the CellKeyTM 
system an appropriate technology to attend to the goal of the present project. 
   
Choice of animal models 
Multiple models in a multitude of animals have been created to understand the 
pathogenesis of AIS. Given the unclear origin of this disease in humans, various methods 
have been used. In most cases, these animal models sufficiently mimic scoliotic deformities 
observed in patients and have contributed to the generation of various hopeful hypotheses 
which continue to be investigated.  
The neuroendocrine hypothesis pointing to a melatonin deficiency as the source for 
AIS has generated great interest. This hypothesis stems from the fact that experimental 
pinealectomy in different vertebrate species, [232], [53], [233], [234], [235] rats, mice, 
[80], [236], [2], [76], [237] rabbits [238] and Atlantic salmon [239]  result in scoliosis that 
closely resembles AIS. However, despite low circulating levels of melatonin, bipedal 
ambulation appears to be required to generate scoliosis in mammalians. Indeed, Machida 
and collaborators (1999) have shown that melatonin deficiency secondary to pinealectomy 
alone does not produce scoliosis in rats if the quadrupedal condition is maintained. [80] 
Also, mice which are genetically deficient in melatonin develop scoliosis only when they 
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gain bipedal ambulation following amputation of their forelimbs and tails. [2] In that 
context, the underlying injury is not to be negated. Indeed, injury may induce production of 
various factors and enhance their circulating levels including plasma OPN, which is one of 
the concerns in the project. Therefore, it is possible that one or many factors induced by 
injury contribute to the development of spinal deformities, in agreement with the 
multifactorial etiology of this complex disease. In this regard, the genetic modification by 
either deletion of specific genes to dissect the individual genetic and cellular components 
that contribute to the mechanisms underlying pathophysiological events in various complex 
diseases has been very useful in gaining some understandings of their pathogenesis. 
It is well known that mice are the main species used in the field of genetic 
modification and this for many reasons, such as their small size and low cost of housing 
compared to larger vertebrates, their short generation time and their fairly well defined 
genetics.  Importantly, C57Bl/6 mice deficient in OPN have been created in certain 
specialised laboratories. To take advantage of this availability, we chose to use mice of 
C57Bl/6 background and found that genetic deletion of ssp1 gene (encoding OPN) protects 
these mice against scoliosis induced by the amputation of forelimbs and tails, while 
scoliotic bipedal wild type mice exhibited high plasma OPN. These findings undoubtedly 
indicate that this animal model of scoliosis can be a suitable model to examine the 
importance of defective GiPCR signaling in the development of scoliosis under high 
circulating levels of OPN. 
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Physiopathological considerations 
Despite intensive research in the field of AIS, physiopathological events responsible 
for the onset and progression of this disease remain mysterious at this time. Nevertheless, 
accumulating evidence indicate that melatonin deficiency can be an important factor in 
pathological processes that drive scoliotic deformities in animals. However, the 
consideration of this hypothesis for the development of scoliosis in humans has been 
controversial for many years. Indeed, the lack of a significant decrease in circulating 
melatonin levels in AIS patients [94], [96], [240] has raised serious doubts around this 
hypothesis, which has been reconciled in our laboratory by the demonstration of a 
melatonin signaling dysfunction occurring in osteoblasts from AIS patients. [229] Our data 
indicate that AIS results from the inability of melatonin to regulate biological functions 
through its signaling pathway rather than a failure in its bioavailability. Specifically, we 
have observed that primary osteoblasts cultures prepared from bone specimens obtained 
intra-operatively during spinal surgeries of AIS patients with severe deformities, exhibited 
reduced ability to inhibit cAMP production in response to melatonin stimulation, arguing 
for reduced melatonin signaling through Gi proteins. Importantly, we have suggested that 
this defect lies at the level of Gi proteins by demonstrating the presence of increased 
phosphorylation at serine residues, since such post-transcriptional modification is well 
known to affect the activity of Gi proteins. From these findings has emerged the notion that 
biological processes driving the pathogenesis of AIS may implicate defective Gi proteins-
mediated signaling. 
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Nature of defective Gi protein-mediated signaling in adolescent idiopathic 
scoliosis (AIS) 
The major difficulty in investigations regarding the pathogenesis of AIS is its 
heterogeneous nature. [10], [241] Indeed, the heterogeneity of AIS is clearly illustrated by 
the variability of curve patterns and localisations among patients, even those within the 
same family. Similarly, we have reported the heterogeneous appearance of AIS on the 
biochemical aspect by demonstrating the existence of a disparity in the extent of melatonin 
signaling dysfunction among patients, leading to their classification into three functional 
groups. [229], [105], [230]  
Although melatonin receptors can also couple to Gq proteins, the drastic reduction 
in response to melatonin receptor agonists observed in the presence of PTX, excludes the 
possibility that Gq-mediated signaling becomes a predominant or compensatory pathway 
for melatonin signaling in the absence of functional Gi proteins. Moreover, no evidence for 
Gq protein dysfunction was noted since response to agonists specific for GqPCR were 
similar in cells from AIS patients and control subjects. In contrast, we noticed an increased 
response to agonists specific for GsPCR in cells from AIS patients, supporting the notion 
that reduced Gi proteins function leads to increased Gs protein activity. It was noteworthy 
that disparity among AIS patient groups in response to melatonin stimulation was also 
observed in response to GsPCR agonist stimulation. 
Currently, no evidence links this signaling disparity to melatonin receptors. Various 
studies indicate that expression of melatonin is not affected in AIS, [97], [242], [229] and 
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polymorphism analysis of genomic DNA has revealed no correlation between gene variants 
of melatonin receptors and the phenotype of AIS. [97],  [242] Moreover, results presented 
in the present manuscript 1 show that the affinity of melatonin receptor for partial or full 
agonists was preserved in AIS and remained similar among the three functional groups, 
definitively excluding the possibility that different extent of melatonin signaling among the 
three functional groups can be explained by changes in melatonin receptor function. In 
contrast, competition studies performed in this study suggest that AIS is accompanied by a 
decreased sensitivity of Gi proteins for melatonin receptors and results have revealed that 
this decreased sensitivity is at different degrees among the three functional groups. The fact 
that similar profiles of response were obtained with various agonists operating through 
distinct receptors coupled to Gi proteins, argues against an abnormality specifically or 
exclusively related to melatonin receptors. Moreover, we found that this defect was not 
confined to osteoblasts since myoblasts and lymphocytes from the same AIS patients 
displayed similar features in response to all tested compounds. Collectively, these data not 
only indicate that the ability of Gi proteins to transduce extracellular signals is reduced in a 
systemic manner and generalized to all receptors coupled to Gi proteins, but also suggest 
that the mechanism triggering Gi proteins impairment could be the same in all cell types. 
In this regard, results obtained in the present project are consistent with previous 
studies and confirm that AIS is not associated with changes in expression of Gi proteins but 
involves increased phosphorylation of Gi-alpha-subunits. It was striking to observe that the 
Gi protein isoforms were differentially phosphorylated among the three functional groups 
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of AIS patients and that the phosphorylation pattern as well as the kinases potentially 
implicated in this phenomenon, were specific to each functional group. However, further 
investigations are necessary to gain better understanding into the pathological processes 
associated with these disparities between the functional groups of AIS patients. 
Indeed, it is well known that AIS is a multifactorial disease with a genetic 
component. Therefore, we cannot exclude the possibility that mutations in the gene 
encoding for Gi proteins themselves or for proteins implicated in the regulation of their 
function may be responsible for the reported abnormalities. In this regard, arrestin domain 
containing 4 (ARRDC4) gene, a negative regulator of G proteins signaling cascade, has 
been identified as a potential candidate gene on chromosome 15q25-26 in patients affected 
with AIS. [243] Moreover, mutations in G proteins have been reported in human diseases. 
[244] In each case, the mutation has been found on the alpha subunit of G proteins. 
However, because the beta-gamma dimmers are also known to play a decisive role in the 
ability of Gi proteins to mediate signal transduction, mutations or alterations in 
posttranslational processing of any beta or gamma subunits cannot be excluded yet. 
The possibility of a genetic component in the Gi protein impairment in AIS, was 
further supported by the observation that all affected members of the same family displayed 
the similar response to GiPCR stimulation and were classified into the same functional 
subgroup, suggestive of an hereditary transmission of this defect. The expression of 
defective GiPCR signaling at the similar extent in the monozygotic twins affected with AIS 
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lends more credit to the notion that this condition may be inherited. This contrasts with 
other factors such as gender, age at disease onset, curve severity and curve pattern that are 
not conserved among affected twins and family members.  
Nevertheless, we detected the functional reduction of Gi proteins in certain family 
members who have not developed spine deformity. This appears ideally suited to fit in the 
framework of the current concept regarding the contribution of genes versus environment 
in the process leading to AIS. Thus, functional reduction of Gi proteins would provide the 
inherited susceptibility for AIS, yet not sufficient to establish AIS by itself. We propose 
that, for each functional subgroup, there is a threshold of reduction. The genetic 
background may become important only when the functional reduction of Gi proteins 
reaches this threshold.  
One can easily envisage that estrogens could contribute to the reduced functionality 
of Gi proteins, and thus initiate the decisive or aggravating step in the development of AIS. 
Indeed, it is well known that puberty is a crucial period for estrogen production, and certain 
reports indicate that estrogen interferes with G protein activities in various cells. [245],  [246]
 
This effect could be explained by the fact that estrogens have been shown to reduce Gi protein 
levels inside the cells by interfering with their transcription and synthesis. [246] On this basis, 
and because a large amount of Gi proteins are in cells before puberty, it could be speculated 
that functional reduction of Gi proteins is present at birth but has no significant impact prior to  
puberty, this pre-existing condition is however exacerbated by the increase in estrogens at 
puberty. This hypothesis is supported at least in part by our findings that estrogen treatments 
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exacerbate Gi protein impairment in cells from AIS patients (Akoume et al 2013, in 
preparation). This may explain the greater prevalence of AIS in girls than in boys and its 
greater incidence around the time of puberty.  
Although the genetic determinants remain to be defined, results of the first 
manuscript provide solid evidence for a systemic and generalized reduction of Gi protein 
function in AIS, which could be conferred by hereditary and regarded as a prominent factor 
in etiopathology of this disease. 
Contribution of OPN in the development of scoliosis in bipedal 
mice 
For many years, it is has been recognized that OPN is implicated in a variety of 
human diseases. Recently, this chemokine has been suggested to be a potential contributor 
in the pathogenesis of AIS following the observation of its high circulating levels in 
individuals affected with this disease. Therefore, the role of OPN in the development of 
scoliosis was addressed for the first time in the present study using mice in which scoliosis 
was induced by forced bipedal ambulation after amputation of forelimbs and tails. Results 
revealed that these bipedal scoliotic mice exhibited higher plasma OPN and lower response 
to GiPCR stimulation when compared to non-scoliotic quadrupedal mice, suggesting a 
cause-and-effect relationship between these phenomenons. Consistent with this, we found 
that genetic removal of OPN prevented spinal deformities in bipedal mice and improved 
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the response to GiPCR stimulation in their osteoblasts. Furthermore, we demonstrated that 
OPN reduces response to GPCR stimulation, using in vitro assays. 
OPN is well-known to induce various physiologic and pathologic effects by binding 
to CD44 or integrin receptors. Our in vitro assay revealed that OPN interferes with GiPCR 
signaling by interacting with RGD-dependent integrin. We identified α5β1 integrin as the 
main receptor responsible for the inhibitory effect of OPN on GiPCR signaling. It was 
particularly interesting to observe that the treatment of cells with OPN caused decrease in 
the amount of Gi proteins coupled with their cognate receptors, while this treatment 
enhanced their interaction with α5β1 integrin. These findings were interpreted to indicate 
that OPN reduces GiPCR signaling by increasing the sequestration of Gi protein by α5β1 
integrin. Moreover, we found that this OPN treatment also enhanced the phosphorylation of 
Gi proteins, a modification that reduces their activity. Interestingly, these effects of OPN on 
Gi proteins were prevented by the inhibition of various molecular intermediates engaged in 
the integrin signaling pathway.  
In parallel, the examination of the functional status of Gs protein has revealed that 
OPN enhances its phosphorylation state and the interaction with its cognate receptors. This 
suggests that OPN has a reverse effect on Gs and Gi proteins-mediated signaling. Indeed, 
while GiPCRs are decreased, GsPCRs appear to be increased by OPN. This may cause an 
imbalance between bone mass and muscular strength around the spine due to an imbalance 
between myoblast and osteoblast proliferation, and/ or differentiation, and thus offers an 
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explanation for the apparition of the lateral curvature. Although this notion remains strictly 
speculative, our collective findings suggest that OPN is a relevant contributor in the 
pathogenesis of scoliosis in bipedal mice. 
Impact of PTPµ deficiency on spinal deformity progression 
Our demonstration that OPN contributes to the development of scoliosis by 
interfering with GiPCR signaling via a dual mechanism involving α5β1 integrin 
engagement, allowed us to suggest that factors that regulate the interaction of OPN with 
integrin may influence the nature of scoliosis under high circulating OPN conditions. Since 
a recent study has revealed that PTPµ is a key player in the regulation of the interaction 
between integrin and its ligands, [247] we took advantage of the availability of PTPµ 
deficient mice on a C57Bl/6 background to test our hypothesis. Like the wild type 
phenotype, amputation of forelimbs and tails caused increased OPN levels in PTPµ 
deficient mice and this increase was to the same extent in both phenotypes. However, 
bipedal PTPµ deficient mice displayed greater incidence and severity of scoliosis when 
compared to bipedal wild type mice. Moreover, we found that osteoblasts from these mice 
were also less responsive to GiPCR stimulation relative to those from bipedal wild type 
mice. The regression analysis of their respective concentration-curves has revealed that the 
lack of PTPµ influences the response to GiPCR stimulation in a receptor-independent 
manner. In contrast, we found that osteoblasts depleted of PTPµ were more sensitive to the 
inhibitory effect of OPN on GiPCR signaling. This is strongly indicative of an impact of 
PTPµ deficiency which lies at the level of the interaction of OPN with its receptors. The 
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lack of PTPµ increases the interaction of OPN with α5β1 integrin which further supports the 
idea this integrin is the receptor responsible for the inhibitory effect of OPN on GiPCR 
signaling. We further provided the mechanistic insights by demonstrating that the lack of 
PTPµ favours the interaction of OPN with α5β1 integrin via PIPKIγ action. These 
observations suggest that the lack of PTPµ influences the nature of scoliosis by amplifying 
the inhibitory effect of OPN on GiPCR signaling. 
Pathomechanism leading to the development of scoliosis in 
bipedal mice 
Results presented in this thesis support the notion that a defective GiPCR signaling 
occurs in AIS and reveal a causative link between this defect and the circulating OPN 
levels. Our collective findings allowed us to elaborate the hypothetic scenario illustrated at 
figure 9 to explain the mechanism by which OPN reduces GiPCR signaling and how this 
effect is further exacerbated in absence of PTPµ. 
Indeed, it is well known that integrins switch from low affinity to high affinity form 
to interact with their ligands and that integrins switching is favoured by phosphorylated 
PIPK1γ, which is normally dephosphorylated by PTPµ. We propose that the interaction of 
OPN with α5β1 integrin in its high affinity form simultaneously causes a depletion of the 
pool of unphosphorylated Gi proteins and the phosphorylation of different Gi protein 
isoforms, leading to the reduction in the quantity of functional Gi proteins necessary for 
efficient GiPCR signaling. In the absence of PTPµ, PIPK1γ is not deactivated and 
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maintains α5β1 integrin in its high affinity form. This favours its interaction with OPN and 
amplifies the inhibitory effect of OPN on GiPCR signaling, as well as the resulting 
consequences underlying spinal deformities.  
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 General conclusion 
The collective findings presented in this thesis support the notion that the defective 
GiPCR signaling occurring in AIS should be regarded as a key event in the pathologic 
process leading to idiopathic scoliosis. These findings are the first evidence pointing to the 
defective GiPCR signaling as a systemic and generalized defect, likely conferred by 
heredity. The realisation that OPN acts as a strong inhibitor of GiPCR signaling, has served 
to highlight the role of this cytokine as a potential target for future therapeutic 
interventions. Moreover, this study has introduced PTPµ deficiency as a risk factor for the 
development of severe lateral curvature. However, many issues remain to be addressed 
regarding the role of OPN and the impact of PTPµ deficiency in the pathogenesis of AIS. 
Understanding whether these factors contribute to the functional disparity of GiPCR 
signaling among the three functional subgroups of AIS patients, and provide the 
mechanism of action in each functional group are important research goals. These questions 
must be answered before we can fully understand the role of these factors in the disease’s 
processes within in each functional group, and elucidate how they can become targets for 
drug development. 
 
 Perspective  
The work undertaken in this thesis demonstrates the importance of the differential 
Gi protein signaling defect occurring in AIS. Evaluation of this defect may give orthopedic 
surgeons a diagnostic tool which may help them to indentify at an early stage, patients at 
risk of scoliosis whom may benefit from early and minimally invasive surgical 
interventions. The possibility of using PBMCs rather than osteoblasts will undoubtedly 
facilitate the process of classification of AIS patients. We showed how OPN plays an 
essential role in the etiology of AIS by attenuation of the Gi protein signaling through α5β1 
integrin. We then demonstrated that PTPµ deficiency further exacerbates the harmful effect 
of OPN in AIS. PTPµ plays a role in all three groups though differently, and the next step 
will be to identify which proteins control PTPµ function within these different groups. 
 
It is important to study the cause of PTPµ downregulation in the three functional 
AIS groups. Among others, nectin 3 protein is known to control PTPµ activity. Nectin 3 
interacts with other nectins and nectin-like family members. It was also demonstrated that 
there is a physical interaction between nectins and nectins-like proteins with integrins. 
[213] The next step should focus on the expression of these nectins in our AIS functional 
groups and the association between these nectins with nectin-likes and PTPµ or integrin 
α5β1. 
 
Another protein of interest is tetraspan CD151, which is a cell surface glycoprotein. 
It was shown that CD151 physically associates with integrins and integrin α5β1. [248] The 
reduction of the expression of integrin β1 was demonstrated in CD151 knockdown 
  
 
206
podocytes. [249]  It was also shown that integrin β1 and CD151 regulate PTPµ expression. 
[214] Taken together these results lead to the hypothesis that CD151 could play a role in 
AIS through the control of α5β1 integrin.   
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